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Worldwide, cancers remain a leading cause of death. The judicious use of cancer diagnostics 
– broadly defined as tests for cancer – has great potential to reduce disease morbidity and 
mortality. Impeding this potential is the difficulty of creating effective new tests, as the 
techniques successful for one type of cancer frequently cannot be generalized to another. 
Although the ability to detect cancer-specific DNA mutations at the low levels commonly 
encountered in clinical specimens would yield a promising, broadly applicable diagnostic 
strategy, existing technologies have been unacceptably limited in throughput or accuracy. 
Here we describe the development and application of a scalable, generalizable DNA 
sequence-based technology for the reliable detection of mutations. By drastically reducing 
artifacts introduced through sample preparation and massively parallel sequencing, rare 
mutations arising from cancer cells – when present – can be confidently discriminated from 
a large excess of non-mutant DNA. The technology can be directed to virtually any genomic 
region, affording rational test design. When applied to routinely collected Pap specimens, 
our approach detected cancer-specific mutations in 41% (9 of 22) and 100% (24 of 24) of 
women harboring various stages of ovarian and endometrial cancers, respectively. Our 
approach was highly specific, as no false positives were detected in a cohort of Pap 
specimens collected from women without gynecologic cancer. We also demonstrate how the 
urine of patients with urothelial carcinoma can be utilized to predict disease recurrences. 
Eighty-eight percent (7 of 8) of patients with a detectable mutation had recurrences while 
none were detected in the six patients without recurrent disease (P <0.001). Finally we 
present data suggesting that a wide range of cancers shed mutant DNA into blood and that 
these mutations are sensitive and specific markers for disease. Taken together, our results 
demonstrate the potential and feasibility of improved diagnostics for several cancers using a 
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variety of clinical specimens obtainable in a minimally invasive fashion. Larger studies are 
underway as a prelude to implementing these tests in the clinic – a critical step in addressing 
the many unmet clinical needs of patients with cancer. 
Advisor: Bert Vogelstein, M.D. 
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Chapter 1: Introduction 
Mutations are a driving force 
Genetic mutations underlie many aspects of life and death – through evolution and disease, 
respectively. 
 
Accordingly, their measurement is critical to several fields of research. Luria and Delbrück's 
classic fluctuation analysis is a prototypic example of the insights into biological processes 
that can be gained simply by counting the number of mutations in carefully controlled 
experiments 1. Counting de novo mutations in humans, not present in their parents, have 
similarly led to new insights into the rate at which our species can evolve 2,3. Similarly, 
counting genetic or epigenetic changes in tumors can inform fundamental issues in cancer 
biology 4. Mutations lie at the core of current problems in managing patients with viral 
diseases such as AIDS and hepatitis by virtue of the drug-resistance they can cause 5,6. 
Detection of such mutations, particularly at a stage prior to their becoming dominant in the 
population, will likely be essential to optimize therapy.  
 
Exploiting mutations for rational cancer diagnostics 
In comprehensive cancer genome sequence determination, the unbiased analyses considered 
a tour de force a decade ago 7,8 have now become routine 9. As a result, the genomic 
sequences of the most common cancers have been deciphered. As all cancers are caused by 




This insight may potentially revolutionize cancer diagnostics, which are broadly defined as 
tests for the detection of cancers. Goals of these tests include the early detection of disease, 
to identify asymptomatic patients that may undergo curative therapy with high rates of 
success; precision medicine, where disease treatment is tailored to the vulnerabilities specific 
to a particular patient’s disease; and prognosis and surveillance, which guide physician and 
patient expectations for the probability of eradicating existing disease and developing a 
recurrence. By considering the mutation spectrum of a particular cancer, sequence-based 
diagnostics can be rationally designed for virtually any cancer. 
 
The most challenging technical barrier to utilizing mutation detection for cancer diagnostics 
is the relatively low prevalence of mutations seen in some clinical specimens – sometimes as 
low as 0.01% 10. When cancers shed mutant DNA into readily accessible diagnostic 
compartments such as blood and stool, their mutant DNA must be discriminated from a 
large excess of wild-type DNA. At the low proportions commonly observed, reliably 
discriminating these mutations from technical errors may be impossible. The importance of 
accuracy is paramount as results of these tests may influence the decision to use invasive 
follow-up testing. 
 
In the ensuing chapters, I present studies highlighting the feasibility of exploiting mutation 
detection for cancer diagnostics from clinical specimens. First, I describe a generalizable, 
massively parallel sequencing-based method named the Safe-Sequencing System (“Safe-
SeqS”), capable of reliably detecting mutations arising from small populations of cancer cells. 
In the following two chapters, I provide concrete examples of how Safe-SeqS can power 
new diagnostics by applying it to cancers of the gynecologic and urinary tract. Finally I close 
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with a survey of the amount of mutant DNA shed into readily accessible patient specimens 
by a variety of human cancers, which optimistically suggests that the management of several 
cancers can be improved by applying Safe-SeqS or related mutation detection technologies. 
 
Acknowledgments 






Chapter 2: Detection and Quantification of Rare  
Mutations With Massively Parallel 
Sequencing 
Introduction 
In neoplastic diseases, which are all driven by somatic mutations, the applications of rare 
mutant detection are manifold; they can be used to help identify residual disease at surgical 
margins or in lymph nodes, to follow the course of therapy when assessed in plasma, and 
perhaps to identify patients with early, surgically curable disease when evaluated in stool, 
sputum, plasma, and other bodily fluids 10,12,13. 
 
These examples highlight the importance of identifying rare mutations for both basic and 
clinical research. Accordingly, innovative ways to assess them have been devised over the 
years. The first methods involved biologic assays based on prototrophy, resistance to viral 
infection or drugs, or biochemical assays 1,14-20. Molecular cloning and sequencing provided a 
new dimension to the field, as it allowed the type of mutation, rather than simply its 
presence, to be identified 21-26. Some of the most powerful of these newer methods are based 
on Digital PCR, in which individual molecules are assessed one-by-one 27. Digital PCR is 
conceptually identical to the analysis of individual clones of bacteria, cells, or virus, but is 
performed entirely in vitro with defined, inanimate reagents. Several implementations of 
Digital PCR have been described, including the analysis of molecules arrayed in multi-well 
plates, in polonies, in microfluidic devices, and in water-in-oil emulsions 27-32. In each of 
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these technologies, mutant templates are identified through their binding to oligonucleotides 
specific for the potentially mutant base. 
 
Massively parallel sequencing represents a particularly powerful form of Digital PCR in that 
hundreds of millions of template molecules can be analyzed one-by-one. It has the 
advantage over conventional Digital PCR methods in that multiple bases can be queried 
sequentially and easily in an automated fashion. However, massively parallel sequencing 
cannot generally be used to detect rare variants because of the high error rate associated with 
the sequencing process. For example, with the commonly used Illumina sequencing 
instruments, this error rate varies from ~1%33,34 to ~0.05% 35,36, depending on factors such 
as the read length 37, use of improved base calling algorithms 38-40 and the type of variants 
detected 41. Some of these errors presumably result from mutations introduced during 
template preparation, during the pre-amplification steps required for library preparation and 
during further solid-phase amplification on the instrument itself. Other errors are due to 
base mis-incorporation during sequencing and base-calling errors. Advances in base-calling 
can enhance confidence (e.g., 38-41), but instrument-based errors are still limiting, particularly 
in clinical samples wherein the mutation prevalence can be 0.01% or less 10. 
 
Our approach, called "Safe-SeqS" for Safe-Sequencing System, involves two basic steps (Fig. 
1). The first is the assignment of a unique identifier (UID) to each DNA template molecule 
to be analyzed. The second is the amplification of each uniquely tagged template, so that 
many daughter molecules with the identical sequence are generated (defined as a UID-
family). If a mutation pre-existed in the template molecule used for amplification, that 
mutation should be present in every daughter molecule containing that UID (barring any 
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subsequent replication or sequencing errors). A UID-family in which every family member 
has the identical mutation is called a "super-mutant". Mutations not occurring in the original 
templates, such as those occurring during the amplification steps or through errors in base-
calling, should not give rise to super-mutants. Conceptual and practical issues related to UID 
assignment and super-mutants are discussed in detail in the SI text. 
 
Results 
Endogenous UIDs. UIDs, sometimes called barcodes or indexes, can be assigned to 
nucleic acid fragments in many ways. These include the introduction of exogenous 
sequences through PCR 42,43 or ligation 44,45. Even more simply, randomly sheared genomic 
DNA inherently contains UIDs consisting of the sequences of the two ends of each sheared 
fragment (Fig. 2 and Fig. S1). Paired-end sequencing of these fragments yields UID-families 
that can be analyzed as described above. To employ such endogenous UIDs in Safe-SeqS, 
we used two separate approaches: one designed to evaluate many genes simultaneously and 
the other designed to evaluate a single gene fragment in depth (Fig. 2 and Fig. S1, 
respectively).  
 
For the evaluation of multiple genes, we ligated standard Illumina sequencing adapters to the 
ends of sheared DNA fragments to produce a standard sequencing library, then captured 
genes of interest on a solid phase 46. In this experiment, a library made from the DNA of 
~15,000 normal cells was used, and 2,594 bp from six genes were targeted for capture.  After 
excluding known single nucleotide polymorphisms, 25,563 apparent mutations, 
corresponding to 2.4 x 10-4 ± mutations/bp, were also identified (Table 1). Based on 
previous analyses of mutation rates in human cells, at least 90% of these apparent mutations 
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were likely to represent mutations introduced during template and library preparation or 
base-calling errors. Note that the error rate determined here (2.4 x 10-4 mutations/bp) is 
considerably lower than usually reported in experiments using the Illumina instrument 
because we used very stringent criteria for base calling (see SI Materials and Methods).  
 
With Safe-SeqS analysis of the same data, we determined that 69,505 original template 
molecules were assessed in this experiment (i.e., 69,505 UID-families, with an average of 40 
members per family, were identified, Table 1). All of the polymorphic variants identified by 
conventional analysis were also identified by Safe-SeqS. However, only 8 super-mutants were 
observed among these families, corresponding to 3.5 x 10-6 mutations/bp. Thus Safe-SeqS 
decreased the presumptive sequencing errors by at least 70-fold.  
  
A strategy employing endogenous UIDs was also used to reduce false positive mutations 
upon deep sequencing of a single region of interest.  In this case, a library prepared as 
described above from ~1,750 normal cells was used as template for inverse PCR employing 
primers complementary to a gene of interest, so the PCR products could be directly used for 
sequencing (Fig. S1).  With conventional analysis, an average of 2.3 x 10-4 mutations/bp were 
observed, similar to that observed in the capture experiment (Table 1). Given that only 1,057 
independent molecules from normal cells were assessed in this experiment, as determined 
through Safe-SeqS analysis, all mutations observed with conventional analysis likely 
represented false positives (Table 1). With Safe-SeqS analysis of the same data, no super-




Exogenous UIDs. Though the results described above show that Safe-SeqS can increase 
the reliability of massively parallel sequencing, the number of different molecules that can be 
examined using endogenous UIDs is limited. For fragments sheared to an average size of 
150 bp (range 125-175), 36 base paired-end sequencing can evaluate a maximum of ~7,200 
different molecules containing a specific mutation (2 reads x 2 orientations x 36 bases/read x 
50 base variation on either end of the fragment). In practice, the actual number of UIDs is 
smaller because the shearing process is not entirely random.   
  
To make more efficient use of the original templates, we developed a Safe-SeqS strategy that 
employed a minimum number of enzymatic steps. This strategy also permitted the use of 
degraded or damaged DNA, such as found in clinical specimens or after bisulfite-treatment 
for the examination of cytosine methylation 47. As depicted in Fig. 3, this strategy employs 
two sets of PCR primers. The first set is synthesized with standard phosphoramidite 
precursors and contained sequences complementary to the gene of interest on the 3’ end and 
different tails at the 5' ends of both the forward and reverse primers. The different tails 
allowed universal amplification in the next step. Finally, there was a stretch of 12 to 14 
random nucleotides between the tail and the sequence-specific nucleotides in the forward 
primer 42. The random nucleotides form the UIDs. An equivalent way to assign UIDs to 
fragments, not used in this study, would employ 10,000 forward primers and 10,000 reverse 
primers synthesized on a microarray. Each of these 20,000 primers would have gene-specific 
primers at their 3'-ends and one of 10,000 specific, predetermined, non-overlapping UID 
sequences at their 5'-ends, allowing for 108 (i.e., [104]2) possible UID combinations. In either 
case, two cycles of PCR are performed with the primers and a high-fidelity polymerase, 
producing a uniquely tagged, double-stranded DNA fragment from each of the two strands 
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of each original template molecule (Fig. 3). The residual, unused UID assignment primers 
are removed by digestion with a single-strand specific exonuclease, without further 
purification, and two new primers are added. The new primers, complementary to the tails 
introduced in the UID assignment cycles, contain grafting sequences at their 5' ends, 
permitting solid-phase amplification on the Illumina instrument, and phosphorothioate 
residues at their 3' ends to make them resistant to any remaining exonuclease. Following 25 
additional cycles of PCR, the products are loaded on the Illumina instrument. As shown 
below, this strategy allowed us to evaluate the majority of input fragments and was used for 
several illustrative experiments. 
 
Analysis of DNA polymerase fidelity. Measurement of the error rates of DNA 
polymerases is essential for their characterization and dictates the situations in which these 
enzymes can be used. We chose to measure the error rate of Phusion polymerase, as this 
polymerase has one of the lowest reported error frequencies of any commercially available 
enzyme and therefore poses a particular challenge for an in vitro-based approach. We first 
amplified a single human DNA template molecule, comprising a segment of an arbitrarily 
chosen human gene, through 19 rounds of PCR. The PCR products from these 
amplifications, in their entirety, were used as templates for Safe-SeqS as described in Fig. 3. 
In seven independent experiments of this type, the number of UID-families identified by 
sequencing was 624,678 ± 421,274, which is consistent with an amplification efficiency of 92 
± 9.6% per round of PCR.  
 
The error rate of Phusion polymerase, estimated through cloning of PCR products encoding 
β-galactosidase in plasmid vectors and transformation into bacteria, is reported by the 
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manufacturer to be 4.4 x 10-7errors/bp/PCR cycle. Even with very high stringency base-
calling, conventional analysis of the Illumina sequencing data revealed an apparent error rate 
of 9.1 x 10-6 errors/bp/PCR cycle, more than an order of magnitude higher than the 
reported Phusion polymerase error rate (Table 2A). In contrast, Safe-SeqS of the same data 
revealed an error rate of 4.5 x 10-7errors/bp/PCR cycle, nearly identical to that measured for 
Phusion polymerase in biological assays (Table 2A).  The vast majority (>99%) of these 
errors were single base substitutions (Table S1A), consistent with previous data on the 
mutation spectra created by other prokaryotic DNA polymerases 17,48,49. 
 
Safe-SeqS also allowed a determination of the total number of distinct mutational events and 
an estimation of PCR cycle in which the mutation occurred. There were 19 cycles of PCR 
performed in wells containing a single template molecule in these experiments. If a 
polymerase error occurred in cycle 19, there would be only one super-mutant produced 
(from the strand containing the mutation). If the error occurred in cycle 18 there should be 
two super-mutants (derived from the mutant strands produced in cycle 19), etc.  
Accordingly, the cycle in which the error occurred is related to the number of super-mutants 
containing that error. The data from seven independent experiments demonstrate a relatively 
consistent number of observed total polymerase errors (2.2 ± 1.1 x 10-6 distinct 
mutations/bp), in good agreement with the expected number of observations from 
simulations (1.5 ± 0.21 x 10-6 distinct mutations/bp, as detailed in SI text). The data also 
show a highly variable timing of occurrence of polymerase errors among experiments (Table 
S2), as predicted from classic fluctuation analysis 1. This kind of information is difficult to 
derive using conventional analysis of the same next-generation sequencing data, in part 




Analysis of oligonucleotide composition. A small number of mistakes during the 
synthesis of oligonucleotides from phoshoramidite precursors are tolerable for most 
applications, such as routine PCR or cloning. However, for synthetic biology, wherein many 
oligonucleotides must be joined together, such mistakes present a major obstacle to success.  
Clever strategies for making the gene construction process more efficient have been devised 
50,51, but all such strategies would benefit from more accurate synthesis of the 
oligonucleotides themselves. Determining the number of errors in synthesized 
oligonucleotides is difficult because the fraction of oligonucleotides containing errors can be 
lower than the sensitivity of conventional next-generation sequencing analyses.  
 
To determine whether Safe-SeqS could be used for this determination, we used standard 
phosphoramidite chemistry to synthesize an oligonucleotide containing 31 bases that were 
designed to be identical to that analyzed in the polymerase fidelity experiment described 
above. In the synthetic oligonucleotide, the 31 bases were surrounded by sequences 
complementary to primers that could be used for the UID assignment steps of Safe-SeqS 
(Fig. 3). By performing Safe-SeqS on ~300,000 oligonucleotides, we found that there were 
8.9 ± 0.28 x 10-4 super-mutants/bp and that these errors occurred throughout the 
oligonucleotides (Fig. S2A). The oligonucleotides contained a large number of insertion and 
deletion errors, representing 8.2 ± 0.63% and 25 ± 1.5% of the total super-mutants, 
respectively. Importantly, both the position and nature of the errors were highly 
reproducible among seven independent replicates of this experiment performed on the same 
batch of oligonucleotides (Fig. S2A).  This nature and distribution of errors had little in 
common with that of the errors produced by Phusion polymerase (Fig. S2B and Table S3), 
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which were distributed in the expected stochastic pattern among replicate experiments. The 
number of errors in the oligonucleotides synthesized with phosphoramidites was ~60 times higher 
than in the equivalent products synthesized by Phusion polymerase.  These data, in toto, indicate 
that the vast majority of errors in the former were generated during their synthesis rather 
than during the Safe-SeqS procedure.  
  
Does Safe-SeqS preserve the ratio of mutant:normal sequences in the original templates? To 
address this question, we synthesized two 31-base oligonucleotides of identical sequence 
with the exception of nt 15 (50:50 C/G instead of T) and mixed them at nominal 
mutant/normal fractions of 3.3% and 0.33%. Through Safe-SeqS analysis of the 
oligonucleotide mixtures, we found that the ratios were 2.8% and 0.27%, respectively. We 
conclude that the UID assignment and amplification procedures used in Safe-SeqS do not 
greatly alter the proportion of variant sequences and thereby provide a reliable estimate of 
that proportion when unknown. This conclusion is also supported by the reproducibility of 
variant fractions when analyzed in independent Safe-SeqS experiments (Fig. S2A). 
 
Analysis of DNA sequences from normal human cells. The exogenous UID strategy 
(Fig. 3) was then used to determine the prevalence of rare mutations in a small region of the 
CTNNB1 gene from ~100,000 normal human cells from three unrelated individuals. 
Through comparison with the number of UID-families obtained in the Safe-SeqS 
experiments (Table 2B), we calculated that the majority (78 ± 9.8 %) of the input fragments 
were converted into UID-families. There was an average of 68 members/UID-family, easily 
fulfilling the required redundancy for Safe-SeqS (Fig. S3). Conventional analysis of the 
Illumina sequencing data revealed an average of 118,488 ± 11,357 mutations among the 
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~560 Mb of sequence analyzed per sample, corresponding to an apparent mutation 
prevalence of 2.1 ± 0.16 x 10-4 mutations/bp (Table 2B). Only an average of 99 ± 78 super-
mutants were observed in the Safe-SeqS analysis. The vast majority (>99%) of super-
mutants were single base substitutions and the calculated mutation rate was 9.0 ± 3.1 x 10-6 
mutations/bp (Table S1B). Safe-SeqS thereby reduced the apparent frequency of mutations 
in genomic DNA by at least 24-fold (Fig. 4). 
 
We applied the identical strategy to a short segment of mitochondrial DNA in ~1,000 cells 
from each of seven unrelated individuals. Conventional analysis of the Illumina sequencing 
libraries produced with the Safe-SeqS procedure (Fig. 3) revealed an average of 30,599 ± 
12,970 mutations among the ~150 Mb of sequence analyzed per sample, corresponding to 
an apparent mutation prevalence of 2.1 ± 0.94 x 10-4 mutations/bp (Table 2C). Only 135 ± 
61 super-mutants were observed in the Safe-SeqS analysis. As with the CTNNB1 gene, the 
vast majority of mutations were single base substitutions, though occasional single base 
deletions were also observed (Table S1C). The calculated mutation rate in the analyzed 
segment of mtDNA was 1.4 ± 0.68 x 10-5 mutations/bp (Table 2C). Thus, Safe-SeqS thereby 
reduced the apparent frequency of mutations in genomic DNA by at least 15-fold. 
 
Discussion 
The results described above demonstrate that the Safe-SeqS approach can substantially 
improve the accuracy of massively parallel sequencing (Tables 1 and 2). It can be 
implemented through either endogenous or exogenously introduced UIDs and can be 
applied to virtually any sample preparation workflow or sequencing platform. As 
demonstrated here, the approach can easily be used to identify rare mutants in a population 
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of DNA templates, to measure polymerase error rates, and to judge the reliability of 
oligonucleotide syntheses. One of the advantages of the strategy is that it yields the number 
of templates analyzed as well as the fraction of templates containing variant bases. Previously 
described in vitro methods for the detection of small numbers of template molecules (e.g., 
31,52) allow the fraction of mutant templates to be determined but cannot determine the 
number of mutant and normal templates in the original sample.  
   
It is of interest to compare Safe-SeqS to other approaches for reducing errors in next-
generation sequencing. As mentioned in the Introduction, sophisticated algorithms to 
increase the accuracy of base-calling have been developed (e.g., 38-41). These can certainly 
reduce false positive calls, but their sensitivity is still limited by artifactual mutations 
occurring during the PCR steps required for library preparation as well as by (a reduced 
number of) base-calling errors. For example, the algorithm employed in the current study 
used very stringent criteria for base-calling and was applied to short read-lengths, but was 
still unable to reduce the error rate to less than an average of 2.0 x 10-4 errors/bp. This error 
frequency is at least as low as those reported with other algorithms. To improve sensitivity 
further, these base-calling improvements can be used together with Safe-SeqS. Travers et al. 
have described another powerful strategy for reducing errors 53. With this technology, both 
strands of each template molecule are sequenced redundantly after a number of preparative 
enzymatic steps. However, this approach can only be performed on a specific instrument. 
Moreover, for many clinical applications, there are relatively few template molecules in the 
initial sample and evaluation of nearly all of them is required to obtain the requisite 
sensitivity. The approach described here with exogenously introduced UIDs (Fig. 3) fulfills 
this requirement by coupling the UID assignment step with a subsequent amplification in 
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which few molecules are lost. Our endogenous UID approaches (Fig. 2 and Fig. S1) and the 
one described by Travers et al. are not well-suited for this purpose because of the inevitable 
losses of template molecules during the ligation and other preparative steps. 
 
How do we know that the mutations identified by conventional analyses in the current study 
represent artifacts rather than true mutations in the original templates? Strong evidence 
supporting this is provided by the observation that the mutation prevalence in all but one 
experiment was similar - 2.0 x 10-4 to 2.4 x 10-4 mutations/bp (Tables 1 and 2). The exception 
was the experiment with oligonucleotides synthesized from phosphoramidites, in which the 
error of the synthetic process was apparently higher than the error rate of conventional 
Illumina analysis when used with stringent base-calling criteria. In contrast, the mutation 
prevalence of Safe-SeqS varied much more, from 0.0 to 1.4 x 10-5 mutations/bp, depending 
on the template and experiment. Moreover, the mutation prevalence measured by Safe-SeqS 
in the most controlled experiment, in which polymerase fidelity was measured (Table 2A), 
was almost identical to that predicted from previous experiments in which polymerase 
fidelity was measured by biological assays. Our measurements of mutation prevalence in the 
DNA from normal cells are consistent with some previous experimental data. However, 
estimates of these prevalences vary widely and may depend on cell type and sequence 
analyzed (see SI text). We therefore cannot be certain that the few mutations revealed by 
Safe-SeqS represented errors occurring during the sequencing process rather than true 
mutations present in the original DNA templates. Potential sources of error in the Safe-SeqS 




Like all techniques, Safe-SeqS has limitations. For example, we have demonstrated that the 
exogenous UIDs strategy can be used to analyze a single amplicon in depth. This technology 
may not be applicable to situations wherein multiple amplicons must be analyzed from a 
sample containing a limited number of templates. Multiplexing in the UID assignment cycles 
(Fig. 3) may provide a solution to this challenge. A second limitation is that the efficiency of 
amplification in the UID assignment cycles is critical for the success of the method. Clinical 
samples can contain inhibitors that reduce the efficiency of this step. This problem can 
presumably be overcome by performing more than two cycles in the UID assignment PCR 
step (Fig. 3), though this would complicate the determination of the number of templates 
analyzed. The specificity of Safe-SeqS is currently limited by the fidelity of the polymerase 
used in the UID assignment PCR step, i.e., 8.8 x 10-7 mutations/bp in its current 
implementation with two cycles. Increasing the number of cycles in the UID assignment 
PCR step to five would decrease the overall specificity to ~2 x 10-6 mutations/bp. However, 
this specificity can be increased by requiring more than one super-mutant for mutation 
identification - the probability of introducing the same artifactual mutation twice or three 
times would be exceedingly low ([2 x 10-6] 2 or [2 x 10-6] 3, respectively). In sum, there are 
several simple ways to vary the Safe-SeqS procedure and analysis to realize the needs of 
specific experiments. 
 
Luria and Delbrück, in their classic paper in 1943, wrote that their "prediction cannot be 
verified directly, because what we observe, when we count the number of resistant bacteria 
in a culture, is not the number of mutations which have occurred but the number of 
resistant bacteria which have arisen by multiplication of those which mutated, the amount of 
multiplication depending on how far back the mutation occurred." The Safe-SeqS procedure 
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described here can verify such predictions because the number as well as the time of 
occurrence of each mutation can be estimated from the data, as noted in the experiments on 
polymerase fidelity. In addition to templates generated by polymerases in vitro, the same 
approach can be applied to DNA from bacteria, viruses, and mammalian cells. We therefore 
expect that this strategy will provide definitive answers to a variety of important biomedical 
questions. 
 
Materials and Methods 
Endogenous UIDs. To create endogenous UIDs, DNA was fragmented to an average size 
of ~200 bp by acoustic shearing (Covaris), then end-repaired, A-tailed, and ligated to Y-
shaped adapters according to standard Illumina protocols. DNA was captured 46 with a filter 
containing 2,594 nt corresponding to six cancer genes. For the inverse PCR experiments 
(Fig. S1), we ligated custom adapters (IDT, Table S4) instead of standard Y-shaped Illumina 
adapters to sheared cellular DNA. Inverse PCR was performed using KRAS forward and 
reverse primers (Table S4) and 1U of Phusion polymerase. The KRAS-specific primers both 
contained grafting sequences for hybridization to the Illumina GA IIx flow cell (Table S4). 
Further details are provided in SI Materials and Methods. 
 
Exogenous UIDs. Each strand of each template molecule was encoded with a 12 or 14 
base UID using two cycles of amplicon-specific PCR, as described in the text and Fig. 3. The 
amplicon-specific primers both contained universal tag sequences at their 5' ends for a later 
amplification step. The UIDs constituted 12 or 14 random nucleotide sequences appended 
to the 5' end of the forward amplicon-specific primers (Table S4). Following 2 cycles of PCR 
for UID assignment, the products were digested with a single strand DNA specific nuclease. 
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Primers complementary to the introduced universal tags and containing 3' terminal 
phosphorothioates (Table S4) were added and 25 additional cycles of PCR were performed. 
Further details are provided in SI Materials and Methods. 
 
Sequencing. Sequencing of all the libraries described above was performed using an 
Illumina GA IIx instrument as specified by the manufacturer. High quality reads were 
grouped into UID-families based on their endogenous or exogenous UIDs. Only UID-
families with two or more members were considered, as described in detail in the SI 
Materials and Methods. 
 
Supplementary Materials and Methods 
Endogenous UIDs. Genomic DNA from human pancreas or cultured lymphoblastoid cells 
was prepared using Qiagen kits.  The pancreas DNA was used for the capture experiment 
and the lymphoblastoid cells were used for the inverse PCR experiment.  DNA was 
quantified by optical absorbance and with qPCR.  DNA was fragmented to an average size 
of ~200 bp by acoustic shearing (Covaris), then end-repaired, A-tailed, and ligated to Y-
shaped adapters according to standard Illumina protocols.  The ends of each template 
molecule provide endogenous UIDs corresponding to their chromosomal positions.  After 
PCR-mediated amplification of the libraries with primer sequences within the adapters, 
DNA was captured 46 with a filter containing 2,594 nt corresponding to six cancer genes.  
After capture, 18 cycles of PCR were performed to ensure sufficient amounts of template 




For the inverse PCR experiments (Fig. S1), we ligated custom adapters (IDT, Table S4) 
instead of standard Y-shaped Illumina adapters to sheared cellular DNA.  These adapters 
retained the region complementary to the universal sequencing primer but lacked the 
grafting sequences required for hybridization to the Illumina GA IIx flow cell.  The ligated 
DNA was diluted into 96 wells and the DNA in each column of 8 wells was amplified with a 
unique forward primer containing one of 12 index sequences at its 5' end plus a standard 
reverse primer (Table S4).  Amplifications were performed using Phusion HotStart I (NEB) 
in 50 uL reactions containing 1X Phusion HF buffer, 0.5 mM dNTPs, 0.5 uM each forward 
and reverse primer (both 5’-phosphorylated), and 1U of Phusion polymerase.  The following 
cycling conditions were used: one cycle of 980C for 30s; and 16 cycles of 980C for 10s, 650C 
for 30s, and 720C for 30s. All 96 reactions were pooled and then purified using a Qiagen 
MinElute PCR Purification Kit (cat. no. 28004) and a QIAquick Gel Extraction kit (cat. no. 
28704).  To prepare the circular templates necessary for inverse PCR, DNA  was diluted to 
~1 ng/uL and ligated with T4 DNA Ligase (Enzymatics) for 30min at room temperature in 
a 600uL reaction containing 1X T4 DNA Ligation Buffer and 18,000U of T4 DNA Ligase.  
The ligation reaction was purified using a Qiagen MinElute kit.  Inverse PCR was performed 
using Phusion Hot Start I on 90 ng of circular template distributed in twelve 50 uL reactions, 
each containing 1X Phusion HF Buffer, 0.25mM dNTPs, 0.5uM each  of KRAS forward and 
reverse primers (Table S4) and 1U of Phusion polymerase.  The KRAS-specific primers both 
contained grafting sequences for hybridization to the Illumina GA IIx flow cell (Table S4).  
The following cycling conditions were used:  one cycle of 980C for 2 min; and 37 cycles of 
980C for 10s, 610C for 15s, and 720C for 10s.  The final purification was performed with a 
NucleoSpin Extract II kit (Macherey-Nagel) and eluted in 20uL NE Buffer.  The resulting 
DNA fragments contained UIDs composed of three sequences:  two endogenous ones, 
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represented by the two ends of the original sheared fragments plus the exogenous sequence 
introduced during the indexing amplification.  As 12 exogenous sequences were used, this 
increased the number of distinct UIDs by 12-fold over that obtained without exogenous 
UIDs.  This number could easily be increased by using a greater number of distinct primers. 
 
Exogenous UIDs. Genomic DNA from normal human colonic mucosae or blood 
lymphocytes was prepared using Qiagen kits.  The DNA from colonic mucosae was used for 
the experiments on CTNNB1 and mitochondrial DNA, while the lymphocyte DNA was 
used for the experiments on CTNNB1 and on polymerase fidelity.  DNA was quantified 
with Digital PCR 27 using primers that amplified single-copy genes from human cells 
(Analysis of Polymerase Fidelity and CTNNB1), qPCR (mitochondrial DNA), or by optical 
absorbance (oligonucleotides).  Each strand of each template molecule was encoded with a 
12 or 14 base UID using two cycles of amplicon-specific PCR, as described in the text and 
Fig. 3.  The amplicon-specific primers both contained universal tag sequences at their 5' ends 
for a later amplification step.  The UIDs constituted 12 or 14 random nucleotide sequences 
appended to the 5' end of the forward amplicon-specific primers (Table S4). These primers 
can generate 16.8 and 268 million distinct UIDs, respectively.  It is important that the 
number of distinct UIDs greatly exceed the number of original template molecules to 
minimize the probability that two different original templates acquired the same UID.  The 
UID assignment PCR cycles included Phusion Hot Start II (NEB) in a 45 uL reaction 
containing 1X Phusion HF buffer, 0.25mM dNTPs, 0.5 uM each forward (containing 12-14 
Ns) and reverse primers, and 2U of Phusion polymerase.  To keep the final template 
concentrations <1.5 ng/uL, multiple wells were used to create some libraries.  The following 
cycling conditions were employed: one cycle of 980C for 30s; and two cycles of 980C for 10 
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s, 610C for 120 s, and 720C for 10 s. To ensure complete removal of the first round primers, 
each well was digested with 60 U of a single strand DNA specific nuclease (Exonuclease-I; 
Enzymatics) at 370C for 1hr. After a 5 min heat-inactivation at 980C, primers complementary 
to the introduced universal tags (Table S4) were added to a final concentration of 0.5uM 
each.  These primers contained two terminal phosphorothioates to make them resistant to 
any residual Exonuclease-I activity.  They also contained 5’ grafting sequences necessary for 
hybridization to the Illumina GA IIx flow cell.  Finally, they contained an index sequence 
between the grafting sequence and the universal tag sequence. This index sequence enables 
the PCR products from multiple different individuals to be simultaneously analyzed in the 
same flow cell compartment of the sequencer.  The following cycling conditions were used 
for the subsequent 25 cycles of PCR:  980C for 10s and 720C for 15s.  No intermediate 
purification steps were performed in an effort to reduce the losses of template molecules.   
 
After the second round of amplification, wells were consolidated and purified using a Qiagen 
QIAquick PCR Purification Kit (cat. no. 28104) and eluted in 50 uL EB Buffer (Qiagen).  
Fragments of the expected size were purified after agarose (mtDNA libraries) or 
polyacrylamide (all other libraries) gel electrophoresis.  For agarose gel purification, the eight 
6-uL aliquots were loaded into wells of a 2% Size Select Gel (Invitrogen) and bands of the 
expected size were collected in EB Buffer as specified by the manufacturer.  For 
polyacrylamide gel purification, ten 5-uL aliquots were loaded into wells of a 10% TBE 
Polyacrylamide Gel (Invitrogen).  Gel slices containing the fragments of interest were 




Analysis of Phusion polymerase fidelity. Amplification of a fragment of human genomic 
DNA within the BMX (RefSeq Accession NM_203281.2) gene was first performed using 
the PCR conditions described above.  The template was diluted so that an average of one 
template molecule was present in every 10 wells of a 96-well PCR plate.  Fifty uL PCR 
reactions were then performed in 1X Phusion HF buffer, 0.25mM dNTPs, 0.5uM each 
forward and reverse primers (Table S4), and 2U of Phusion polymerase.  The cycling 
conditions were one cycle of 980C for 30s; and 19 cycles of 980C for 10 s, 610C for 120 s, 
and 720C for 10s. The primers were removed by digestion with 60 U of Exonuclease-I at 
370C for 1hr followed by a 5 min heat-inactivation at 980C.  No purification of the PCR 
product was performed, either before or after Exonuclease-I digestion.  The entire contents 
of each well were then used as templates for the exogenous UIDs strategy described above.   
 
Sequencing. Sequencing of all the libraries described above was performed using an 
Illumina GA IIx instrument as specified by the manufacturer.  The total length of the reads 
used for each experiment varied from 36 to 73 bases.  Base-calling and sequence alignment 
was performed with the Eland pipeline (Illumina).  Only high quality reads meeting the 
following criteria were used for subsequent analysis:  (i) the first 25 bases passed the standard 
Illumina chastity filter; (ii) every base in the read had a quality score ≥20; and (iii) ≤ 3 
mismatches to expected sequences. For the exogenous UID libraries, we additionally 
required the UIDs to have a quality score ≥30.  We noticed a relatively high frequency of 
errors at the ends of the reads in the endogenous UID libraries prepared with the standard 
Illumina protocol, presumably introduced during shearing or end-repair, so the first and last 




Safe-SeqS analysis. High quality reads were grouped into UID-families based on their 
endogenous or exogenous UIDs. Only UID-families with two or more members were 
considered.  Such UID-families included the vast majority (≥99%) of the sequencing reads.  
To ensure that the same data was used for both conventional and Safe-SeqS analysis, we also 
excluded UID-families containing only one member from conventional analysis.  
Furthermore, we only identified a base as "mutant" in conventional sequencing analysis if 
the same variant was identified in at least two members of at least one UID-family (i.e., two 
mutations) when comparing conventional analysis to that of Safe-SeqS with exogenous 
UIDs.  For comparison with Safe-SeqS with endogenous UIDs, we required at least two 
members of each of two UID-families (i.e., four mutations) to identify a position as 
"mutant" in conventional analysis.  With either endogenous or exogenous UIDs, a super-
mutant was defined as a UID-family in which ≥95% of members shared the identical 
mutation.  Thus, UID-families with <20 members had to be 100% identical at the mutant 
position, while a 5% combined replication and sequencing error rate was permitted in UID-
families with more members.  To determine polymerase fidelity using Safe-SeqS, and to 
compare the results with previous analyses of Phusion polymerase fidelity, it was necessary 
to realize that the previous analyses would only detect mutations present in both strands of 
the PCR products 14.  This would be equivalent to analyzing PCR products generated with 
one less cycle with Safe-SeqS, and the appropriate correction was made in Table 2A.  Unless 
otherwise specified, all values listed in the text and Tables represent means and standard 
deviations. 
 
Error-generating processes. Apparent mutations, defined as any base call that varies from 
the expected base at a defined position, can result from a variety of processes.   
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1. Mutations present in the template DNA.  For templates derived from normal human 
cells, these include mutations that were present in the zygote, occurred later during 
embryonic and adult development, or were present in a contaminant inadvertently 
introduced into the sample.  These mutations are expected to be present in both strands 
of the relevant templates.  If the mutation occurred only in the last cell-cycle of a cell 
whose DNA was used as template, the mutation would be present in only one strand of 
the template.  
2. Chemically-modified bases present in the templates.  It has been estimated that there are 
many thousands of oxidized bases present in every human cell 55.  When such DNA is 
amplified by Phusion polymerase, an apparent mutation in one strand may result.   
3. Errors introduced during the shearing process required to generate small fragments for 
sequencing.  Acoustic shearing generates short-lived, high temperatures that can damage 
DNA. 
4. Errors introduced during end-repair of the sheared fragments.  The source of these 
errors can be polymerase infidelity or through incorporation of chemically-modified 
bases in the dNTPs used for polymerization. 
5. Errors introduced by other enzymatic steps, particularly if the enzymes are impure and 
contaminated with nucleases, polymerases, or ligases. 
6. Errors introduced during PCR amplification to prepare the libraries for capturing or for 
inverse PCR. 
7. Errors during PCR after capturing or during inverse PCR amplification.  
8. Errors introduced into the UID assignment cycles of Safe-SeqS (Fig. 3).  
9. Errors introduced into the library amplification cycles of Safe-SeqS performed with 
exogenous UIDs.  Note that if UID assignment primers from process #8 are not 
completely removed, they could potentially amplify DNA fragments containing errors 
introduced during these cycles, creating a new super-mutant. 
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10. Errors introduced into the first bridge-PCR cycle on the Illumina flow cell.  If 
amplification is inefficient, an error introduced into the second bridge-PCR cycle could 
also result in a cluster containing a mutation in most of its component molecules. 
11. Errors in base-calling. 
 
Achieving accuracy with Safe-SeqS. With conventional sequencing-by-synthesis 
approaches, all the error-producing processes described above are relevant, resulting in a 
relatively high number of false-positive mutation calls (Tables 1 and 2).  Safe-SeqS minimizes 
the number of false-positive mutation calls in several ways.  Safe-SeqS with exogenous UIDs 
results in the fewest false-positive mutation calls because it requires the fewest enzymatic 
steps.  With exogenous UIDs, error-generating processes #3 to #7 are completely 
eliminated because these steps aren't performed.  Safe-SeqS with exogenous UIDs also 
drastically reduces errors resulting from error-generating processes #10 and #11 because of 
the way the data is analyzed. 
 
After Safe-SeqS with exogenous UIDs, the only false-positive errors remaining should be 
those introduced during the UID assignment PCR cycles (error-generating process #8) or 
residual UID-containing primers during the library amplification cycles (error-generating 
process #9).  The errors from error-generating process #8 can theoretically be eliminated by 
requiring at least two super-mutants to identify a position as "mutant.”  This requirement is 
reasonable because every pre-existing mutation in a double stranded DNA template should 
give rise to two super-mutants, one from each strand.  Furthermore, this requirement would 
eliminate error-generating process #2 (damaged bases in the original templates) because such 
bases, when copied, should give rise to only one super-mutant.  Finally, errors generated 
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during the library amplification cycles (process #9) will not be amplified by residual UID-
containing primers if those primers are completely removed, such as performed here with 
excess Exonuclease-I. 
 
With endogenous UIDs, the mistakes introduced by processes #10 and #11 are drastically 
reduced because of the way in which the data is analyzed (as with exogenous UIDs).  Errors 
introduced in processes #2 to #7 can be minimized by requiring that a mutation be 
observed in at least two UID-families, for the reasons stated in the paragraph above.  With 
this requirement, few false-positive mutations, in theory, should be identified. 
 
In practice, the situation is complicated by the fact that the various amplifications are not 
perfect, so every strand of every original template molecule is not recovered as a UID-family.  
This efficiency can vary from sample to sample, depending in part on the concentration of 
inhibitors present in clinical samples.  Moreover, with exogenous UIDs, a polymerase error 
during the library amplification step can create a new UID-family that wasn't represented in 
the UID assignment step.  If this error occurred in a mutant template, an additional, artificial 
super-mutant would be created.   
 
These factors can be managed by incorporating various additional criteria into the analyses.  
For example, one might require UID-families to contain more than two, five or ten 
members.  Another requirement could be that the exogenous UIDs of super-mutants not be 
related to any other UID in the library by a one-base difference.  This would eliminate 
artificial super-mutants generated during the library amplification steps (noted in above 
paragraph).  We routinely instituted this requirement in our Safe-SeqS analyses, but it made 
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little difference (<1%) in the number of super-mutants identified.  Specificity for mutations 
can be further increased by requiring more than one super-mutant to identify a position as 
"mutant,” as described above for endogenous UIDs.  By requiring multiple super-mutants, 
the specificity can be even further increased by requiring that each strand of the original 
double stranded template contain the mutation or, when libraries are amplified using 
multiple wells, that rare mutations share an introduced sequence that identifies the well in 
which the mutations were amplified.  Such decisions involve the usual trade-off between 
specificity and sensitivity.  In our experiments with exogenous UIDs (Table 2), we required 
only one super-mutant to identify a position as "mutant" and included all UID-families with 
more than one member.  As endogenous UIDs was associated with more error-generating 
processes than with exogenous UIDs, we required two super-mutants to identify a position 
as mutant in the experiments reported in Table 1 and also included all UID-families with 
more than one member. 
 
Mutation prevalences in normal human tissues. The experiments reported in Tables 1 
and 2, in which > 10,000 templates were assessed, show that mutations are present in the 
nuclear DNA of normal human cells at a frequency of 3.5 x 10-6 to 9.0 x 10-6 mutants/bp 
depending on the region analyzed.  It is impossible to determine whether this low level 
represents genuine mutations present in the original templates or the sum of genuine 
mutations plus artifactual mutations from the error-generating processes described above.  
Mutation prevalences in human cells have not been widely investigated, in part because they 
are so infrequent.  However, several clever techniques to identify rare mutants have been 
devised and can in principle be used for comparison.  Unfortunately, estimates of human 
mutation prevalences vary widely, ranging from as many as 10-5 mutants/bp to as many as 
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10-8 mutants/bp 15,16,20,56-59.  In several of these studies, the estimates are complicated by the 
lack of data on the nature of the actual mutations - they could in some cases be caused by 
losses of whole chromosomes, in others by missense mutations, and in others mainly by 
nonsense mutations or small insertions or deletions.  Additionally, these studies used various 
sources of normal cells and examined different genes, making direct comparisons difficult.  
Estimates of the prevalences and rates of mitochondrial DNA mutations similarly vary 22,60-65.  
It will be of interest in future work to analyze the same DNA templates and genes with 
various technologies to determine the basis for these different estimates. 
 
But let us assume that all of the mutations identified with Safe-SeqS represent genuine 
mutations present in the original DNA templates from normal cells.  What does this tell us 
about the number of generations though which these cells have proceeded since the 
organism was conceived?  There is a simple relationship between mutation rate and mutation 
prevalence:  the mutation prevalence equals the product of the mutation rate and the 
number of generations that the cell has gone through since conception.  The somatic 
mutation rate has been determined in previous studies to be ~ 10-9 mutants/bp/generation, 
though this estimate also varies from study to study for reasons related to those mentioned 
above with respect to mutation prevalence.  Combining this literature-derived estimate of 
mutation rate with our estimates of mutation prevalence suggests that the normal cells 
analyzed (lymphocytes, lymphoblastoid cell lines or colonic mucosae) had proceeded 
through 3,500 to 8,900 generations, representing cells dividing every 3 to 7 days for the 




Computer simulation of polymerase-introduced errors. The timing of mutations 
introduced by polymerases greatly alters the final number of mutations observed 1.  For 
example, two mutations would differ in prevalence by ~64-fold if introduced 6 cycles apart 
(26).  Because polymerases introduce mutations in a stochastic manner, a simple Monte Carlo 
method was employed for the simulations.  In these simulations, we used the manufacturer's 
estimate of the Phusion polymerase error rate with an appropriate adjustment for ability of 
Safe-SeqS to detect mutations in only one strand 14.  Note that errors introduced in cycle 19, 
as well as in the two UID assignment cycles, would result in changes in only one strand of 
the duplex - i.e., result in one super-mutant rather than two.  In each experiment, we 
assumed that there was a constant efficiency of amplification given by the total number of 
templates obtained at the end of the experiment (i.e., if the number of UID-families was N, 
then we assumed that the number of templates increased by a factor of N/219 in each cycle).  
One-thousand simulations were performed for each of seven experiments, and the results 
reported in Table S2. 
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Table 2-1. Safe-SeqS with Endogenous UIDs 
Conventional Analysis Capture Inverse PCR 
High quality bp 106,958,863 1,041,346,645 
Mean high quality bp read depth 38,620× 2,085,600× 
Mutations identified 25,563 234,352 
Mutations/bp 2.4E-04 2.3E-04 
   Safe-SeqS Analysis 
  High quality bp 106,958,863 1,041,346,645 
Mean high quality bp read depth 38,620× 2,085,600× 
UID-families 69,505 1,057 
Average # of members/UID-family  40 21,688 
Median # of members/UID-family 19 4 
Super-mutants identified 8 0 




Table 2-2.  Safe-SeqS with Exogenous UIDs 




Conventional analysis of 7 replicates 
  
High quality bp 996,855,791 64,030,757 
Total mutations identified 198,638 22,515 
Mutations/bp 2.0E-04 1.7E-05 
Calculated Phusion Error Rate 
(errors/bp/cycle) 
9.1E-06 7.7E-07 
   
Safe-SeqS analysis of 7 replicates 
  
High quality bp 996,855,791 64,030,757 
UID-families 624,678 421,274 
Members/UID-family 107 122 
Total super-mutants identified 197 143 
Super-mutants/bp   9.9E-06 2.3E-06 
Calculated Phusion Error Rate 
(errors/bp/cycle) 
4.5E-07 1.0E-07 




Table 2-2.  Continued 
 
B.  CTNNB1 mutations in DNA from normal human cells 
 
Conventional analysis of 3 individuals 
  
High quality bp 559,334,774 66,600,749 
Total mutations identified 118,488 11,357 
Mutations/bp 2.1E-04 1.6E-05 
   
Safe-SeqS analysis of 3 individuals 
  
High quality bp 559,334,774 66,600,749 
UID-families 374,553 263,105 
Members/UID-family 68 38 
Total super-mutants identified 99 78 
Super-mutants/bp   9.0E-06 3.1E-06 
   
C.  Mitochondrial mutations in DNA from normal human cells 
Conventional analysis of 7 individuals 
  
High quality bp 147,673,456 54,308,546 
Total mutations identified 30,599 12,970 
Mutations/bp 2.1E-04 9.4E-05 
   
Safe-SeqS analysis of 7 individuals 
  
High quality bp 147,673,456 54,308,546 
UID-families 515,600 89,985 
Members/UID-family 15 6 
Total super-mutants identified 135 61 
Super-mutants/bp   1.4E-05 6.8E-06 
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Table 2-S2. Continued 
 
*See Supplementary Information for details of the simulations 
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Table 2-S4. Continued 
39 
 
Figure 2-1. Essential Elements of Safe-SeqS. 
In the first step, each fragment to be analyzed is assigned a unique identification (UID) 
DNA sequence (green or blue bars). In the second step, the uniquely tagged fragments are 
amplified, producing UID-families, each member of which has the same UID. A super-








Figure 2-2. Safe-SeqS with Endogenous UIDs Plus Capture. 
The sequences of the ends of each fragment produced by random shearing (variously 
colored bars) serve as the unique identifiers (UIDs). These fragments are ligated to adapters 
(yellow and orange bars) so they can subsequently be amplified by PCR. One uniquely 
identifiable fragment is produced from each strand of the double-stranded template; only 
one strand is shown. Fragments of interest are captured on a solid phase containing 
oligonucleotides complementary to the sequences of interest. Following PCR amplification 
to produce UID-families with primers containing 5’ “grafting” sequences (black and red 
bars), sequencing is performed and super-mutants are defined as in Fig. 1.  
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Figure 2-3. Safe-SeqS with Exogenous UIDs. 
DNA (sheared or unsheared) is amplified with a set of gene-specific primers. One of the 
primers has a random DNA sequence (e.g., a set of 14 N’s) that forms the unique identifier 
(UID; variously colored bars), located 5’ to its gene-specific sequence, and both have 
sequences that permit universal amplification in the next step (yellow and orange bars). Two 
UID assignment cycles produce two fragments - each with a different UID - from each 
double-stranded template molecule, as shown. Subsequent PCR with universal primers, 
which also contain “grafting” sequences (black and red bars), produces UID-families which 
are directly sequenced. Super-mutants are defined as in the legend to Fig. 1. 
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Figure 2-4. Single Base Substitutions Identified by Conventional and Safe-SeqS 
Analysis. 
The exogenous UID strategy depicted in Fig. 3 was used to produce PCR fragments from 
the CTNNB1 gene of three normal, unrelated individuals. Each position represents one of 
87 possible single base substitutions (3 possible substitutions/base x 29 bases analyzed). 
These fragments were sequenced on an Illumina GA IIx instrument and analyzed in the 
conventional manner (A) or with Safe-SeqS (B). Safe-SeqS results are displayed on the same 
scale as conventional analysis for direct comparison; the inset is a magnified view. Note that 
most of the variants identified by conventional analysis are likely to represent sequencing 





Figure 2-S1. Safe-SeqS with endogenous UIDs plus inverse PCR. 
The sequence of the ends of each fragment produced by random shearing serve as unique 
identifiers (UIDs; variously colored bars).  These fragments are ligated to adapters (yellow 
and orange bars) as in a standard Illumina library preparation.  One uniquely tagged 
fragment is produced from each strand of the double-stranded template; only one strand is 
shown.  Following circularization with a ligase, inverse PCR is performed with gene-specific 
primers that also contain 5’ “grafting” sequences (black and red bars).  This PCR produces 
UID-families which are directly sequenced.  Super-mutants are defined as in Fig. 1.  
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Figure 2-S2. Single base substitutions position vs. error frequency in oligonucleotides 
synthesized with phosphoramidites and Phusion 
A representative portion of the same 31-base DNA fragment synthesized with 
phosphoramidites (A) or Phusion polymerase (B) was analyzed by Safe-SeqS.  The means 
and standard deviations for seven independent experiments of each type are plotted.  There 
was an average of 1,721 ± 383 and 196 ± 143 SBS super-mutants identified in the 
phosphoramidite-synthesized and Phusion-generated fragments, respectively.  The y-axis 
indicates the fraction of the total errors at the indicated position.  Note that the errors in the 
phosphoramidite-synthesized DNA fragment were consistent among the seven replicates, as 
would be expected if the errors were systematically introduced during the synthesis itself.  In 
contrast, the errors in the Phusion-generated fragments appeared to be heterogeneous 




Figure 2-S3. UID-family member distribution. 
The exogenous UID strategy depicted in Fig. 3 was used to produce PCR fragments from a 
region of CTNNB1 from three normal, unrelated individuals (Table 2B); a representative 
example of the UID-families with ≤ 300 members (99% of total UID-families)  generated 
from one individual is shown.  The y-axis indicates the number of different UID-families 





Chapter 3: Evaluation of DNA From the 




Since the introduction of the Papanicolaou test, the incidence and mortality of cervical 
cancer in screened populations has been reduced by more than 75% 66,67. In contrast, deaths 
from ovarian and endometrial cancers have not substantially decreased during that same time 
period.  As a result, more than 69,000 women in the U.S. are estimated to be diagnosed with 
ovarian or endometrial cancer in 2012 68.  Although endometrial cancer is more common 
than ovarian cancer, the latter is more lethal.  In the U.S., approximately 15,000 and 8,000 
women are expected to die each year from ovarian and endometrial cancers, respectively 68.  
World-wide, over 200,000 deaths from these tumors are expected this year alone 69,70. 
 
In an effort to replicate the success of cervical cancer screening, several approaches for the 
early detection of endometrial and ovarian cancers have been proposed.  For endometrial 
cancers, efforts have focused on cytology and transvaginal ultrasound (TVS).  Cytology can 
indeed indicate a neoplasm within the uterus in some cases, albeit with low specificity 71.  
TVS is used to measure the thickness of the endometrium, because it is known that 
endometria harboring a cancer are thicker than normal endometria 72.  As with cytology, 
screening measurement of the endometrial thickness with TVS lacks sufficient specificity 
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because benign lesions, such as polyps, can also result in a thickened endometrium.  
Accordingly, neither cytology nor TVS fulfills the requirements for a screening test 71,73. 
 
Even greater efforts have been made to develop a screening test for ovarian cancer, 
including the assessment of serum CA-125 levels in conjunction with TVS.  CA-125 is a high 
molecular weight transmembrane glycoprotein expressed by coelomic- and Müllerian-
derived epithelia that is elevated in a subset of ovarian cancer patients with early stage 
disease and in some cases prior to clinical diagnosis 74,75.  The specificity of CA-125 is limited 
by the fact that it is also elevated in a variety of benign conditions, such as pelvic 
inflammatory disease, endometriosis and ovarian cysts 76.  Although TVS can visualize the 
ovary, it can only detect large tumors and cannot definitively distinguish benign from 
malignant tumors.  Several clinical screening trials with serum CA-125 and TVS have been 
conducted but none have shown a survival benefit.  In fact, some have shown an increase in 
morbidity compared to controls because false positive tests elicit further evaluation by 
laparoscopy or exploratory laparotomy 77-79. 
 
Accordingly, the U.S. Preventative Services Task Force, the American Cancer Society, the 
American Congress of Obstetricians and Gynecologists, and the National Comprehensive 
Cancer Network do not recommend routine screening for endometrial or ovarian cancers in 
the general population.  In fact, these organizations warn that “the potential harms outweigh 
the potential benefits” 80-83.  An exception to this recommendation has been made for 
patients with a hereditary predisposition to ovarian cancer, such as those with germline 
mutations in a BRCA gene or those with Lynch syndrome.  It is recommended that BRCA 
mutation carriers be screened every 6 months with TVS and serum CA-125, starting at a 
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relatively early age.  Screening guidelines for women with Lynch syndrome include annual 
endometrial sampling and TVS beginning between age 30 and 35 82,84. 
 
The mortality associated with undetected gynecologic malignancies has made the 
development of an effective screening tool a high priority.  An important observation that 
inspired the current study is that asymptomatic women occasionally present with abnormal 
glandular cells (AGCs) detected in a cytology specimen as part of their routine cervical 
cancer screening procedure.  Although AGCs are associated with premalignant or malignant 
disease in some cases 85-89, it is often difficult to distinguish the AGCs arising from 
endocervical, endometrial, or ovarian cancer from one another and from more benign 
conditions. 
 
We reasoned that more sophisticated molecular methods might be able to detect the 
presence of cancer cells in endocervical specimens at higher sensitivities and specificities 
than possible with conventional methods.  In particular, we hypothesized that somatic 
mutations characteristic of endometrial and ovarian cancers would be found in the DNA 
purified from routine liquid-based Pap specimens (henceforth denoted as "Pap specimens"; 
Fig. 1).  Unlike cytologically abnormal cells, such oncogenic DNA mutations are specific, 
clonal markers of neoplasia that should be absent in non-neoplastic cells.  The experiments 
described here were carried out to test this hypothesis. 
 
Results 
There were four components to this study: I. Establishing the somatic mutations typically 
present in endometrial and ovarian cancers; II. Identifying at least one mutation in each 
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tumor from 46 patients with these cancers; III. Determining whether the mutations 
identified in these tumors could also be detected in Pap specimens from the same patients; 
and IV. Developing a technology that could directly assess cells from Pap specimens for 
mutations commonly found in endometrial or ovarian cancers. 
 
Prevalence of somatically mutated genes in endometrial and ovarian cancers. There 
are five major histopathologic subtypes of epithelial ovarian cancers (Table 1).  The most 
prevalent subtype is high-grade serous (60% of total), followed by endometrioid (15%), clear 
cell (10%), low-grade serous carcinoma (8%), mucinous (2%), and transitional cell carcinoma 
(2%) 90-92.  The majority of these cases were found at an advanced stage and the combined 5-
year survival 68,93 for these malignancies is approximately 27% (Table 1).  Genome-wide 
studies 94-96 have identified commonly mutated genes among the most prevalent ovarian 
cancer subtypes (Table 2).   
 
Such comprehensive studies have not yet been reported for the endometrioid and mucinous 
subtypes, which collectively represent ~20% of ovarian cancer cases (Table 1).  However, 
commonly mutated genes in the endometrioid and mucinous subtypes have been reported 97.  
In aggregate, the most commonly mutated gene in epithelial ovarian cancers was TP53, 
which was mutated in 69% of these cancers (Table 2).  Other highly mutated genes included 
ARID1A, BRAF, CTNNB1, KRAS, PIK3CA, and PPP2R1A (Table 2). 
 
Among endometrial cancers, the endometrioid subtype is by far the most common, 
representing 85% of the total (Table 1).  Because cancers of this subtype are so frequent and 
have not been analyzed at a genome-wide level, we evaluated them through whole-exome 
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sequencing.  The DNA purified from 22 sporadic endometrioid carcinomas, as well as from 
matched non-neoplastic tissues, was used to generate 44 libraries suitable for massively 
parallel sequencing.  The clinical aspects of the patients and histopathologic features of the 
tumors are listed in table S1.  Though the examination of 22 cancers cannot provide a 
comprehensive genome landscape of a tumor type, it is adequate for diagnostic purposes, as 
these only require the identification of the most frequently mutated genes. 
 
Among the 44 libraries, the average coverage of each base in the targeted region was 149.1 
with 88.4% of targeted bases represented by at least ten reads.  After applying stringent 
criteria for the identification of somatic mutations (as described in Materials and Methods), 
the sequencing data clearly demarcated the tumors into two groups: ten cancers (termed the 
N Group, for non-highly mutated) harbored <100 somatic mutations per tumor (median 32, 
range 7 to 50), and 12 cancers (termed the H Group, for highly mutated) harbored >100 
somatic mutations per tumor (median 674, range 164 to 4,629) (table S1).   
 
The high number of mutations in the Group H tumors was consistent with a deficiency in 
DNA repair.  Eight of the 12 Group H tumors had microsatellite instability (MSI-H, table 
S1), supporting this conjecture.  Moreover, six of the Group H tumors contained somatic 
mutations in the mismatch repair genes MSH2 or MSH6, but none of the Group N cancers 
contained mutations in mismatch repair genes (table S2).  Mismatch repair deficiency is 
known to be common among endometrial cancers and these tumors occur in 19-71% of 
women with inherited mutations of mismatch repair genes (i.e., patients with Hereditary 




A complete list of the 12,795 somatic mutations identified in the 22 cancers is provided in 
table S2.  The most commonly mutated genes included the PI3K pathway genes PTEN and 
PIK3CA 99, the APC pathway genes APC and CTNNB1, the fibroblast growth factor 
receptor FGFR2, the adapter protein FBXW7, and the chromatin-modifying genes ARID1A 
and MLL2 (Table 2).  Genes in these pathways were mutated in both Group N and H 
tumors. Our results are consistent with prior studies of endometrioid endometrial cancer 
that had evaluated small numbers of genes, though mutations in FBXW7, MLL2 and APC 
had not been appreciated to occur as frequently as we found them.  It was also interesting 
that fewTP53 mutations (5%) were found in these endometrial cancers (Table 2 and table 
S2), a finding also consistent with prior studies. 
 
Papillary serous carcinomas of the endometrium account for 10-15% of endometrial cancers, 
and a recent genome-wide sequencing study of this tumor subtype has been published 100.  
The most common mutations in this subtype are listed in Table 2.  The least common 
subtype of endometrial cancers is clear cell carcinoma 101, which occur in <5% of cases.  
Genes reported to be mutated in these cancers were garnered from the literature (Table 2). 
 
Identification of mutations in tumor tissues. We acquired tumors from 46 cancer 
patients for whom Pap specimens were available.  These included 24 patients with 
endometrial cancers and 22 with ovarian cancers; their clinical, demographic and 
histopathologic features are listed in table S3. 
 
Somatic mutations in the 46 tumors were identified through whole-exome sequencing as 
described above (table S2) or through targeted sequencing of genes frequently mutated in the 
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most common subtypes of ovarian or endometrial cancer (Table 2).  Enrichment for these 
genes was achieved with a custom solid phase capture assay comprised of oligonucleotides 
(“capture probes”) complementary to a panel of gene regions of interest.  For the 
oncogenes, we only targeted their commonly mutated exons, whereas we targeted the entire 
coding regions of the tumor suppressor genes.   
 
DNA sequencing libraries were generated from tumors and their matched non-neoplastic 
tissues, then captured with the assay described above.  After amplification by PCR, four to 
eight captured DNA libraries were sequenced per lane on an Illumina GA IIx instrument.  
In each of the 46 cases, we identified at least one somatic mutation (table S3) that was 
confirmed by an independent assay, as described below. 
 
Identification of somatic mutations in Pap specimens. In the liquid-based Pap smear 
technique in routine use today, the clinician inserts a small brush into the endocervical canal 
during a pelvic exam and rotates the brush so that it dislodges and adheres to loosely 
attached cells or cell fragments. The brush is then placed in a vial of fixative solution (e.g., 
ThinPrep).  Some of the liquid from the vial is used to prepare a slide for cytological analysis 
or for purification of HPV DNA.  In our study, an aliquot of the DNA purified from the 
liquid was assessed for the presence of DNA from the cancers of the 46 patients described 
above.  Preliminary studies showed that the fixed cells or cell fragments in the liquid 
contained >95% of the total DNA in the vial.  We therefore purified DNA from the cell 
pellets when the amount of available liquid was greater than 3 mL (as occurs with some 
liquid-based Pap smear kits) and, for convenience, purified DNA from both the liquid and 
cells when smaller amounts of liquid were in the kit.  In all cases, the purified DNA was of 
57 
 
relatively high molecular weight (95% >5 kb).  The average amount of DNA recovered from 
the 46 Pap specimens was 9.9 ± 14.8 μg (table S3). 
 
We anticipated that, if present at all, the amount of DNA derived from neoplastic cells in the 
Pap smear fluid would be relatively small compared to the DNA derived from normal cells 
brushed from the endocervical canal.  This necessitated the use of an analytic technique that 
could reliably identify a rare population of mutant alleles among a great excess of wild-type 
alleles.  A modification of one of the Safe-SeqS (Safe-Sequencing System) procedures 
described in 11, in which DNA templates are amplified with modified gene-specific primers, 
was designed for this purpose (Fig. 2). 
 
In brief, a limited number of PCR cycles was performed with a set of gene-specific primers. 
One of the primers contained 14 degenerate “N” bases (i.e., equal probability of being an 
“A”, “C”, “G”, or “T”) located 5' to its gene-specific sequence, and both primers contained 
sequences that permitted universal amplification in the next step.  The 14 “N” bases formed 
unique identifiers (UID) for each original template molecule.  Subsequent PCR products 
generated with universal primers were purified and sequenced.  If a mutation preexisted in a 
template molecule, that mutation should be present in every daughter molecule containing 
that UID, and such mutations are called  “supermutants” 11.  Mutations not occurring in the 
original templates, such as those occurring during the amplification steps or through errors 
in base calling, should not give rise to supermutants.  The Safe-SeqS approach used here is 
capable of detecting 1 mutant template among 5,000 to 1,000,000 wild-type templates, 




We designed Safe-SeqS primers (table S4) to detect at least one mutation from each of the 46 
patients described in table S3.  In the 24 Pap specimens from patients with endometrial 
cancers, the mutation present in the tumor was identified in every case (100%).  The median 
fraction of mutant alleles was 3%, and ranged from 0.01% to 80% (Fig. 3 and table S3).  
Amplifications of DNA from non-neoplastic tissues were used as negative controls in these 
experiments to define the detection limits of each queried mutation.  In all cases, the fraction 
of mutant alleles was significantly different from the background mutation levels determined 
from the negative controls (P <0.001, binomial test).  There was no obvious correlation 
between the fraction of mutant alleles and the histopathologic subtype or the stage of the 
cancer (Fig. 3 and table S3).   
 
In endometrial cancer cases PAP 041 and PAP 083, two mutations found in the tumor DNA 
were evaluated in the Pap specimens (table S3).  In both cases, the mutations were identified 
in DNA from the Pap smear (table S3).  Moreover, the ratios between the mutant allele 
fractions of the two mutations in the Pap specimens were correlated with those of the 
corresponding tumor samples.  For example, in the Pap smear of case PAP 083 the mutant 
allele fractions for the CTNNB1 and PIK3CA mutations were 0.143% and 0.064%, 
respectively - a ratio of 2.2 (0.14% to 0.064%).  In the primary tumor from PAP 083, the 
corresponding ratio was 2.0 (79.5% to 39.5%). 
 
Similar analysis of Pap smear DNA from ovarian cancer patients revealed detectable 
mutations in nine of the 22 patients (41%).  The fraction of mutant alleles was smaller than 
in endometrial cancers (median of 0.49%, range 0.021% to 5.9%; see Fig. 3 and table S3). All 
but one of the cases with detectable mutations were epithelial tumors; the exception was a 
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dysgerminoma, a malignant germ cell tumor of the ovary (table S3).  As with endometrial 
cancers, there was no statistically significant correlation between the fraction of mutant 
alleles and histopathologic criteria.  However, most ovarian cancers are detected only at an 
advanced stage, and this was reflected in the patients available in our cohort. 
 
A genetic test for screening purposes. The results described above document that mutant 
DNA molecules from most endometrial cancers and some ovarian cancers can be found in 
routinely collected Pap specimens.  However, in all 46 cases depicted in Fig. 3, a specific 
mutation was known to occur in the tumor, and an assay was subsequently designed to 
determine whether that mutation was also present in the corresponding Pap specimens.  In a 
screening setting, the presence and genotype of tumors would obviously not be known prior 
to evaluation by such a test.  We therefore designed a prototype test based on Safe-SeqS that 
could assess several genes and could be used in a screening setting (Fig. 2).   
This multiplexed approach included 50 primer pairs that amplified segments of 241 to 296 
bp containing frequently mutated regions of DNA. The regions to be amplified were chosen 
from the results described in Section I and included exons from APC, AKT1, BRAF, 
CTNNB1, EGFR, FBXW7, KRAS, NRAS, PIK3CA, PPP2R1A, PTEN, and TP53.  In 
control experiments, 46 of the 50 amplicons were shown to provide information on a 
minimum of 2,500 templates as the number of templates sequenced can be determined 
directly from sequencing with Safe-SeqS (Fig. 2). Given the accuracy of Safe-SeqS, this 
number was adequate to comfortably detect mutations existing in >0.1% of template 
molecules 11.  The regions covered by these 46 amplicons (table S5), encompassing 10,257 
bp, were predicted to be able to detect at least one mutation in >90% of either endometrial 




This test was applied to Pap specimens of 14 cases - twelve endometrial and two ovarian - as 
well as 14 Pap specimens collected from normal women.  The two ovarian cancers used 
were stage IA and IV. The endometrial cancers were stage I (n=10), stage II (n=1), and stage 
IV (n=1).  The 14 cancer cases were arbitrarily chosen from those which had mutant allele 
fractions >0.1% (table S3) and therefore above the detection limit of the multiplexed assay.  
In all 14 Pap specimens from women with cancer, the mutation expected to be present (table 
S3) was identified (Fig. 4 and table S6). The fraction of mutant alleles in the multiplexed test 
was similar to that observed in the original analysis of the same samples where only one 
Safe-SeqS primer pair per amplicon was employed (table S3 and table S6).  Importantly, no 
mutations were detected in the 14 Pap specimens from women without cancer (Fig. 4). 
 
Discussion 
Georgios Papanicolaou published his seminal work, entitled “Diagnosis of Uterine Cancer 
by the Vaginal Smear,” in 1943 102.  At that time, he suggested that endocervical sampling 
could in theory be used to detect not only cervical cancers but also other cancers arising in 
the female reproductive tract, including endometrial carcinomas.  The research reported here 
moves us much closer to that goal.  In honor of Papanicolaou’s pioneering contribution to 
the field of early cancer detection, we have named the approach described herein as the 
“PapGene" test. 
 
One of the most important developments over the last several years is the recognition that 
all human cancers are the result of mutations in a limited set of genes and an even more 
limited set of pathways through which these genes act 103.  The whole-exome sequencing 
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data we present, combined with previous genome-wide studies, provide a striking example of 
the common genetic features of cancer (Table 2).  Through the analysis of particular regions 
of only 12 genes (table S5), we could detect at least one driver mutation in the majority of 
nine different gynecologic cancers (Table 1).  Though several of these 12 genes were tumor 
suppressors, and therefore difficult to therapeutically target, knowledge of their mutational 
patterns provides actionable opportunities for cancer diagnostics. 
 
The most important finding in this paper is that diagnostically useful amounts of cells or cell 
fragments from endometrial and ovarian cancers are present in the cervix and can be 
detected through molecular genetic approaches.  Detection of malignant cells from 
endometrial and ovarian carcinomas in cervical cytology specimens is relatively uncommon.  
Microscopic examination cannot always distinguish them from one another, from cervical 
carcinomas, or from more benign conditions. In our study, 100% of endometrial cancers 
(n=24), even those of low grade, and 41% of ovarian cancers (n=22), shed cells into the 
cervix that could be detected from specimens collected as part of routine Pap specimens.  
This finding, in conjunction with technical advances allowing the reliable detection of 
mutations present in only a very small fraction of DNA templates, provided the foundation 
for the PapGene test. 
 
This study provides proof-of-principle for endocervical DNA testing for gynecologic 
cancers, but there are important limitations that need to be addressed before this approach 
can be used in the clinic. The test, even in its current format, appears to be promising as a 
screening tool for endometrial cancer, as the data in Fig. 3 show that even the lowest stage 
endometrial cancers could be detected through the analysis of DNA in Pap specimens.  
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However, only 41% of ovarian cancers could be detected in Pap specimens, even when the 
mutations in their tumors were known.  In eight of the nine Pap specimens from ovarian 
cancer patients that contained detectable mutations, the mutant allele fractions were >0.1% 
and therefore within the range currently detectable by PapGene testing (table S3).  Further 
improvements in the technology could increase the technical sensitivity of the PapGene test 
and allow it to detect more ovarian cancers.  One improvement would involve an increase in 
the number of potential gene targets assessed by the PapGene test.  Development of an 
improved method of collection may be more important to improve sensitivity.  The current 
liquid specimen is designed for the detection of cervical cancer and as such employs a brush 
that collects cells from the ectocervix and only minimally penetrates the endocervical canal.  
A small cannula introduced into the endometrial cavity, similar to the Pipelle endometrial 
biopsy instrument, could theoretically be used to obtain a more highly enriched sample of 
cells coming from the endometrium, fallopian tube and ovary 104. Specificity must also be 
addressed further in the future.  Although a greater number of healthy controls need to be 
evaluated, it is encouraging that none evaluated so far had detectable mutations.  This result 
is consistent with the idea that mutation-based screening should be exquisitely specific 
because mutations should not be found in normal cells.  As noted in the Introduction, 
specificity is a major limitation of current screening tests in general, and for ovarian cancer in 
particular. 
 
The quantitative nature of the PapGene test also opens the possibility of using it to monitor 
the response to hormonal agents (e.g., progestins) when treating young women with low risk 
endometrial cancers.  Some of these women choose to preserve  fertility, undergoing medical 
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therapy rather than hysterectomy 105, and PapGene testing could be performed at regular 
intervals to monitor them for local cancer recurrence or progression.  
 
Even if the tumors detected were advanced, detection of pre-symptomatic ovarian cancers 
could also be of benefit.  It has been demonstrated that one of the most important 
prognostic indicators for ovarian cancer is the amount of residual disease after surgical 
debulking.  Initially, debulking was considered optimal if the residual tumor was less than 2 
cm.  Subsequently, the threshold was reduced to 1 cm, and now surgeons attempt to remove 
any visible tumor.  With each improvement in surgical debulking, survival has lengthened 106.  
The earlier these advanced stage ovarian cancer are diagnosed, the lower the overall tumor 
burden and the better the chance at optimal debulking.  Furthermore, it is possible that a 
small volume of tumor is likely to be more sensitive to cytotoxic chemotherapy than the 
large, bulky disease typical of symptomatic high-grade serous carcinoma. 
An essential aspect of any screening approach is that it should be relatively inexpensive and 
easily incorporated into standard medical practice.  Evaluation of HPV DNA is already part 
of routine Pap smear testing because HPV analysis increases the test's sensitivity 107,108.  The 
DNA purification component of the PapGene test is identical to that used for HPV, so this 
component is clearly feasible.  The preparation of DNA, multiplex amplification, and 
sequencing constituting the PapGene test can be performed at a cost comparable to a 
routine HPV test in the U.S. today.  Note that the increased sensitivity provided by the Safe-
SeqS component of the PapGene test can be implemented on any next-generation 
sequencing instrument, not just those used in this study.  With the reduction in the cost of 





There are millions of Pap smear tests performed annually in the U.S.  Could PapGene 
testing be performed on such a large number of specimens?  We believe so, because the 
entire DNA purification and amplification process can be automated, just as it is for HPV 
testing.  Though it may now seem unrealistic to have millions of these sophisticated 
sequence-based tests performed every year, it would undoubtedly have seemed unrealistic to 
have widespread, conventional Pap smear testing performed when Papanicolaou published 
his original paper in 1943 102. Even today, when many cervical cytology specimens are 
screened with automated technologies, at least two to eight percent of samples require 
evaluation by a skilled cytopathologist 109.  In contrast, the analysis of PapGene testing is 
done completely in silico and the read-out of the test is objective and quantitative.  
 
In sum, these data highlight the high specificity of mutation-based diagnostics paired with 
the sensitivity of interrogating local-regional bodily secretions for tumor-derived DNA.  
PapGene testing has the capacity to increase the utility of conventional cytology screening 
through the unambiguous detection of DNA from endometrial and ovarian carcinomas, and 
lays the foundation for a new generation of screening tests.   
 
Materials and Methods 
Patient Samples. All samples for this study were obtained according to protocols approved 
by the Institutional Review Boards of The Johns Hopkins Medical Institutions (Baltimore, 
MD), Memorial Sloan Kettering Cancer Center (New York, NY), University of Sao Paulo 
(Sao Paulo, Brazil), and ILSbio, LLC (Chestertown, MD).  Demographic, clinical and 
pathologic staging data were collected for each case.  All histopathology was centrally re-
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reviewed by board-certified pathologists.  Staging was based on 2009 FIGO criteria 110.  
Purified DNA from tumor and normal tissue as well as liquid-based Pap smears were 
quantified in all cases with qPCR, employing the primers and conditions previously 
described 111.  Unless otherwise indicated, all patient-related values are reported as mean ± 1 
standard deviation.  Additional details are provided in Supplementary Materials and 
Methods. 
 
Microsatellite instability testing. Tumor samples were designated as follows: MSI-high if 
two or more mononucleotides varied in length compared to the germline DNA; MSI-low if 
only one locus varied; and microsatellite stable (MSS) if there was no variation compared to 
the germline.  Pentanucleotide loci confirmed identity in all cases.  Additional details are 
provided in Supplementary Materials and Methods. 
Preparation and sequencing of captured Illumina DNA libraries. Preparation of 
Illumina genomic DNA libraries and selection for exomic DNA were performed according 
to the manufacturer’s recommendations.  Exomic capture was performed with the 
SureSelect Human Exome Kit V 4.0 (Agilent), while the custom solid phase capture assay 
was performed by modifications of previously described methods 112,113.  Paired-end 
sequencing with an Illumina GA IIx Genome Analyzer provided 2 x 75 base reads from 
each fragment.  Known polymorphisms recorded in dbSNP Build 130 114 in the sequence 
tags that passed filtering were removed from the analysis.  Identification of high confidence 
mutations was performed as described previously 95.  Additional details are provided in 




Assessment of low-frequency mutations. Primers were designed as described previously 
11 with Primer3 115.  Sixty-six ng of templates were prepared for sequencing as described 
previously 11, with modifications that facilitated the amplification of multiple gene regions in 
a single well of a 96-well PCR plate.  With the primers described in table S4, 66 ng of 
templates were amplified in two rounds of PCR (Fig. 2) for the single amplicon assays.  The 
multiplexed assays were performed in similar fashion utilizing six independent amplifications 
– each containing 66 ng of DNA (i.e., ~400 ng total) – per sample with the primers 
described in table S5.  High quality sequence reads were analyzed as previously described 11 
by utilizing the quality scores generated by default, which indicate the probability that an 
individual base call was made in error 116.  The template-specific portion of the reads was 
matched to a reference sequence set with a custom script (available from the authors upon 
request).  Additional details are provided in Supplementary Materials and Methods. 
 
Supplementary Materials and Methods 
Patient Samples. All samples for this study were obtained according to protocols approved 
by the Institutional Review Boards of The Johns Hopkins Medical Institutions (Baltimore, 
MD), Memorial Sloan Kettering Cancer Center (New York, NY), University of Sao Paulo 
(Sao Paulo, Brazil), and ILSbio, LLC (Chestertown, MD).  Demographic, clinical and 
pathologic staging data were collected for each case.  All histopathology was centrally re-
reviewed by board-certified pathologists.  Staging was based on 2009 FIGO criteria 110. 
 
Fresh-frozen tissue specimens of surgically resected neoplasms of the ovary and 
endometrium were assessed for neoplastic cellularity by a board-certified pathologist.  Serial 
frozen sections were used to guide the trimming of Optimal Cutting Temperature (OCT) 
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compound embedded frozen tissue blocks to enrich the fraction of neoplastic cells for DNA 
extraction.   
 
Formalin-fixed paraffin embedded (FFPE) tissue samples were assessed by a board-certified 
pathologist (Propath LLC, Dallas, TX) for tumor cellularity and to demarcate area of high 
tumor cellularity.  Tumor tissues from serial 10 micron sections on slides from the original 
tumor block were macrodissected with a razorblade to enrich the fraction of neoplastic cells 
for DNA extraction. 
 
The source of normal DNA was matched whole blood or non-neoplastic normal adjacent 
tissue. 
 
Liquid-based Pap smear specimens were collected with cervical brushes and transport 
medium from Digene HC2 DNA Collection Device (Qiagen) or ThinPrep 2000 System 
(Hologic) and stored according to the manufacturer’s recommendations. 
 
Unless otherwise indicated, all patient-related values are reported as mean ± 1 standard 
deviation. 
 
DNA Extraction. DNA was purified from tumor and normal tissue as well as liquid-based 
Pap smears with an AllPrep kit (Qiagen) according to the manufacturer’s instructions.  DNA 
was purified from tumor tissue by adding 3 mL RLTM buffer (Qiagen) and then binding to 
an AllPrep DNA column (Qiagen) according to the manufacturer's protocol.  DNA was 
purified from Pap smear liquids by adding five volumes of RLTM buffer when the amount 
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of liquid was less than 3 mL.  When the amount of liquid was >3 mL, the cells and cell 
fragments were pelleted at 1,000 x g for five minutes and the pellets were dissolved in 3 mL 
RLTM buffer.  DNA was quantified in all cases with qPCR, employing the primers and 
conditions previously described 111. 
 
Microsatellite instability testing. Microsatellite instability was detected with the MSI 
Analysis System (Promega), containing five mononucleotide repeats (BAT-25, BAT-26, NR-
21, NR-24 and MONO-27) and two pentanucleotide repeat loci, per the manufacturer’s 
instructions. After amplification, the fluorescent PCR products were sized on an Applied 
Biosystems 3130 capillary electrophoresis instrument (Invitrogen).  Tumor samples were 
designated as follows: MSI-high if two or more mononucleotides varied in length compared 
to the germline DNA; MSI-low if only one locus varied; and microsatellite stable (MSS) if 
there was no variation compared to the germline.  Pentanucleotide loci confirmed identity in 
all cases. 
 
Preparation of Illumina DNA libraries and capture for exomic sequencing. 
Preparation of Illumina genomic DNA libraries for exomic and targeted DNA captures was 
performed according to the manufacturer’s recommendations.  Briefly, 1-3 μg of genomic 
DNA was used for library preparation with the TruSeqDNA Sample Preparation Kit 
(Illumina).  The DNA was acoustically sheared (Covaris) to a target size of ~200 bp.  The 
fragments were subsequently end-repaired to convert overhangs into blunt ends.  A single 
“A” nucleotide was then added to the 3’ ends of blunt fragments to later prevent them from 
self-ligation; a corresponding “T” on the 3’ end of adaptor molecules provided the 
complementary overhang.  After ligation to adaptors, the library was amplified with 8-14 
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cycles of PCR to ensure yields of 0.5 and 4 μg for exomic and targeted gene captures, 
respectively.  
 
Exomic capture was performed with the SureSelect Human Exome Kit V 4.0 (Agilent) 
according to the manufacturer’s protocol, with the addition of TruSeq index-specific blocks 
in the hybridization mixture (AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC-
XXXXXX-ATCTCGTATGCCGTCTTCTGCTTGT, where the six base “XXXXXX” 
region denotes one of 12 sample-specific indexes). 
 
Targeted gene enrichment. Targeted gene enrichment was performed by modifications of 
previously described methods 112,113.  In brief, targeted regions of selected oncogenes and 
tumor suppressor genes were synthesized as oligonucleotide probes by Agilent 
Technologies.  Probes of 36 bases were designed to capture both the plus and the minus 
strand of the DNA and had a 33-base overlap.  The oligonucleotides were cleaved from the 
chip by incubating with 3 mL of 35% ammonium hydroxide at room temperature for five 
hours. The solution was transferred to two 2 mL tubes, dried under vacuum, and redissolved 
in 400 µL of ribonuclease (RNase) – and deoxyribonuclease (DNase) –free water.  Five 
microliters of the solution was used for PCR amplification with primers complementary to 
the 12-base sequence common to all probes: 5'-TGATCCCGCGACGA*C-3' and 5'-
GACCGCGACTCCAG*C-3', with * indicating a phosphorothioate bond.  The PCR 
products were purified with a MinElute Purification Column (Qiagen), end-repaired with 
End-IT DNA End-Repair Kit (Epicentre), and then purified with a MinElute Purification 




The major differences between the protocol previously described 112,113 and the one used in 
the present study involved the amplification of the ligated PCR products and the solid phase 
capture method as noted below.  Biotinylated capture probes were prepared by amplifying 
50 ng of ligated PCR products with the REPLI-g Midi Kit (Qiagen) supplemented with 2.5 
nmol Biotin-16-dUTP (Roche) in a 27.5 µL reaction incubated at 30oC for 16 hours. After 
inactivating the polymerase by incubating at 65oC for three mins, the biotinylated capture 
probes were purified with QIAquick PCR Purification Columns.  For capture, 4-5 μg of 
library DNA was incubated with 1 μg of the prepared probes in a hybridization mixture as 
previously described  112.  The biotinylated capture probes and captured library sequences 
were subsequently purified with 500 μg Dynabeads MyOne Streptavidin C1 (Invitrogen).  
After washing as per the manufacturer’s recommendations, the captured sequences were 
eluted with 0.1 M NaOH and then neutralized with 1 M Tris-HCl (pH 7.5).  Neutralized 
DNA was desalted and concentrated with a MinElute Purification Column in 20 µL.  The 
eluate was amplified in a 100 µL Phusion Hot Start II (Thermo Scientific) reaction 
containing 1X Phusion HF buffer, 0.25 mM dNTPs, 0.5 µM each forward and reverse 
TruSeq primers, and 2 U polymerase with the following cycling conditions: 98°C for 30 s; 14 
cycles of 98°C for 10s, 60°C for 30 s, and 72°C for 30 s; and 72°C for 5 min.  The amplified 
pool containing enriched target sequences was purified with an Agencourt AMPure XP 
system (Beckman) and quantified with a 2100 Bioanalyzer (Agilent). 
 
Next-generation sequencing and somatic mutation identification. After capture of 
targeted sequences, paired-end sequencing with an Illumina GA IIx Genome Analyzer 
provided 2 x 75 base reads from each fragment.  The sequence tags that passed filtering were 
aligned to the human genome reference sequence (hg18) and subsequent variant-calling 
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analysis was performed with the ELANDv2 algorithm in the CASAVA 1.6 software 
(Illumina).  Known polymorphisms recorded in dbSNP Build 130 114 were removed from the 
analysis.  Identification of high confidence mutations was performed as described previously 
95. 
 
Assessment of low-frequency mutations 
Primer Design.  We attempted to design primer pairs to detect mutations in the 46 cancers 
described in the text. Primers were designed as described previously 11 with Primer3 115.  Sixty 
percent of the primer pairs amplified the expected fragments; in the other 40%, a second or 
third set of primer pairs had to be designed to reduce primer dimers or non-specific 
amplification. 
 
Sequencing Library Preparation. Templates were prepared for sequencing as described 
previously 11, with modifications noted below that facilitated the amplification of multiple 
gene regions in a single well of a 96-well PCR plate.  In brief, each strand of each template 
molecule was encoded with a 14 base unique identifier (UID) – comprised of degenerate 
“N” bases (equal probability of being an “A,” “C,” “G,” or “T”) - with two to four cycles of 
amplicon-specific PCR (“UID assignment PCR cycles,” see Fig. 2).  Both forward and 
reverse gene-specific primers contained universal tag sequences at their 5' ends, providing 
the primer binding sites for the second-round amplification, but only the forward primer 
contained the UID, which was positioned between the 5' universal tag and the 3’ gene-
specific sequences.  Four “N” bases were additionally included in the reverse primer to 
facilitate sequencing analysis of paired-end libraries (table S4).  The UID assignment PCR 
cycles were performed on 66 ng of DNA in a 50 µL reaction containing 1X Phusion HF 
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buffer, 0.25 mM dNTPs, 0.5 µM each of forward (containing 14 “N” bases) and reverse 
primers, and 2 U of Phusion Hot Start II Polymerase (Thermo Scientific).  Carryover of 
residual UID-containing primers to the second-round amplification, which can complicate 
template quantification 11, was minimized through a 15 s exonuclease digestion at 370C to 
degrade unincorporated primers.  In Kinde et al. 11, Exonuclease-I (Enzymatics) was chosen 
to eliminate the residual UID-containing primers, however we found that a different 
exonuclease – RecJf (New England Biolabs) – followed by purification with AMPure XP 
beads (Beckman) and elution in 10 µL of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0), 
more extensively removed the UID-containing primers and yielded more robust 
amplification products.  The eluted templates were amplified in a second-round PCR with 
primers containing the grafting sequences necessary for hybridization to the Illumina GA IIx 
flow cell at their 5’ ends (Fig. 2).  The reverse amplification primer additionally contained an 
index sequence between the 5 ’grafting and 3’ universal tag sequences to enable the PCR 
products from multiple individuals to be simultaneously analyzed in the same flow cell 
compartment of the sequencer 11.  The second-round amplification reactions contained 1X 
Phusion HF buffer, 0.25 mM dNTPs, 0.5 µM each of forward and reverse primers, and 2 U 
of Phusion Hot Start II Polymerase in a total of 50 µL.  After an initial heat activation step at 
980 C for 2 minutes, twenty-three cycles of PCR were performed with the following cycling 
conditions: 980C for 10 s, 650C for 15 s, and 720C for 15 s.  The multiplexed assay was 
performed in similar fashion utilizing six independent amplifications – each containing 66 ng 
of DNA (i.e.,~400 ng total) – per sample with the primers described in table S5.  The PCR 
products were purified with AMPure XP beads and used directly for sequencing on either 




Data Analysis. High quality sequence reads were analyzed as previously described 11.  Briefly, 
we selected reads that contained high quality basecalls in their UID region (i.e., the first 14 
cycles) by utilizing the quality scores generated by default, which indicate the probability that 
an individual base call was made in error 116.  Reads in which each of the 14 bases comprising 
the UID (representing one original template strand; see Fig. 2) had a quality score ≥15 were 
grouped by their UIDs and only the UIDs supported by more than one read were retained 
for further analysis.  The template-specific portion of the reads that contained the sequence 
of an expected amplification primer was matched to a reference sequence set with a custom 
script (available from the authors upon request).  Artifactual mutations – introduced during 
the sample preparation or sequencing steps – were eliminated by requiring that >50% of 
reads sharing the same UID contained the identical mutation (a “supermutant,” Fig. 2).  For 
the 46 assays querying a single amplicon, we required that the fraction of mutant alleles was 
significantly different from the background mutation levels determined from a negative 
control (P <0.001, binomial test).  As mutations are not known a priori in a screening 
environment, we used a more agnostic metric to detect mutations in the multiplexed assay.  
A threshold supermutant frequency was defined for each sample as equaling the mean 
frequency of all supermutants plus six standard deviations of the mean.  Only supermutants 
exceeding this threshold were designated as mutations and reported in Fig. 4 and table S6. 
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Table 3-1. Epidemiology of Ovarian and Endometrial Tumors in the United States. 








Ovarian Epithelial High-grade serous 60% 13,368 9% 
  
Endometrioid 15% 3,342 71% 
  
Clear cell 10% 2,228 62% 
  
Low-grade serous 8% 1,782 40% 
  
Mucinous 2% 446 65% 
  
Transitional cell 2% 446 57% 
  
Other 3% 668 N/A 
      Endometrial Type I: Endometrioid Endometrioid 85% 40,060 91% 
 Type II: Non-Endometrioid 
Papillary serous 10% 4,713 45% 
  Clear cell 5% 2,357 68% 
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Table 3-2. Genetic characteristics of ovarian and endometrial cancers. 
Tissue Type Subtype Somatically mutated genes (frequency) 
Ovarian Epithelial High-grade serous TP53 (96%) 
   
CSMD3 (6%) 
   
FAT3 (6%) 
   
BRCA1 (3%) 
   
BRCA2 (3%) 
  
Endometrioid TP53 (68%) 
   
ARID1A (30%) 
   
CTNNB1 (26%) 
   
PTEN (17%) 
   
PIK3CA (15%) 
   
KRAS (10%) 
   
PPP2R1A (11%) 
   
CDKN2A (12%) 
   
BRAF (8%) 
  
Clear cell ARID1A (57%) 
   
PIK3CA (40%) 
   
PPP2R1A (7%) 
   
KRAS (4.7%) 
  
Low-grade serous BRAF (38%) 
   
KRAS (19%) 
  
Mucinous TP53 (56%) 
   
KRAS (40%) 
   
PPP2R1A (33%) 
   
CDKN2A (16%) 
    PTEN (11%) 
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Table 3-2. Continued 
Tissue Type Subtype Somatically mutated genes (frequency) 
Endometrial Type I: Endometriod Endometrioid PTEN  (64%) 
   
PIK3CA (59%) 
   
ARID1A  (55%) 
   
CTNNB1  (32%) 
   
MLL2  (32%) 
   
FBXW7  (27%) 
   
RNF43  (27%) 
   
APC  (23%) 
   
FGFR2 (18%) 
   
KRAS  (9%) 
   
PIK3R1 (9%) 
   
EGFR (14%) 
   
AKT1 (5%) 
   
NRAS (5%) 
   
TP53  (5%) 
 
Type II: Non-Endometrioid Papillary serous TP53 (82%) 
   
PIK3CA (24%) 
   
FBXW7 (20%) 
   
PPP2R1A (18%) 
  
Clear Cell TP53 (45%) 
   
PPP2R1A (33%) 
   
PIK3CA (29%) 
   
PTEN (13%) 
   
PIK3R1 (9%) 
   KRAS (5%) 
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Table 3-S1. Summary Characteristics of Endometrial Cancers (Endometrioid 




Table 3-S2. Mutations Identified by Whole-Exome Sequencing in 22 Endometrioid 
Endometrial Cancers. 
[Too large to display] 
Full table available at http://stm.sciencemag.org/content/5/167/167ra4/suppl/DC1 
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Table 3-S3. Clinical Characteristics and Mutations Assessed in Pap Specimens 
[Too large to display] 
Full table available at http://stm.sciencemag.org/content/5/167/167ra4/suppl/DC1 
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Table 3-S4. Primers Used to Assess Individual Mutations in Pap Specimens. 
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Table 3-S5. Primers Used to Simultaneously Assess 12 Genes in Pap Specimens with the Multiplexed Safe-SeqS Strategy. 
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Table 3-S6. Mutations Identified in Pap Specimens through Simultaneous Assessment of 12 Genes. 
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Figure 3-1. Schematic of the PapGene test. 
Tumor cells shed from ovarian or endometrial cancers are carried into the endocervical 
canal. These cells can be captured by the brush used for performing a routine Pap smear. 
The brush contents are transferred into a liquid fixative, from which DNA is isolated.  By 
means of next-generation sequencing, this DNA is queried for mutations that indicate the 





Figure 3-2. Diagram of the modified Safe-SeqS (Safe-Sequencing System) assay used 
allowing for the simultaneous detection of mutations in 12 different genes. 
Top left: DNA templates from three exons of different genes (yellow, purple, and brown 
rectangles) to be queried for mutations.  Note that only one of the templates contains a 
mutation (star) that exists before any sample preparatory steps or sequencing.  Top right: 
Safe-SeqS primer pairs contain binding sites for universal primers (“UPS”, blue), a unique 
identifier (“UID”, red), and gene-specific sequences (colors match the targeted exon).  Next, 
the templates and primers are combined into a single PCR compartment and a UID along, 
with UPS binding sites, are attached to each targeted template after a low number of PCR 
cycles (“UID assignment”).  The Safe-SeqS primers are removed and subsequent PCR with 
universal primers, additionally containing the sequences required for attachment to the 
sequencing instrument (“GP”, black), prepare the templates for next-generation sequencing.  
When mutations preexist in template DNA before sample preparation, all of the sequenced 
daughter molecules sharing the same UID will contain the same mutation (a “supermutant”).  
In contrast, artifactual mutations caused by sample preparation or sequencing are unlikely to 
be observed in most other daughter molecules sharing the same UID (“Artifact”).  Note that 
only one of two DNA strands are depicted for clarity. 
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Figure 3-3. Mutant allele fractions in Pap smear fluids. 
The fraction of mutant alleles from each of 46 Pap smear fluids is depicted.  The stage of 
each tumor is listed on the Y-axis. The X-axis demonstrates the % mutant allele fraction (cut 
off <10%) as determined by traditional Safe-SeqS.  Mutant allele frequencies are higher than 
10% in some cases but are depicted at 10% in this figure for clarity.  Precise mutation 





Figure 3-4. Heat map depicting the results of multiplex testing of 12 genes in Pap 
smear fluids. 
The PapGene test interrogates 46 gene regions with each block on the Y-axis representing 
one region analyzed for the indicated gene.  The 28 samples assessed (14 from healthy 
women without cancer, 14 from women with cancer) are indicated on the X-axis.  Mutations 
are indicated as colored blocks, with white indicating no mutation, yellow indicating a 
mutant fraction of 0.1% to 1%, orange indicating a mutant fraction of 1% to 10%, and red 
indicating a mutant fraction of >10%. 
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Chapter 4: TERT Promoter Mutations Occur Early  
in Urothelial Neoplasia and Are 
Biomarkers of Early Disease and Disease 
Recurrence in Urine 
 
Introduction 
Urothelial carcinoma of the bladder is the most common malignancy of the urinary tract 
with 73,000 new cases and 15,000 deaths expected in 2013 in the US alone 118. These 
invasive carcinomas arise from histologically well-defined papillary and flat precursor lesions, 
providing a potential opportunity for early detection and treatment 119. Although urine 
cytology enjoys a reasonable sensitivity and specificity for detecting high-grade neoplasms, 
its performance in detecting low-grade tumors is poor, with a sensitivity and specificity of 
4% and 30%, respectively 120. 
 
A number of urine-based markers have been developed to improve the accuracy of 
noninvasive screening and surveillance in bladder cancer. Among Food and Drug 
Administration (FDA) approved tests, the Immunocy test (Scimedx Corp, Danville, NJ), 
nuclear matrix protein 22 (NMP22) immunoassay test (Matritech, Cambridge, MA) and 
multitarget fluorescence in situ hybridization (FISH) (UroVysion; Abbott Park, IL) 121 have 
demonstrated an overall sensitivity of 70% and a specificity range of up to 89%. 
Performance inconsistencies, as a result of variability in pre-analytical and analytical 
specimen factors, have impeded their wide-spread clinical use. 
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Activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene lead to 
increased telomerase expression and, in doing so, allow some neoplasms to overcome the 
end-replication problem and avoid senescence. TERT promoter mutations were initially 
described in melanoma 122,123 and have subsequently been described in a discrete spectrum of 
cancer types, including 66% of muscle-invasive urothelial carcinomas of the bladder 122,124. 
TERT is therefore the most frequently mutated gene in advanced forms of this disease, and 
the localization of these mutations to a small gene region in the TERT promoter provides an 
extraordinary opportunity for biomarker development 124. 
 
For TERT promoter mutations to be a useful marker of early, curable disease, these 
mutations should be present in pre-invasive bladder tumors and shed into the urine. To this 
end, we have in this study evaluated the sequence of the TERT promoter in a large number 
of curable precursor neoplasms of the urinary bladder. We also determined the sequence of 
the TERT promoter in a separate group of superficial bladder cancers and corresponding 
follow-up urine samples to establish the feasibility of detecting TERT mutations in urine and 
their potential utility in predicting recurrence. 
 
Materials and Methods 
Patient Samples. This study was approved by the Institutional Review Board of Johns 
Hopkins University, School of Medicine. Two different sets of samples were analyzed in our 
study. The first sample set included 76 noninvasive papillary urothelial carcinomas and flat 
carcinoma in situ (CIS) lesions obtained by transurethral bladder resection (TURB) between 
2000 and 2012. All specimens were rom the Surgical Pathology archives and were selected 
only on the basis of specimen availability. Pertinent patient demographics and clinical 
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information were obtained from electronic medical records. All sections were reviewed by 
three urological pathologists (EM, SFF and GJN) to confirm the original diagnoses. To 
enrich for neoplastic cells within the tissues, representative formalin-fixed paraffin-
embedded (FFPE) blocks were cored with a sterile 16 gauge needle and tumor areas showing 
at least 50% neoplastic cellularity were selected microscopically. For eight of the cases, 
benign adjacent urothelium was macrodissected from FFPE blocks.  The cores were placed 
in a 1.5 mL sterile tube for subsequent DNA purification using an AllPrep DNA/RNA Mini 
Kit (Qiagen, cat. no. 80204).  DNA was purified from peripheral blood buffy coats of 15 
patients using the same Qiagen kit.   
 
For the second sample set, we prospectively collected urine samples from 15 separate 
patients undergoing follow-up cystoscopy for previously diagnosed non-muscle-invasive 
urothelial carcinoma. We purposely biased this cohort to include patients that recurred 
within the follow-up period.  Immediately prior to follow-up cystoscopy, 25 mL of raw urine 
was collected and subsequently pelleted by centrifugation at 3,000 g for 10 minutes. The 
pellets were stored at -80 ̊ C in 1.5 mL tubes for subsequent DNA extraction. For 14 of these 
patients, matched FFPE from the original diagnostic TURB was retrieved. These included 
13 high-grade urothelial carcinomas (pTa HG and pT1 HG in six and seven cases, 
respectively), and one low-grade papillary urothelial carcinoma (pTa LG). Twenty 8 µm-thick 
sections were cut from one representative tissue block in each case and areas containing at 
least 70% neoplastic cells were microdissected and used for DNA purification using a 




Mutation analysis. Due to their tremendous throughput, massively parallel sequencing 
instruments are highly cost-effective for DNA mutation analysis. However, sample 
preparation and sequencing steps introduce artifactual mutations into analyses at a low, but 
significant frequency. To better discriminate genuine TERT promoter mutations from 
artifactual sequencing variants introduced during the sequencing process, we used Safe-SeqS, 
a sequencing error-reduction technology described previously 11,117. As depicted in Fig. 1, 
Safe-SeqS amplification primers were designed to amplify a 126-bp segment containing the 
region of the TERT promoter previously shown to harbor mutations in melanomas and 
other tumors 122-124. The forward and reverse amplification primers contained the TERT-
specific sequences at their 3’ ends and a universal priming site (UPS) at their 5’ end.  The 
reverse primer additionally contained a 14-base unique identifier (UID) comprised of 14 
degenerate N bases (equal likelihood of being an A, C, T, or G) between the UPS and gene-
specific sequences. The sequences of the forward and reverse primers were either 5’-
CACACAGGAAACAGCTATGACCATGGGCCGCGGAAAGGAAG and 5’- 
CGACGTAAAACGACGGCCAGTNNNNNNNNNNNNNNCGTCCTGCCCCTTCAC
C, or CACACAGGAAACAGCTATGACCATGGCGGAAAGGAAAGGGAG  and 5’- 
CGACGTAAAACGACGGCCAGTNNNNNNNNNNNNNNCCGTCCCGACCCCTC 
(UPS sequences underlined). These primers were used to amplify DNA in 25 µL PCR 
reactions in 1X Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific, cat. no. F-
548L) containing 0.5 µM forward and reverse primers (described above). After incubation at 
98ºC for 120 seconds, 10 cycles of PCR were performed in the following manner: 98ºC for 
10 seconds, 63ºC for 120 seconds, and 72ºC for 120 seconds was performed. Reactions were 
purified with AMPure XP beads (Beckman Coulter) and eluted in 100 µL of Buffer EB 
(Qiagen, cat. no. 19086). For the second stage of amplification, 5 µL of purified PCR 
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products were amplified in 25 µL reactions containing 1X Phusion Flash High-Fidelity PCR 
Master Mix and 0.5 µM amplification primers that each contained the first-stage UPS at their 
3’ ends and the grafting sequences required to hybridize to the sequencing instrument flow 
cell at their 5’ ends 11,117. The reverse amplification primer additionally included a 6 bp index 
sequence, unique to each sample, inserted between the UPS and grafting sequences. After 
incubation at 98ºC for 120 seconds, 17 cycles of PCR were performed in the following 
manner: 98ºC for 10 seconds, 63ºC for 120 seconds, and 72ºC for 120 seconds. The PCR 
products were purified with AMPure and sequenced on a MiSeq instrument. 
 
Data were analyzed as previously described 11,117. Briefly, the amplified TERT promoter 
region of reads containing UIDs, where each base of the UID region had instrument-derived 
quality scores ≥15, was matched to a reference sequence using a custom script. TERT 
promoter sequences with five or fewer mismatches were retained for further analysis. Tumor 
samples were considered positive if the fraction of mutations exceeded 1% of alleles (which 
was a frequency at least 10x higher than found in control DNA templates from FFPE 
tissues). Urine samples were considered positive when the frequency of mutation exceeded 
0.1% of alleles (a frequency at least 10x higher than found in control DNA templates from 
urine samples of patients without TERT mutations in their primary tumors). All sequencing 
assays scored as positive were confirmed in at least one additional, independent PCR and 
sequence assay. 
 
Statistical analysis. The data were analyzed using Stata/SE 12 (StataCorp Inc., College 
Station, TX). Pearson’s chi-squared test was used for analysis of association of categorical 





TERT promoter mutation in papillary and “flat” noninvasive urothelial carcinoma. 
We used a massively parallel sequencing technology to determine the presence and 
representation of mutant TERT promoter alleles in urothelial cancers. A graphical depiction 
of the method is shown in Fig. 1 and detailed procedures are provided in the Materials and 
Methods. In addition to revealing whether mutations are present with a population of DNA 
templates, this technique provides an accurate determination of the fraction of mutant alleles 
in the sample. Clinicopathologic characteristics of the 76 noninvasive urothelial carcinomas 
analyzed in the first phase of this study are summarized in Table 1. They included 59 
papillary tumors – 28 low-grade (pTa LG) and 31 high-grade (pTa HG) – plus 17 “flat” 
urothelial carcinoma in situ (CIS). These patients were typical of those with this form of 
cancer; their average age was 66 years and most (82%) were males (Table 1). 
 
TERT promoter mutations were identified in 56/76 (74%) of these urothelial carcinomas 
(Table 2).  In contrast, none of the eight samples of adjacent normal urothelium harbored 
TERT promoter mutations.  Additionally, we did not detect TERT promoter mutations in 
15 samples of peripheral blood from the same patients.  Twelve of the blood samples and 
five of the normal urothelial samples were from patients whose tumors harbored TERT 
promoter mutations.  These data demonstrate that the TERT promoter mutations in these 
patients were unequivocally somatic and limited to the neoplastic urothelium in the bladder. 
The predominant alterations were g.1295228C>T (minus strand of chromosome 5, hg19 
assembly) and g.1295250C>T mutations, which accounted for 75% and 20% of the total 
alterations, respectively. In addition, we identified one g.1295228C>A mutation and two 
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g.1295242C>T mutations not previously reported (Table S1). The mutations were found in 
all types and grades of these early cancers: in 76% of papillary lesions and 65% of flat 
lesions; in 86% of low-grade and in 68% of high-grade lesions (Table 2). None of these 
differences among subgroups were statistically significant. 
 
The results described above show that TERT promoter mutations occur early in bladder 
cancers and did not correlate with grade or type.  Such early mutations would not be likely 
associated with recurrence or progression, but to evaluate this possibility, our series of 
samples included cases both with and without recurrence during follow up. In Tables 3 and 
4, the relationship between TERT promoter mutation status and tumor recurrence or 
progression, respectively, are displayed:  TERT promoter mutation status was not associated 
with likelihood of recurrence or progression in any subgroup. 
 
TERT promoter mutation in urine samples. We next evaluated whether TERT promoter 
mutations could be identified in cells in the urine. As noted in the Introduction, urine 
samples are routinely taken at follow-up visits following TURB procedures to help 
determine whether residual tumor cells are present (via cytology or other methods). We first 
assessed the tumors obtained from 14 patients undergoing TURB for relatively early (non-
muscle invasive) disease. Of these, 11 (79%) harbored TERT promoter mutations (Table 5), 
as expected from the evaluation of the first cohort (Table 2). All of the mutations in the 
second cohort were at either g.1295228C>T or g.1295250C>T (Table 5). 
The 14 patients were monitored for recurrence at subsequent visits. Mutations were assessed 
in the cell pellets from the urines obtained at the first follow-up visit after TURB in these 14 
patients, as described in the Materials and Methods. There was a striking correlation between 
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the presence of a TERT promoter mutation in the urine, the presence of the mutation in the 
original tumor, and recurrence. In the three of 14 patients without a TERT promoter 
mutation in their tumor, no mutation was evident in their urine sample, as expected (Table 
5). Of the 11 patients in whom a TERT mutation was present in the tumor, seven patients 
were observed to have a mutation in the DNA isolated from their urine cell pellets; in each 
case, the mutation was identical to that observed in the primary tumor removed via TURB 
(Table 5). The bladder cancers in each of these seven patients recurred, either at the first 
follow-up or thereafter. The proportion of mutant alleles in the cells pelleted from the urine 
of these patients was often substantial, ranging from 0.17% to 23% with a median of 4.4% 
(Table 5). We also identified a TERT promoter mutation in a urine sample from which no 
prior tumor was available; this tumor also recurred (Table 5). In contrast, no TERT 
mutations were evident in the urine samples of four patients whose original tumors 
contained a TERT promoter mutation: the tumors of three of these patients never recurred 
while the fourth developed a recurrence 3.5 months after the urine sample was collected 
(Table 5). As shown in Table 6, the presence of detectable TERT promoter mutations in the 
urine was strongly associated with recurrence of urothelial carcinoma (P <0.001; Pearson’s 
correlation coefficient =0.87). 
 
Discussion 
TERT promoter mutations are detectable in urine, and their presence in urine is strongly 
associated with bladder cancer recurrence. Muscle-invasive urothelial carcinoma is 
responsible for the vast majority of bladder cancer related deaths and many of these deaths 
could be prevented if precursor lesions were detected and surgically excised prior to their 
invasion into the muscle 125-128. New strategies for the early detection of such lesions are 
97 
 
therefore urgently needed 9.  Our results show that TERT promoter mutations are the most 
common genetic alteration in noninvasive bladder cancer identified to date, occurring in the 
majority (74%) of such precursor lesions. They occur in cancers developing through both 
the papillary and flat routes to tumor progression 129, and occur in low-grade as well as high-
grade tumors. We also show that these mutations can be detected in the urine of patients 
with bladder cancer. Altogether, these results suggest that TERT promoter mutations may 
provide a useful biomarker for the early detection of bladder cancers in the future, and that 
prospective studies of patients at high risk for this disease are warranted.  
 
Given the high prevalence of TERT promoter mutations in early bladder neoplasia, their 
presence or absence in tumors is of limited prognostic value. However, superficial bladder 
cancers are currently the most costly solid tumor (per patient) in the US 130,131. Noninvasive 
methods to monitor these patients could reduce the cost of caring for these patients as well 
as the discomfort associated with invasive procedures. Our results are highly encouraging 
with respect to this potential application. Among patients with TERT mutations in their 
primary tumors, there was a highly significant correlation between the presence of mutations 
in subsequent urine collections and recurrence (Table 6).   
 
Our results therefore suggest two potential avenues for application of TERT promoter 
mutations in the clinic: early detection in high-risk patients and monitoring of patients with 
bladder cancer, both through the analysis of urine specimens. It is important to note that 
both these applications will require further study prior to implementation. For example, we 
have not yet shown that bladder cancer patients have detectable mutations in urine prior to 
tumor diagnosis; all of our urine samples were taken at follow-up visits after surgery. 
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Additionally, our study involved only a small number of patients, and we have yet to 
demonstrate that the analysis of urine for TERT mutations improves upon conventional 
cytology or clinical criteria, nor whether it could partially replace cystoscopy in certain 
circumstances. Still, our study provides a strong proof-of-principle: TERT promoter 
mutations occur early, are specific for neoplasia, and can be identified in the urine with 
currently available technologies. Future large-scale studies will be required to determine the 
clinical utility of this approach for screening or monitoring purposes.  
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Table 4-4. Correlation of TERT promoter mutation status and tumor progression  
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Table 4-5. Correlation of TERT mutation status in original diagnostic transurethral 









Table 4-S1. TERT promoter mutation status in 59 pTa and 17 carcinoma in situ 
(CIS) patients.  
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Table 4-S1. Continued. 
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Figure 4-1. TERT promoter locus. 
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Chapter 5: Detection of Circulating Tumor DNA in 




Cancer will occur in more than 1.6 million individuals this year in the United States alone, 
but a clinically proven circulating biomarker that can be used to help guide patient 
management will be available for only a minority of them, even in the setting of widespread 
metastasis 133-138.  While serum-based protein biomarkers such as carcinoma antigen-125 (CA-
125), carcinoembryonic antigen (CEA) and prostate specific antigen (PSA) are commonly 
used for this purpose, these proteins are also found in the serum of individuals without 
cancer, albeit in lower concentrations 134-136. Additionally, these markers are not found to be 
elevated in a substantial portion of patients with advanced cancers 137,138. 
A new generation of biomarkers has become available with the discovery of the genetic 
alterations that are responsible for the initiation and progression of human cancers 9,139-142. 
With the influx of genomic information from recent cancer genome sequencing studies, it is 
now known that virtually all cancers of every type harbor somatic genetic alterations. These 
alterations include single base substitutions, insertions, deletions and translocations (the 
latter including those associated with the creation of gene fusions, gene amplifications or 
losses of heterozygosity). These somatic mutations occur at negligible frequencies in normal 





There are two sources of tumor DNA that can be non-invasively assessed in the circulation:  
cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) 143,144. 
Circulating tumor DNA is comprised of small fragments of nucleic acid that are not 
associated with cells or cell fragments 145. In contrast, circulating tumor cells represent intact, 
often viable, cells that can be purified from blood by virtue of physicochemical 
characteristics or cell surface molecules that distinguish them from normal blood cells 146. 
Many studies have shown that both ctDNA and CTCs are present in advanced neoplasia, 
though only a few studies have compared the amounts of CTCs and ctDNA templates in the 
same patients 147-150. The studies comparing the two approaches have reached opposing 
conclusions, likely due to technical issues that limited interpretation of either the ctDNA or 
CTC content.  Furthermore, the mechanism by which CTCs or ctDNA are released into the 
circulation are unclear, although it is possible that ctDNA actually comes from CTCs.  One 
of the purposes of the current study was to compare the quantities of ctDNA and CTCs in 
the circulation of the same patients using an unbiased approach. 
 
Most studies of ctDNA published to date have each evaluated patients with a single tumor 
type.  In light of considerable differences in DNA preparation and analytic techniques in 
these studies, it has been difficult to directly compare the amounts of ctDNA among tumor 
types 147,151-157.  Comparisons of studies are also challenging due to differences in the types of 
data that are reported.  For example, it is often impossible to compare real-time PCR results 
with those reporting the fraction of mutant template molecules assessed, or to compare 
results based on the analysis of serum with those based on plasma.  To directly compare 
different tumor types and to determine the spectrum of cancers in which ctDNA 
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measurements could prove clinically useful, we evaluated a large number of tumor types in 
the current study.  We purified plasma and tumor DNA using regimented protocols for all 
samples and used digital technologies to evaluate ctDNA levels from each tumor so that we 
could report the number of mutant templates per milliliter of plasma in each case (Fig. 1). 
This approach also allowed us to directly compare directly the two most commonly used 
types of tumor-specific genetic alterations found in the circulation – single base substitutions 
and rearrangements. 
 
One of the most immediate applications of ctDNA has been termed the “liquid biopsy” 151.  
In research studies as well as in clinical practice, it is often difficult to obtain tumor samples 
for genetic analyses. Some tumors are only accessible through fine needle aspirates (lung 
cancer, for example) with insufficient material available for genotyping, whereas in other 
cases it can be challenging or time-consuming to acquire samples from different medical 
centers 158.  Additionally, once a targeted therapy is initiated in a patient with multiple 
metastases, clinicians frequently search for early evidence of recurrence or mechanisms 
underlying resistance, a scenario in which liquid biopsies are particularly valuable.  For 
example, they can provide temporal measurements of the total tumor burden as well as 
identify specific mutations that arise during therapy 147,151,154,159.  Though the liquid biopsy 
approach has been shown to be promising, its sensitivity and specificity with respect to 
conventional tumor biopsies has not been evaluated in a large, clinically relevant cohort.  In 
the current study, we evaluated the sensitivity and specificity of this approach in patients 
with colorectal cancers who were candidates for EGFR blockade.  We also used liquid 
biopsies to identify mutations that were responsible for recurrence in patients who initially 
responded to EGFR blockade. In aggregate, these studies provide a wealth of information 
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on the potential utility, as well as the limitations, of ctDNA measurements for the 
assessment of patients with various cancers.  
 
Results 
Patients with metastatic cancers. We began this study with an evaluation of 136 
metastatic tumors originating from 14 different tissue types, as well as of 41 patients with 
primary brain tumors (glioma and medulloblastoma). Primary brain tumors were also 
included because they are generally lethal but rarely metastasize.  We also included 10 
additional cases, comprised of stage III ovarian (n=7) and hepatocellular carcinomas (n=3) 
in this particular evaluation because stage IV cases were rare and Stage III disease is more 
representative of advanced disease in these two tumor types. The clinical characteristics of 
these patients are summarized in Table 1.  Targeted sequencing, exomic sequencing, or 
whole genome sequencing was used to identify mutations in the tumors, as described in the 
Materials and Methods.  In these advanced cases, least one genetic alteration - a point 
mutation (151 cases) or genetic rearrangement (36 cases) - was found in each of the tumors 
studied (table S1).  Except for a subset of mutations at the known hotspots of the KRAS, 
NRAS, PIK3CA, and BRAF genes (which are well-known to be somatic), all other genetic 
alterations were demonstrated to be somatic through evaluation of DNA from non-
neoplastic cells of the same patients.  Circulating tumor DNA was assessed by one of three 
digital methods (see Methods).  These methods yielded comparable results when applied to 
the same plasma samples (fig. S1) and all were able to detect one mutant template in the 
DNA purified from up to 5 mL plasma.  The amounts of plasma available from each patient 




Circulating tumor DNA was detected in the majority of the studied patients with solid 
tumors outside the brain (112 of 136; 82%). However, the fraction of patients with 
detectable ctDNA varied with tumor type (Likelihood ratio test, p-value < 0.001). As shown 
in Fig. 2A and fig. S2, most patients with stage III ovarian and liver cancers and metastatic 
cancers of the pancreas, bladder, colon, stomach, breast, liver, esophagus, head and neck, as 
well as patients with neuroblastoma and melanoma, harbored detectable levels of ctDNA, 
although small sample sizes for some tumor types led to wide confidence intervals.  In 
contrast, less than 50% of patients with medulloblastomas or metastatic cancers of the 
kidney, prostate, or thyroid, and less than 10% of patients with gliomas, harbored detectable 
ctDNA.  The number of patients with some of the tumor types depicted in Fig. 2A was 
small, limiting the statistical significance of comparisons among tumor types, but patients 
with gliomas (low or high grade; table S1) were less likely to harbor ctDNA than patients 
with metastatic cancers of the pancreas, colon, breast, esophagus/stomach, or ovary (Fig. 2A 
and Fig. S2). 
 
Though ctDNA was detectable in most patients with metastatic cancers, the concentration 
of ctDNA varied among patients, even those with the same tumor type (Fig. 2B and table 
S1).  Some of this variability was due to differences in copy number of the genes assayed in 
different tumors.  For example, if the queried gene was amplified 50-fold in the tumor of 
Patient A, whereas the queried gene in the tumor of Patient B was present at normal copy 
number, the amount of ctDNA would be expected to be 50-fold higher in Patient A than in 
Patient B (see section entitled "Comparison of rearrangements with single base substitutions 
in ctDNA" below). However, great variability was also observed among cancers in which 




Patients with localized disease. We next evaluated ctDNA in patients with localized 
disease, that is, no clinical or radiographic evidence of distant metastasis at the time of 
sample collection. Among 223 patients with localized cancers of all types evaluated, 
detectable levels of ctDNA were found in 55% (122 of 223 patients; table S1).  This fraction 
was lower than observed in patients with metastatic disease from all tumor types in which a 
sufficient number of samples were available (breast, colon, pancreas, gastroesophageal; Fig. 
3A; Cochran-Mantel-Haenszel chi-squared test, p < 0.001). Detectable levels of ctDNA were 
present in 49 to 78% of patients with localized tumors and in 86% to 100% of patients with 
metastatic tumors of these four types (Fig. 3A).   
Differences in the fraction of patients with detectable levels of ctDNA also correlated with 
stage:  47% of patients with Stage I cancers of any type had detectable ctDNA, whereas the 
fraction of patients with detectable ctDNA was 55%, 69% and 82% for patients with Stage 
II, III, and IV, respectively (Fig. 3B; Somers' Dxy rank correlation = 0.337).  The 
concentration of ctDNA in the plasma similarly increased with stage (Fig. 3C). 
 
Comparison of ctDNA with CTCs. For these experiments, DNA was isolated from the 
cellular compartment of blood obtained after centrifugation; these pellets contained 
circulating tumor cells as well as WBCs, platelets, and other cellular fragments.  In each case, 
whole genome sequencing of tumor DNA was used to identify somatic rearrangements.  
PCR-based assays were then used to identify these rearrangements in blood pellets (CTCs) 
or in the blood supernatants (plasma) of the same patients.  This experiment could be 
performed with tumor-specific rearrangements, but not with tumor-specific point mutations, 
for the reasons given in the Discussion.  We did not identify any cases in which CTCs were 
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detected but in which ctDNA was absent. However, in many cases in which ctDNA was 
detected (13 of 16; 81%), no CTCs were detectable with the identical assay (Table 2).  
Moreover, in the 3 cases wherein both CTC and ctDNA levels were detectable, the average 
number of mutant fragments in the plasma was >50-fold higher than analogous levels in 
CTCs (Table 2). 
 
Comparison of rearrangements with single base substitutions in ctDNA. We were also 
interested in comparing the quantity of two different types of genetically altered DNA 
fragments in the circulation of the same patients. Though practical issues precluded us from 
identifying a rearrangement in all patients in this study (see Discussion), tumor-specific 
rearrangements as well as tumor-specific point mutations were identified in 19 patients (table 
S2).  The rearrangements were identified by whole genome sequencing of tumor DNA and 
the point mutations identified by targeted sequencing.  In each case, the alteration was 
shown to be somatic via evaluation of normal DNA from the same patients. In 18 of the 19 
patients harboring a circulating point mutation, a circulating rearrangement was also 
detectable (table S2).  The one exception was a patient (CRC 37) with a circulating point 
mutation in TP53 in which the rearrangement identified in that patient’s tumor could not be 
identified in her plasma (table S2). The absolute number of circulating DNA fragments with 
point mutations vs. rearrangements was highly correlated (Fig. 4; correlation coefficient = 
0.96).  However, in four patients, the number of circulating fragments containing 
rearrangements was > 10-fold that of the queried point mutation (table S2).  The reason for 
this was that the rearrangements we chose for analysis often arose as a result of gene 





The sensitivity and specificity of liquid biopsy. The results described above were 
obtained by first identifying a mutation in a tumor and then determining whether that same 
mutation was detectable in the plasma. For certain liquid biopsy applications, the mutation in 
the tumor is not known a priori and all mutations of interest are queried at once.  To 
determine the sensitivity of the liquid biopsy approach, we evaluated the plasma and tumors 
of 206 patients with metastatic colorectal cancer in a blinded fashion (table S3).  This cohort 
of patients was completely distinct from the 410 patients described above and in tables S1 
and S2.  For each case, we determined whether mutations at codons 12 or 13 of KRAS were 
present in either the primary tumor or in 2 ml plasma drawn prior to treatment.  The KRAS 
gene was chosen for this study because of its clinical relevance; the absence of a KRAS gene 
mutation in the primary tumor is a prerequisite for treatment of metastatic CRC patients 
with antibodies that block EGFR160. We identified 69 patients (33% of the 206) who 
harbored circulating mutant KRAS in their plasma. Circulating KRAS mutations were not 
detected in 127 of 128 patients with KRAS wild-type tumors, yielding an uncorrected 
specificity of 99.2%.  Importantly, the mutation identified in the 69 plasma samples was 
always identical to that identified in the tumors, further emphasizing the specificity of the 
liquid biopsy. In addition to these 69 tumors, we identified ten cases (of 206) in which 
mutations were present in the primary tumors but not in the plasma, yielding a sensitivity of 
87.2%.  Percent concordance between KRAS mutation status in the plasma and tumor tissue 
was 95% and the agreement was highly significant (Kappa statistic 0.88, p<0.0001). 
 
We next evaluated 26 clinical and pathologic characteristics to better understand the 
observed false negative results (tables S3 and S4). The factors associated with a false negative 
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ctDNA result (mutant KRAS in the tumor but no mutants detectable in the plasma) were a 
low CEA level, mucinous histology, low ALT, low white blood cell count and younger age 
(table S4 and S5). CEA levels were also positively correlated with the concentration of 
mutant KRAS fragments in the plasma (table S6 and S7).  These observations are consistent 
with the idea that lower tumor burdens (reflected by normal CEA levels) are associated with 
lower ctDNA levels.  
 
We next examined the relationship between the concentration of ctDNA and survival. 
Beginning with a model of known prognostic factors (age, Eastern Cooperative Oncology 
Group (ECOG) Performance Status (PS), and CEA), and assuming linearity for these 
adjustment variables, we found that ctDNA concentration provided added value in 
predicting survival (Likelihood ratio test, p = 0.00253, df=3). We then estimated the 2-year 
survival rate for differing concentration of ctDNA, holding the other predictors constant 
(Fig. 5).We observed a steady decrease in survival rate as ctDNA concentration increased. 
 
Monitoring patients for resistance-conferring mutations. Liquid biopsies can also be 
used to monitor patients being treated with targeted agents, providing an early warning of 
recurrence and information about the genetic basis of resistance.  For example, KRAS codon 
12 and 13 mutations were shown to develop in 38% of 24 patients who first responded to 
EGFR blockade, then progressed 151. In each case, the KRAS gene mutation was not present 
in the primary tumor but had presumably arisen in a small population of cells within a 
metastatic lesion and expanded under the influence of the EGFR blockade. In the current 
study, we wished to determine whether other resistance mutations, besides those at KRAS 
codons 12 and 13, could be identified in liquid biopsies of patients treated with EGFR 
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blockade.  We therefore designed a multiplexed, sequencing-based assay to query known 
mutated hot-spots of several genes in the EGFR pathway: the regions within and 
surrounding KRAS codons 12, 13, 59, 60, and 61, NRAS codons 12, 13, 59, 60, and 61; 
BRAF codons 599 and 600, EGFR codons 712 - 721, 738 - 748, 790 - 800, and 847 - 859 
and PIK3CA codons 538 – 549 and 1039 - 1050.  The 24 cases assessed included 17 of those 
previously assessed for KRAS mutations 151 plus seven additional cases of patients who had 
first responded, then progressed, while being treated with blocking antibodies to EGFR 
(panitumumab or cetuximab).  The primary tumors of 9 of these cases were unavailable, so 
we used pre-treatment DNA from plasma to assess whether any of the queried mutations 
were detected prior to administration of EGFR antibodies; none of the mutations listed in 
Fig. 6 were found prior to antibody treatment. 
We identified emergent circulating mutations of at least one MAPK pathway gene in 23 of 
the 24 patients (96%).  The number of different mutations identified in the circulation of 
individual patients averaged 2.9 (range 0 to 12).  The development of different mutations in 
the same patient is not surprising given that each of these patients had multiple lesions; each 
lesion that responds to EGFR blockade and then progresses is expected to harbor at least 
one resistance mutation 151,161. 
 
In total, we observed 70 somatic mutations that were not detected in the tumor or in the 
plasma prior to EGFR blockade and only appeared after therapy was initiated (table S8; Fig. 
6).  Half of the mutations (34 of 70) occurred in KRAS codon 12.  These mutations are 
known to cause resistance to EGFR blockade when present in the primary tumor, and have 
been observed to arise after EGFR blockade in vitro as well as in vivo 151,161.  One mutation in 
BRAF was observed.  Several previous studies have shown that BRAF V600E mutations, 
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when present in primary tumors, are associated with failure to achieve a response to EGFR 
blockade 162-164. Two other patients developed mutations in the kinase domain of EGFR 
(codons 714 and 794; table S8; Fig. 6).  Mutations at these residues have been previously 
observed in primary CRC, albeit infrequently, and resistance to EGFR blockade has been 
shown to result from genetic alterations in the EGFR gene 165,166. We did not identify 
treatment-related mutations in the known PIK3CA gene hot spots (exon 9 and 20) 167. 
 
The most surprising observation in the EGFR blockade component of our study was the 
large number of mutations in codon 61 of either the KRAS or NRAS gene (table S6; Fig. 6).  
Fifteen of the 24 patients (62.5%) harbored at least one codon 61 mutation, and the 31 
mutations in these 15 patients comprised 45% of the total (69) mutations observed.  Forty 
eight percent of the codon 61 mutations were in NRAS and the remainder were in KRAS 
(table S6; Fig. 6).   
 
Discussion 
Through the study of 640 patients, we have learned that mutant DNA fragments are found 
at relatively high concentrations in the circulation of most patients with metastatic cancer 
and at lower but detectable concentrations in a substantial fraction of patients with localized 
cancers.  These results have several translational implications and suggest important avenues 
of future research. 
 
Monitoring disease in advanced cancer patients. A genetic alteration could be identified 
in the tumor of all 410 patients evaluated in this part of study, making ctDNA a widely 
applicable biomarker for cancer patients. Moreover, >80% of patients with metastatic 
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disease had detectable levels of ctDNA, higher than that reported for most conventional 
biomarkers168. Unlike proteins such as CEA or CA19-9, which are expressed in normal cells 
as well as in neoplastic cells, genetic alterations of a clonal nature are only found in 
neoplasms.  Our data indicate that measurements of ctDNA can also provide therapeutic, 
predictive and prognostic information in patients with metastatic disease.  As shown in Fig. 
5, metastatic colorectal cancer patients with relatively low levels of ctDNA lived significantly 
longer than patients with higher levels, and there was a striking correlation between ctDNA 
concentration and survival. A similar association between survival and ctDNA concentration 
has recently been reported in patients with advanced breast cancers 147. 
 
Though these advantages of ctDNA render it promising for monitoring patients, there are 
potential limitations.  The specific mutations are defined by evaluation of the primary tumor, 
adding both time and expense to patient management.  This may be less of an obstacle in the 
future as more cancer patients have their tumors genetically analyzed to guide therapeutic 
decisions. The genetic alterations used to guide therapies can also be used for ctDNA 
analysis.  A more serious issue relates to the utility of monitoring patients with advanced 
cancers, either with ctDNA or with other biomarkers 169,170.  On one hand, patients and their 
physicians are anxious to know, as soon as possible, whether disease has progressed.  
Imaging studies are often non-informative or slow to reflect progression. Repeated imaging 
also subjects patients to radiation, while monitoring ctDNA is non-invasive. On the other 
hand, it has not yet been shown that monitoring patients with advanced disease with any 
biomarker provides clinical as opposed to psychological benefits.  Knowing that progression 
(or response) has occurred prior to changes in clinical symptoms may not prolong survival 




Methodological comparisons. There are two sources of tumor DNA accessible in the 
blood (CTCs and ctDNA), and two types of genetic alterations that can be most easily 
assessed in either source (point mutations and translocations). Previous studies that 
compared ctDNA with CTCs reached mixed conclusions. For example, one group 
concluded that ctDNA was present less often than CTCs 148; this group used state-of-the-art 
methods to detect CTCs, but did not use a highly sensitive method to detect ctDNA.  The 
second group concluded that ctDNA was present more often than CTCs 147; this group used 
a sensitive method for analyzing ctDNA but used a relatively insensitive method for 
analyzing CTCs.  More recently, much higher levels of ctDNA than CTCs were found in 2 
of 3 pediatric patients with neuroblastomas 150. 
 
To investigate this issue further, we assessed both ctDNA and CTCs in the same blood 
sample from patients with typical solid tumors. We simply separated the cellular component 
from plasma and determined the fraction of cells or cell equivalents, respectively, in which 
tumor-specific rearrangements could be identified. Because we did not attempt to physically 
separate tumor cells from normal WBCs, technical issues related to the efficiency of CTC 
purification were eliminated.  The comparison between DNA from CTCs and ctDNA 
cannot easily be performed with point mutations because the background levels of point 
mutations in PCR based assays is too high, even with the sensitive methods used in our 
study.  This background precludes the detection of point mutations at levels less than 1 in 
100,000 cells 11,171.  Because in cancer patients there exists a mixture of several million normal 
cells with very few CTC per ml of blood, a technology that is more sensitive is required.  The 
detection of rearrangements is well suited for this task, as it has been shown that one 
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mutation can be reliably detected among millions of wild-type template molecules; PCR 
errors do not generate specific rearrangements 172. 
 
Using patient-specific rearrangements as a tool, we were able to show that the level of 
ctDNA was always higher than the level of CTCs.  In 13 of 16 patients, ctDNA levels were 
relatively high while no CTCs at all could be detected. This does not mean that ctDNA is 
preferable to CTCs for the detection or monitoring of cancer.  Rather, the optimal 
technology depends on many other factors, including cost and throughput, for which CTC 
detection has advantages.  But this comparison does suggest that the vast majority of ctDNA 
is not derived directly from CTCs.  As the half-life of ctDNA is short (<1.5 hours) 159, in fact 
shorter than that of CTCs 173, our work suggests that the mutant molecules in the plasma are 
generally not derived from the circulating tumor cells. 
 
Another comparison of interest concerns translocations and point mutations.  Our results 
(table S2) show that the number of ctDNA fragments per mL of plasma for translocations 
and point mutations were similar in the majority of cases studied.  However, in 1 of 19 cases, 
a point mutation was detected in a plasma sample in which the studied rearrangement was 
absent. The likely reason for this was that the point mutation was in a driver gene that 
occurred relatively early in tumorigenesis while the rearrangement was sub-clonal, perhaps 
not contributing to the development of the tumor.  In 4 other cases, rearrangements were 
detected at ten-fold higher levels than the point mutations (table S2). In these cases, the 




From a practical perspective, these data suggest the following conclusions:  maximal 
sensitivity for detecting a genetic alteration can be achieved by using a rearrangement present 
within an amplicon.  Many tumors, particularly advanced ones, contain such amplifications, 
making them relatively easy to detect with low coverage (10x) genome sequencing.  As with 
the comparison between CTCs and ctDNA, however, this greater sensitivity does not mean 
that rearrangements are preferred over point mutations for clinical use.  The discovery of a 
rearrangement in a patient's tumor, and the work and time required to develop and test 
primer pairs that can efficiently detect the rearrangement(s) in the degraded DNA 
characteristic of plasma, is considerable. In contrast, a panel of assays detecting the most 
commonly mutated point mutations is currently simpler and less expensive to implement in 
the clinical setting. 
 
Early detection of localized cancers. Until therapeutic agents with much greater potency 
and minimal side effects are developed, the current best hope for reducing cancer morbidity 
and mortality is early detection of neoplastic disease 9. Prior to metastasis, most solid tumors 
can be cured by extant surgical methods, and even when occult metastasis has occurred, 
adjuvant therapy or additional surgery can lead to cure in some patients.  One of the 
encouraging results of our study is that ctDNA was found in the majority of patients with 
localized disease, when their chances of a favorable outcome are highest (Fig. 3). Even in 
patients with Stage I disease, who are nearly always curable by surgery alone, 47% of patients 
were shown to have detectable levels of ctDNA in their plasma.  In Stage III disease, which 
is curable in many patients with certain forms of cancer, more than two-thirds of patients 




Though early detection strategies based on ctDNA are promising, numerous obstacles must 
be overcome before they can be applied clinically.  The fraction of patients with detectable 
ctDNA represents the maximum obtainable with the amount of plasma collected in this 
study (Table S1).  In a screening setting, with the exception of pancreatic ductal 
adenocarcinomas (where one gene, KRAS, is mutated in almost all cases 174, the mutation of 
interest would not be known a priori and a panel of genes would have to be assessed. Our 
study on the EGFR blockade cohort shows that it is indeed possible to assess several genes 
at once for the detection of relatively rare mutations in plasma (table S6). 
 
In addition to these technical challenges, biomedical issues will have to be addressed by any 
ctDNA-based screening test. False positive findings can be problematic for any screening 
assay 175. Experience thus far suggests that benign tumors and non-neoplastic conditions do 
not generally give rise to ctDNA 176, so the "over-diagnosis" of benign tumors is not likely to 
pose a major problem.  However, other studies suggest that a tumor containing ~50 million 
malignant (rather than benign) cells releases sufficient DNA for detection in the circulation 
151.  A cancer of this size is far below that required for definitive imaging at present.  How 
would a patient who had a positive ctDNA test be managed if follow-up imaging tests were 
negative?  A related issue is the fact that the type of mutation does not provide many clues 
to the tumor type.  For example, a patient with a circulating TP53 mutation, in the absence 
of other mutations, could have a cancer in any of several organs. Another question concerns 
the value of detecting early cancers.  In pancreatic ductal adenocarcinomas, for example, it 
might be argued that most patients with a positive ctDNA test will die from their disease 
anyway, given the aggressive nature of this form of cancer. Though these obstacles are 
formidable, we would argue that the presence of detectable amount of a mutant driver gene 
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is a cause for serious concern given the known causal relationships between such mutations 
and cancer. Indeed, this point distinguishes mutation-based biomarkers from all other types 
of biomarkers yet described. 
 
Liquid biopsies. Our studies demonstrate two uses for liquid biopsies.  The first - assessing 
plasma for the presence of specific mutations that can direct patient management - is 
clinically actionable.  We show here that the sensitivity of the liquid biopsy for testing KRAS 
codon 12 is 88.2% in patients with metastatic CRC.  Though conventional tumor biopsies 
are preferable, these often cannot be obtained for logistic or medical reasons.  When tumor 
tissue specimens from metastatic cancer patients are unavailable, liquid biopsies offer an 
alternative that can be rapidly implemented without the pain, risk, and expense entailed by a 
biopsy of one of the metastatic lesions.  Of note is the fact that ctDNA from neoplasms 
confined to the CNS (Fig. 2A) and those with mucinous features (table S4) was infrequently 
detectable.  This suggests that physical obstacles such the blood-brain barrier and mucin 
could prevent ctDNA from entering the circulation. 
 
Tracking Resistance. A second use of liquid biopsies is for identifying resistance mutations 
that occur when patients first respond to therapy, then progress.  The detection of ctDNA 
requires tumor cells to die, and even tumor cells that are resistant to therapy turn over 
rapidly; they die almost as frequently as they are born151. Thus it is expected, and in fact 
observed, that the DNA fragments from drug-resistant cancer cells are found in the plasma.  
Though this approach is mainly of interest for research purposes at present, the obtained 
information can be clinically informative.  A good example of this principle is provided by 
our discovery of remarkably frequent mutations at codon 61 of NRAS and of KRAS, 
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representing 46% of the detected mutations in patients resistant to EGFR blockade.  Codon 
61 mutations of KRAS and NRAS have previously been observed to occur in primary 
colorectal cancers, but very infrequently compared to the prevalence at which we found 
them in patients progressing after EGFR blockade 164. KRAS codon 61 mutations have been 
observed to be associated with primary resistance to EGFR blockade when they occur in 
primary colorectal cancers 163,164,177.  There are no prior studies indicating that NRAS codon 
61 mutations are associated with acquired resistance, but the results in Fig. 6 leave little 
doubt as to their role.  This finding provides unequivocal evidence that these mutations 
confer resistance to therapy - the probability that recurrent mutations at these positions 
occurred by chance alone is essentially nil 151.  It also  supports studies showing that KRAS, 
BRAF, NRAS and EGFR mutations compromise the efficacy of EGFR blockade in patients 
with colorectal cancer177,178. 
 
Collectively, codon 600 mutations of BRAF, codon 61 mutations of KRAS, and codons 12 
or 61 mutations of NRAS occur approximately half as often as mutations in KRAS 12 or 13 
in primary colorectal cancers 179.  These data therefore strongly suggest that patients being 
considered for treatment with EGFR blockading agents should be tested for these additional 
mutations.  This conclusion was independently supported by a clinical study reported during 
the review of our manuscript 180.  Patients harboring mutations at these positions are unlikely 
to benefit from these agents and would be better served by other therapeutic approaches. 
 
Summary. In summary, we demonstrate that ctDNA can be used as a feasible biomarker for 
a variety of different solid tumor types and clinical indications.  The clinical utility of this 
biomarker, and the risks and benefits accruing from knowledge of ctDNA levels, can only be 
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addressed through longitudinal studies of ctDNA in appropriate populations of patients, as 
is currently underway for CTCs 181.  The studies reported here lay the groundwork for such 
future studies. 
 
Supplementary Materials and Methods 
Samples. All samples were collected after Institutional Review Board (IRB) approval at 
participating institutions, under full compliance with HIPAA guidelines.  Tumors and 
adjacent normal tissues were either frozen at a minimum of -80 C or formalin-fixed and 
paraffin- embedded (FFPE) according to standard histopathologic procedures.  Tumors 
were macro-dissected under a dissecting microscope to ensure a neoplastic cellularity of 
>60%.  DNA was purified from the macrodissected frozen tumors using AllPrep (Qiagen, 
cat #80204) and from macrodissected paraffin-embedded tumors with a Qiagen FFPE Kit 
(Qiagen cat #56494).  Translocations, but not point mutations, were previously reported for 
three of the CRCs 172,182.  Translocation data, but not all clinical correlatives, were previously 
reported for eight of the nine neuroblastomas recorded in table S1 112; these cases were 
included in the current study for comparative purposes only. For white blood cell DNA 
extraction, cells were pelleted at 1000 g prior to the preparation of plasma. DNA from these 
cells was purified using AllPrep (Qiagen, cat #80204).  Plasma was used for ctDNA 
measurements in all experiments except in 17 of the 24 cases described in table S6, in which 
serum was used.  DNA from plasma or serum was purified using QIAamp Circulating 
Nucleic Acid kit (Qiagen cat# 55114).  Total plasma DNA concentration was measured 
using quantitative PCR as  described 111. The amounts of plasma available from all patients 
except those used for the liquid biopsy studies are listed in table S1; for the liquid biopsy 
study in table S3, 2 ml plasma was available and for the liquid biopsy study in table S6, 1 ml 
127 
 
serum or 2 ml plasma was used.  One plasma draw was used for each patient except those 
described in table S6, in which two plasma draws were obtained: one prior to initiating 
EGFR blockade and one sample when the tumors had recurred after a clinical response. 
 
Tumor Mutational Profiling. A tiered approach was used to identify somatic mutations in 
tumors.  For pancreatic cancers, genomic regions encompassing KRAS codons 12,13, 59, 60 
and 61 were amplified and the sequence of the PCR products determined via  ligation of 
mutant-specific probes 112 or via SafeSeqS 11, as it is well known that nearly all pancreatic 
ductal adenocarcinomas harbor mutations in the KRAS gene 174, 183.  For colorectal cancers, 
PCR was used to amplify the KRAS, BRAF, TP53, SMAD4, PIK3CA, and APC genes and 
the sequence of the PCR products was determined, generally using SafeSeqS, as described 
below. For all other cancers, paired-end libraries were generated and regions encompassing 
100 genes commonly mutated in cancers were captured as described previously 112.  For 
tumors that did not contain detectable mutations of these genes, exomic sequencing was 
performed after capture of the same libraries via SureSelect (Agilent), as previously described 
184,185.  In cases in which rearrangements were analyzed using PARE (personalized analysis of 
rearranged ends), 172,182, genomic libraries were constructed for whole genome sequencing 
with a physical coverage of ~10x.  Whenever possible, we selected rearrangements within 
amplified segments of the genome.  Such rearrangements would be represented more often 
in tumor DNA than in DNA from normal cells, theoretically increasing the sensitivity of 
detection of the altered fragment in plasma. Once putative rearrangements were identified 
on the basis of sequencing data, PCR primers were designed to amplify PCR products of 100 
bp that spanned the rearrangement.  The rearrangements were confirmed to be somatic by 
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demonstrating that PCR products were generated from the DNA of the tumor but not from 
DNA of non-neoplastic cells of the same patient. 
 
Mutation Detection in ctDNA or CTCs. In the early phases of this study, single base 
substitutions and small insertions or deletions (indels) were assessed either by BEAMing or 
112,152 or by a PCR/ligation method 112,152.  For the latter method, 25% of the plasma DNA 
was aliquotted into wells of a 384-well plate so that an average of 1 ng was contained in each 
well.  After PCR and ligation as described 112,152, all wells were individually evaluated via gel 
electrophoresis and fluorescence imaging.  If all wells contained a mutation, the plasma 
DNA was re-diluted for more precise quantification. If no wells contained a mutation, then a 
further 65% of the plasma was aliquotted and the assay repeated; ~10% of the plasma was 
used to determine DNA concentration and to confirm that the plasma and tumor were 
derived from the same patient via single nucleotide polymorphism analysis. In the latter 
stages of this study, mutations were assessed by SafeSeqS, an approach in which template 
molecules are individually assessed via massively parallel sequencing 11. For SafeSeqS, 25% of 
the plasma DNA was aliquotted into wells of a 96-well plate so that an average of 3 ng DNA 
was contained in each well. The DNA from each well was then amplified using well-specific 
index primers, and the DNA from all wells was pooled and subjected to massively parallel 
sequencing and analysis as described 11.  If no mutations were detected, a further 65% of the 
plasma was aliquotted and the assay repeated; ~10% of the plasma was used to determine 
DNA concentration and to confirm that the plasma and tumor were derived from the same 
patient via single nucleotide polymorphism analysis. In each experiment, equivalent amounts 
of DNA from non-neoplastic cells were included in adjacent wells performed to ensure that 
the identified mutations were not the result of errors generated during PCR or other steps of 
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the procedures 11.  SafeSeqS was used to assess all of the 206 metastatic colorectal cancer 
patients assayed for mutations in the liquid biopsy study (table S3) as well as to assess the 24 
patients assayed for resistance mutations after EGFR blockade (table S6). 
 
To assess differences in assay performance among the methods used to assess ctDNA, we 
quantified the amount of mutations in 20 plasma samples that had been evaluated by all 
three methods used for detecting point mutations (BEAMing 31, PCR-Ligation 112, or Safe-
SeqS 11).  We found that the results were comparable, as evident from the data in fig. S1. All 
three methods could detect one mutant template in the DNA from 5 ml plasma, as 
determined by spiking known amounts of mutant KRAS DNA in plasma DNA from 
normal individuals. 
 
Rearrangements in ctDNA or CTCs were detected and quantified by digital PCR, using 
PARE (Paired Analysis of Rearranged Ends) as described previously 11,172 with the following 
modifications.  First, 25% of the plasma DNA was aliquotted into wells of a 384-well plate 
so that an average of 3 ng (plasma) or 300 ng (WBCs containing CTCs) were contained in 
each well.  After amplification, a portion of each well was evaluated by polyacrylamide gel 
electrophoresis to determine whether a PCR product of the predicted size was present. If all 
wells contained a mutation, the DNA was re-diluted for more precise quantification. If no 
wells contained a mutation, then a further 65% of the plasma was aliquotted and the assay 
repeated. To further verify that the PCR fragments of the expected size contained the 
intended rearrangement, ligation reactions were performed on each PCR fragment as 
described 112,152.  The two oligonucleotides used in the ligation reaction spanned the 
breakpoint so that ligation only occurred if the PCR products assessed contained the 
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rearrangement (fig. S3).  Control experiments with DNA from non-neoplastic cells of the 
same patients showed that each rearrangement reported in this study was not found in the 
germ line of that patient. 
 
Statistical Analyses. Proportions of patients with detectable ctDNA, with 95% Wilson 
confidence intervals, the rank of the proportion and ctDNA concentration by cancer type, 
with 95% bootstrapped confidence intervals, are listed. Proportions of patients with 
detectable ctDNA were compared across cancer types with a likelihood ratio chi-square test 
from a logistic model of detectable ctDNA, across stage of disease with Somers’ Dxy rank 
correlation, and across both cancer type and stage of disease for breast, colon, pancreas, and 
gastroesophageal cancers using a Cochran-Mantel-Haenszel chi-squared test. 
 
For the liquid biopsy cohort of metastatic colorectal cancer patients, the sensitivity and 
specificity, along with 95% confidence intervals, for detecting a plasma KRAS mutation 
compared to the detection of a tissue KRAS mutation were calculated. We also report the 
percent concordance and kappa statistic for the agreement between liquid biopsy and tissue 
samples. 
 
Clinical characteristics of the false negative and true negative groups were compared with 
Pearson’s chi-square test for categorical variables and Wilcoxon Mann Whitney tests for 
continuous variables. Those variables which had <20% missingness of the dependent 
variable were included in a multivariable logistic regression model of true negative status 




In cases with detectable levels of mutant KRAS fragments in the plasma, the association of 
clinical characteristics with the log ctDNA levels was evaluated using univariable linear 
regression models. Logarithm transformations were made for the dependent variable and 
some continuous predictor variables to correct for skewness. Those variables which had 
<20% missingness of the dependent variable were included in a multivariable linear 
regression using lasso penalties. 
 
Overall survival was calculated from the time of ctDNA measurement to the date of death 
or last follow-up. The known prognostic factors (age, ECOG PS and CEA), linearity 
assumed, were included in a multivariable Cox proportional hazards model with ctDNA 
concentration level transformed with a natural spline function. The 2-year survival 
probability estimates were plotted against ctDNA concentration levels, fixing the other 
covariates at the mean (continuous variables) or mode (categorical variables).  The other 
prognostic factors, MSI and BRAF status, had more than 20% missing values and were not 
adjusted in the multivariable model. The variables were selected based on their clinical 
relevance, and none were removed by statistical significance testing. 
 
Statistical analyses were performed using the R statistical package (version 2.15.1). 
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Table 5-S1. Mutations in 410 patients with various malignancies. 
Sample ID #





Mutation - nucleotide alteration









Clinical Stage Age Sex
Evaluated as part of 
the metastatic cohort 
(fig. 2A and fig. 2B)
BLD 21 Bladder 3000 Intra-chromosomal; Inversion - chr12:68441745-chr12:67966237 Not applicable 226 PARE 2
BLD 24 Bladder 2000 Inter-chromosomal; chr2:204396710-chr1:154286405 Not applicable 3.9 PARE 2
BLD 29 Bladder 2000 Inter-chromosomal; chr10:127675281-chr20:17940042 Not applicable 0.0 PARE 2
BLD 30 Bladder 3000 Inter-chromosomal; chr7:57625307-chr16:10203013 Not applicable 0.0 PARE 2
BLD 41 Bladder 5000 TP53 c.841G>A TP53 p.D281N 655 SafeSeqS 4 62 M X
BLD 44 Bladder 1000 TP53 c.839G>C TP53 p.R280T 2,450 SafeSeqS 2 77 M
BLD 46 Bladder 2500 TP53 c.853G>A TP53 p.E285K 2.0 SafeSeqS 4 82 M X
BLD 47 Bladder 2000 TP53 c.991C>T TP53 p.Q331X 308 SafeSeqS 4 77 M X
BLD 48 Bladder 2000 CTNNB1 c.110C>T CTNNB1 p.S37F 6.5 SafeSeqS 3 73 M
BLD 50 Bladder 2000 TP53 c.184G>T TP53 p.E62X 0.0 SafeSeqS 3 77 M
 CP2 Breast 4000 Intra-chromosomal; Duplication - chr7:86899034-chr7:92758338 Not applicable 10,900 PARE 4 X
 CP3 Breast 4000 Intra-chromosomal; Duplication - chr18:52644480-chr18:53770564 Not applicable 2,780 PARE 4 X
 CP4 Breast 4000 Intra-chromosomal; Inversion - chr11:33844453-chr11:20019027 Not applicable 970 PARE 4 X
 CP5 Breast 4000 Intra-chromosomal; Deletion - chr9:26742593-chr9:14289825 Not applicable 95 PARE 4 X
 CP6 Breast 4000 Intra-chromosomal; Deletion - chr8:89365486-chr8:89237886 Not applicable 233 PARE 4 X
 CP7 Breast 4000 Intra-chromosomal; Duplication - chr21:43764815-chr21:46124984 Not applicable 600 PARE 4 X
 CP8 Breast 4000 Intra-chromosomal; Inversion - chr17:38444351-chr17:38395199 Not applicable 1.3 PARE 4 X
 CP9 Breast 4000 Inter-chromosomal; chr10:64401594-chr3:28363857 Not applicable 115 PARE 4 X
BR 801 Breast 2000 NOTCH1 c.7171C>T NOTCH1 p.Q2391X 0.0 SafeSeqS 3 62 F
BR 802 Breast 2000 TP53 c.713G>A TP53 p.C238Y 33 SafeSeqS 3 55 F
BR 803 Breast 2000 TP53 c.214_215insC TP53 p.P72fs 21,900 SafeSeqS 3 54 F
BR 804 Breast 2000 TP53 c.733G>A TP53 p.G245S 128 SafeSeqS 3 62 F
BR 805 Breast 2000 NOTCH1 c.4873G>T NOTCH1 p.E1625X 28 SafeSeqS 3 81 F
BR 806 Breast 2000 TP53 c.637C>T TP53 p.R213X 110 SafeSeqS 3 81 F
BR 807 Breast 2000 TP53 c.329G>C TP53 p.R110P 0.0 SafeSeqS 2 55 F
BR 831 Breast 2000 Intra-chromosomal; Inversion - chr5:170838182-chr5:150490356 Not applicable 0.0 PARE 2 77 F
BR 832 Breast 2000 Intra-chromosomal; Deletion - chr18:32113305-chr18:32008616 Not applicable 0.0 PARE 2 47 F
BR 833 Breast 2000 Intra-chromosomal; Duplication - chr2:30643115-chr2:30607641 Not applicable 2,480 PARE 2 77 F
BR 834 Breast 2000 Inter-chromosomal; chr8:111657741-chr5:64600981 Not applicable 41 PARE 2 57 F
BR 837 Breast 2000 Intra-chromosomal; Inversion - chr1:85446612-chr1:84923571 Not applicable 3.0 PARE 2 43 F
BR 838 Breast 2000 Intra-chromosomal; Inversion - chr17:35367968-chr17:35389930 Not applicable 0.0 PARE 2 52 F
BR 839 Breast 2000 Inter-chromosomal; chr5:64292782-chr12:12639702 Not applicable 0.0 PARE 2 82 F
BR 840 Breast 2000 AKT1 c.49G>A AKT1 p.E17K 0.0 SafeSeqS 2 76 F
BR 841 Breast 2000 Inter-chromosomal; chr8:10996593-chr6:106894670 Not applicable 688 PARE 2 42 F
BR 842 Breast 2000 Intra-chromosomal; Inversion - chr17:35339193-chr17:34860391 Not applicable 0.0 PARE 2 52 F
BR 843 Breast 2000 TP53 c.659A>G TP53 p.Y220C 0.0 SafeSeqS 1 67 F
BR 848 Breast 5000 Intra-chromosomal; Deletion - chr19:33,559,434-cgr19:35,505,204 Not applicable 9,900 PARE 2 28 F
BREAST10-1 Breast 3000 TP53 c.332T>A TP53 p.L111Q 1,170 PCR-Ligation 4 56 F X
BREAST2-1 Breast 3000 FBXL4 c.1187T>A FBXL4 p.I396N 0.0 SafeSeqS 4 82 F X
BREAST3-1 Breast 3000 TP53 c.536A>G TP53 p.H179R 7,500 PCR-Ligation 4 76 F X
BREAST4-1 Breast 3000 PIK3CA c.3140A>G PIK3CA p.H1047R 0.0 PCR-Ligation 4 71 F X
BREAST5-1 Breast 3000 EIF4B c.1756-1G>C Not applicable 122 SafeSeqS 4 80 F X
CP10 Breast 4000 TP53 c.637C>T TP53 p.R213X 2,660 SafeSeqS 4 X
CRC 02 Colorectal 5000 Inter-chromosomal; chr12:73097777-chr1:63099083 Not applicable 22,000 PARE 1 65 M
CRC 03 Colorectal 5000 Intra-chromosomal; chr11:98914172-chr11:98993460 Not applicable 6,410 PARE 1 66 M
CRC 06 Colorectal 5000 Intra-chromosomal; chr13:27679603-chr13:25685009 Not applicable 85 PARE 1 71 M
CRC 07 Colorectal 5000 Intra-chromosomal; chr4:85109657-chr4:85408635 Not applicable 42 PARE 1 57 F
CRC 11 Colorectal 1000 Intra-chromosomal; Deletion - chr21:35145207-chr21:36324769 Not applicable 103,000 PARE 4 56 F X
CRC 12 Colorectal 1000 Intra-chromosomal; Deletion - chr6:58080933-chr6:67229823 Not applicable 79 PARE 4 48 F X
CRC 13 Colorectal 1000 TP53 c.743G>A TP53 p.R248Q 13 SafeSeqS 4 87 F X
CRC 14 Colorectal 5000 Intra-chromosomal; Duplication - chr8:141375810-chr8:141405769 Not applicable 31 PARE 4 35 F X
CRC 21 Colorectal 5000 Intra-chromosomal; chr1:237741691-chr1:244145093 Not applicable 685 PARE 2 60 M
CRC 27 Colorectal 5000 Intra-chromosomal; chr13:102839339-chr13:105470344 Not applicable 55 PARE 2 49 F
CRC 30 Colorectal 5000 Intra-chromosomal; chr20:2658058-chr20:2770031 Not applicable 1,470,000 PARE 3 73 F
CRC 31 Colorectal 2000 Inter-chromosomal; chr1:174709633-chr2:177720185 Not applicable 35 PARE 1 87 F
CRC 32 Colorectal 2000 Intra-chromosomal; Deletion - chr18:2502911-chr18:5004367 Not applicable 37 PARE 2 82 M
CRC 33 Colorectal 2000 Intra-chromosomal; Deletion - chr2:149076017-chr2:149290239 Not applicable 0.0 PARE 2 73 F
CRC 34 Colorectal 2000 Intra-chromosomal; Inversion - chr21:40439891-chr21:40525788 Not applicable 0.0 PARE 2 77 F
CRC 35 Colorectal 2000 Intra-chromosomal; Deletion - chr1:21891451-chr1:21892730 Not applicable 5.0 PARE 2 72 M
CRC 36 Colorectal 2000 Intra-chromosomal; Duplication - chr20:52263938-chr20:52260592 Not applicable 0.0 PARE 2 72 F
CRC 37 Colorectal 2000 Intra-chromosomal; Duplication - chr3:170782510-chr3:170870975 Not applicable 0.0 PARE 1 72 F
CRC 38 Colorectal 2000 Intra-chromosomal; Deletion - chr3:60080713-chr3:60031900 Not applicable 0.0 PARE 1 66 F
CRC 39 Colorectal 2000 Intra-chromosomal; Inversion - chr17:61955923-chr17:29976989 Not applicable 0.0 PARE 2 66 M
CRC 40 Colorectal 2000 Intra-chromosomal; Duplication - chr10:95185791-chr10:99077846 Not applicable 25 PARE 1 77 M
CRC 41 Colorectal 2000 APC c.3871C>T APC p.Q1291X 2.8 SafeSeqS 1 52 M
CRC 42 Colorectal 2000 BRAF c.1799T>A BRAF p.V600E 8.8 SafeSeqS 1 72 F
CRC 51 Colorectal 4000 Inter-chromosomal; chr8:30060122-chr1:190065347 Not applicable 3,850 PARE 4 70 M X
CRC 53 Colorectal 5000 Intra-chromosomal; Deletion - chr16:52977177-chr16:52965488 Not applicable 7,150 PARE 4 50 M X
CRC 54 Colorectal 5000 Intra-chromosomal; Deletion - chr11:7250750-chr11:19457296 Not applicable 1,240 PARE 4 56 F X
CRC 55 Colorectal 5000 Intra-chromosomal; Inversion - chr8:38281631-chr8:39225849 Not applicable 295 PARE 4 53 M X
CRC 58 Colorectal 5000 Intra-chromosomal; Deletion - chr20:14839816-chr20:14863644 Not applicable 1,370 PARE 4 50 F X
CRC 59 Colorectal 5000 KRAS c.35G>A KRAS p.G12D 277 SafeSeqS 4 48 F X
CRC 60 Colorectal 5000 Intra-chromosomal; Inversion - chr17:35277642-chr17:35163714 Not applicable 73,300 PARE 4 53 M X
CRC 61 Colorectal 5000 TP53 c.818G>A TP53 p.R273H 427 SafeSeqS 4 35 F X
CRC 62 Colorectal 5000 TP53 c.455C>T TP53 p.P152L 361 SafeSeqS 4 63 M X
CRC 63 Colorectal 5000 TP53 c.844C>T TP53 p.R282W 1,490 SafeSeqS 4 69 M X
CRC 64 Colorectal 4000 KRAS c.38G>A KRAS p.G13D 113 SafeSeqS 4 37 F X
CRC 65 Colorectal 5000 KRAS c.38G>A KRAS p.G13D 973 SafeSeqS 4 58 M X
CRC 66 Colorectal 5000 KRAS c.35G>C KRAS p.G12A 1,220 SafeSeqS 4 64 F X
CRC 67 Colorectal 5000 TP53 c.396G>C TP53 p.K132N 1.9 SafeSeqS 4 43 F X
CRC Bio 162 Colorectal 1000 APC c.3927_3931delAAAGA APC p.E1309_I1311fs 909 BEAMing 4 48 M X
CRC Bio 168 Colorectal 1000 KRAS c.35G>A KRAS p.G12D 374 BEAMing 4 38 M X
CRC Bio 180 Colorectal 1000 BRAF c.1799T>A BRAF p.V600E 22,900 SafeSeqS 4 60 M X
CRC Bio 203 Colorectal 1000 KRAS c.35G>A KRAS p.G12D 485 SafeSeqS 4 86 F X
CRC Bio 204 Colorectal 3000 APC c.4348C>T APC p.R1450X 1,440 SafeSeqS 4 36 M X
CRC Bio 23 Colorectal 5000 Intra-chromosomal; Deletion - chr16:6343641-chr16:6727736 Not applicable 28,500 PARE 4 57 F X
CRC Bio 92 Colorectal 1000 APC c.4216C>T APC p.Q1406X 377 SafeSeqS 3 54 F
OLS 13k Colorectal 3000 TP53 c.406C>T TP53 p.Q136X 7.5 PCR-Ligation 3
OLS 14k Colorectal 3000 TP53 c.613T>A TP53 p.Y205N 48 PCR-Ligation 3
OLS 20k Colorectal 3000 TP53 c.613T>A TP53 p.Y205N 48 PCR-Ligation 3
OLS 21k Colorectal 3000 TP53 c.833C>T TP53 p.P278L 24 PCR-Ligation 2
OLS 30k Colorectal 3000 TP53 c.817C>T TP53 p.R273C 3.7 PCR-Ligation 1
OLS 33k Colorectal 3000 KRAS c.35G>T KRAS p.G12V 144 PCR-Ligation 3
OLS 39k Colorectal 3000 PIK3CA c.1624G>A PIK3CA p.E542K 34 PCR-Ligation 3
OLS 47k Colorectal 3000 BRAF c.1799T>A BRAF p.V600E 26 PCR-Ligation 2
OLS 4k Colorectal 3000 KRAS c.35G>A KRAS p.G12D 6.5 PCR-Ligation 3
OLS 52k Colorectal 3000 TP53 c.404_406dupGCC Not applicable 6.5 PCR-Ligation 3
OLS 57k Colorectal 3000 PIK3CA c.1636C>A PIK3CA p.Q546K 11 PCR-Ligation 1
OLS 58k Colorectal 3000 PIK3CA c.1035T>A PIK3CA p.N345K 50 PCR-Ligation 2
OLS 60k Colorectal 3000 KRAS c.34G>T KRAS p.G12C 0.0 PCR-Ligation 1
OLS 61k Colorectal 3000 APC c.4678G>T APC p.E1560X 0.0 PCR-Ligation 1
OLS 62k Colorectal 3000 KRAS c.35G>T KRAS p.G12V 11 PCR-Ligation 3
OLS 66K Colorectal 5000 APC c.4364delA APC p.N1455fs 14 PCR-Ligation 3
OLS 67K Colorectal 5000 BRAF c.1799T>A BRAF p.V600E 23 PCR-Ligation 3
OLS 69k Colorectal 3000 PIK3CA c.1633G>A PIK3CA p.E545K 0.0 PCR-Ligation 1
OLS 72K Colorectal 4000 KRAS c.34G>A KRAS p.G12S 4.2 PCR-Ligation 2
OLS 8k Colorectal 3000 KRAS c.35G>T KRAS p.G12V 17 PCR-Ligation 3
PAP 024 Endometrial 4000 CTNNB1 c.101G>T CTNNB1 p.G34V 0.0 SafeSeqS 3 47 F
PAP 025 Endometrial 5000 TP53 c.291_292delCC TP53 p.V97_P98fs 240 SafeSeqS 1 75 F
PAP 026 Endometrial 5000 NRAS c.35G>A NRAS p.G12D 1.1 SafeSeqS 1 87 F
PAP 030 Endometrial 5000 MSH6 c.2153G>A MSH6 p.S718N 0.0 SafeSeqS 1 74 F
PAP 031 Endometrial 5000 CTNNB1 c.110C>A CTNNB1 p.S37Y 0.0 SafeSeqS 1 61 F
PAP 032 Endometrial 5000 PTEN c.388C>G PTEN p.R130G 0.0 SafeSeqS 1 83 F
PAP 033 Endometrial 5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 1 68 F
PAP 34 Endometrial 5000 KRAS c.100G>A CTNNB1 p.G34R 1.1 SafeSeqS 1 55 F
PAP 35 Endometrial 5000 KRAS c.35G>A KRAS p.G12D 30 SafeSeqS 4 49 F X
PAP 71 Endometrial 5000 PTEN c.388C>G PTEN p.R130G 0.0 SafeSeqS 1 56 F
PAP 80 Endometrial 5000 TP53 c.566delC TP53 p.A189fs 0.0 SafeSeqS 3 94 F
PAP 83 Endometrial 5000 PIK3CA c.3140A>G PIK3CA p.H1047R 0.0 SafeSeqS 1 51 F
CB ESO 03 Gastroesophageal 2000 TP53 c.818G>A TP53 p.R273H 65 SafeSeqS 3 52 F
CB ESO 04 Gastroesophageal 2000 PIK3CA c.263G>A PIK3CA p.R88Q 7.5 SafeSeqS 3 67 M
CB ESO 05 Gastroesophageal 2000 TP53 c.437G>A TP53 p.W146X 0.0 SafeSeqS 3 72 M
CB ESO 07 Gastroesophageal 2000 APC c.7709C>A APC p.S2570X 0.0 SafeSeqS 3 62 M
CB ESO 08 Gastroesophageal 2000 TP53 c.584T>C TP53 p.I195T 0.0 SafeSeqS 3 87 M
CB ESO 09 Gastroesophageal 2500 TP53 c.641A>G TP53 p.H214R 2.3 SafeSeqS 3 67 M
CB ESO 10 Gastroesophageal 2000 TP53 c.375+2A>G Not applicable 0.0 SafeSeqS 3 72 F
CB ESO 11 Gastroesophageal 2000 TP53 c.97-1C>T Not applicable 48 SafeSeqS 3 82 M
CBGP1-1 Gastroesophageal 3000 CDH1 c.1569T>A CDH1 p.Y523X 185 PCR-Ligation 4 71 F X
CBGP3-1 Gastroesophageal 3000 TP53 c.817C>T TP53 p.R273C 67 PCR-Ligation 4 57 M X
CBGP5-1 Gastroesophageal 3000 CDH1 c.563T>A CDH1 p.V188D 220 PCR-Ligation 4 67 F X
CBGP9-1 Gastroesophageal 3000 TP53 c.559+1C>T Not applicable 50 PCR-Ligation 4 95 M X
ESOPL1-1 Gastroesophageal 5000 TP53 c.818G>A TP53 p.R273H 31 PCR-Ligation 4 57 M X
ESOPL2-1 Gastroesophageal 5000 TP53 c.1010G>A TP53 p.R337H 215 PCR-Ligation 4 66 M X
G801 Gastroesophageal 2000 XIRP2 c.8144T>C XIRP2 p.L2715P 1,690 SafeSeqS 3 44 F
G803 Gastroesophageal 2000 CDKN2A c.334delC CDKN2A p.R112fs 1,850 SafeSeqS 2 59 M
G804 Gastroesophageal 2000 RELN c.2005T>C RELN p.Y669H 239 SafeSeqS 4 39 F X
G805 Gastroesophageal 2000 SPTB c.2939C>A SPTB p.T980K 0.0 SafeSeqS 2 79 M
G806 Gastroesophageal 2000 TP53 c.743G>A TP53 p.R248Q 99 SafeSeqS 3 61 M
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G807 Gastroesophageal 2000 PIK3CA c.263G>A PIK3CA p.R88Q 157 SafeSeqS 2 76 M
G809 Gastroesophageal 2000 PIK3CA c.278G>A PIK3CA p.R93Q 0.0 SafeSeqS 3 61 M
CB GLIOMA 22 Glioma 2000 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II oligodendroglioma 23 M X
CB GLIOMA 29 Glioma 5000 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II oligodendroglioma 35 M X
CB GLIOMA 30 Glioma 5000 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II astrocytoma 42 M X
CB GLIOMA 31 Glioma 5000 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II astrocytoma 24 M X
CB GLIOMA10 Glioma 2000 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II oligodendroglioma 43 F X
CB GLIOMA4 Glioma 2000 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II oligodendroglioma 31 M X
CB GLIOMA5 Glioma 3000 TP53 c.856G>A TP53 p.E286K 0.0 SafeSeqS Glioblastoma 44 M X
CBBRP1 Glioma 4800 Intra-chromosomal; Deletion - chr11:29390774-chr11:13324150 Not applicable 0.0 PARE Glioblastoma 74 M X
CBBRP11 Glioma 5000 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Glioblastoma 58 M X
CBBRP12 Glioma 5000 TP53 c.481G>A TP53 p.A161T 0.0 PCR-Ligation Grade II astrocytoma 53 F X
CBBRP2 Glioma 2400 TP53 c.419C>T TP53 p.T140I 0.0 PCR-Ligation Glioblastoma 64 M X
CBBRP23 Glioma 4500 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II oligodendroglioma 35 F X
CBBRP24 Glioma 4800 IDH1 c.394C>A IDH1 p.R132S 0.0 PCR-Ligation Low grade astrocytoma 32 F X
CBBRP25 Glioma 4800 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Grade II oligodendroglioma 24 F X
CBBRP27 Glioma 4800 IDH1 c.394C>A IDH1 p.R132S 0.0 PCR-Ligation Grade II astrocytoma 34 F X
CBBRP28 Glioma 3840 IDH1 c.394C>A IDH1 p.R132S 0.0 PCR-Ligation Grade II astrocytoma 36 M X
CBBRP3 Glioma 5000 Intra-chromosomal; Duplication - chr12:67053391-chr12:56218273 Not applicable 0.0 PARE Glioblastoma 56 F X
CBBRP32 Glioma 1920 IDH1 c.395G>A IDH1 p.R132H 0.0 PCR-Ligation Gliosarcoma X
CBBRP9 Glioma 5000 TP53 c.452C>A TP53 p.P151H 0.0 PCR-Ligation Grade III astrocytoma 55 M X
GLI 101 Glioma 5000 TP53 c.731G>A TP53 p.G244D 0.0 SafeSeqS Glioblastoma 59 M X
GLIOMA 102 Glioma 5000 EGFR c.2156G>A EGFR p.G719D 0.0 SafeSeqS Glioblastoma 62 M X
GLIOMA 105 Glioma 5000 PIK3CA c.263G>A PIK3CA p.R88Q 0.0 SafeSeqS Glioblastoma 46 M X
GLIOMA 106 Glioma 5000 TP53 c.569_570CT>TC TP53 p.P190L 0.0 SafeSeqS Glioblastoma 62 M X
GLIOMA 109 Glioma 5000 PTEN c.799A>T PTEN p.K267X 0.0 SafeSeqS Glioblastoma 78 F X
GLIOMA 110 Glioma 3500 TP53 c.569C>T TP53 p.P190L 0.0 SafeSeqS Glioblastoma 84 F X
YN 406 Glioma 5000 Intra-chromosomal; Deletion - chr7:40716157-chr7:40524100 Not applicable 5.7 PARE Glioblastoma 71 M X
YN 407 Glioma 5000 Intra-chromosomal; Duplication - chr7:54793913-chr7:56081250 Not applicable 5.0 PARE Glioblastoma 64 M X
CB HN 10 Head and Neck Squamous Cell 5000 STK11 c.393C>A STK11 p.Y131X 5.5 SafeSeqS 2 54 M
CB HN 9 Head and Neck Squamous Cell 5000 PIK3CA c.1624G>C PIK3CA p.E542Q 1.6 SafeSeqS 4 79 F X
CBHNP1-1 Head and Neck Squamous Cell 5000 PIK3CA c.112C>T PIK3CA p.R38C 44 PCR-Ligation 4 38 M X
CBHNP2-1 Head and Neck Squamous Cell 5000 TP53 c.1010G>T TP53 p.R337L 1,500 PCR-Ligation 4 59 F X
CBHNP3-1 Head and Neck Squamous Cell 3200 BRAF c.1801A>G BRAF p.K601E 0.0 PCR-Ligation 4 78 M X
CBHNP4-1 Head and Neck Squamous Cell 4000 TP53 c.536A>G TP53 p.H179R 50 PCR-Ligation 4 58 M X
CBHNP6-1 Head and Neck Squamous Cell 5000 TP53 c.579_580TC>AT TP53 p.H193_L194QF 500 PCR-Ligation 4 52 F X
CBHNP7-1 Head and Neck Squamous Cell 5000 AKAP9 c.3395G>T AKAP9 p.R1132L 1,280 SafeSeqS 4 68 M X
HN 14 Head and Neck Squamous Cell 1500 TP53 c.817C>T TP53 p.R273C 19 PCR-Ligation 4 44 F X
HN 305 Head and Neck Squamous Cell 1000 Intra-chromosomal; Deletion - chr11:69177060-chr11:69178251 Not applicable 9.0 PARE 3 50 M
HN16 Head and Neck Squamous Cell 1500 TP53 c.378C>G TP53 p.Y126X 0.0 PCR-Ligation 4 68 M X
HN41 Head and Neck Squamous Cell 1500 PIK3CA c.3140A>T PIK3CA p.H1047L 0.0 PCR-Ligation 4 42 M X
HCC 103 Hepatocellular 5000 TP53 c.536A>G TP53 p.H179R 7.2 SafeSeqS 4 55 F X
HCC 105 Hepatocellular 2000 PALB2 c.1620C>G PALB2 p.N540K 15 SafeSeqS 3 87 F X
HCC 106 Hepatocellular 2000 EGFR c.2014C>G EGFR p.H672D 7,910 SafeSeqS 3 67 F X
HCC 107 Hepatocellular 2000 SLC17A9 c.799G>C SLC17A9 p.E267Q 0.0 SafeSeqS 3 62 M X
CBMB10-1 Medulloblastoma 1000 CTNNB1 c.98C>G CTNNB1 p.S33C 38 PCR-Ligation Medulloblastoma X
CBMB1-1 Medulloblastoma 2000 CTNNB1 c.98C>A CTNNB1 p.S33Y 2.5 PCR-Ligation Medulloblastoma X
CBMB11-1 Medulloblastoma 1000 PTCH1 c.2778G>C PTCH1 p.W926C 0.0 PCR-Ligation Medulloblastoma X
CBMB12-1 Medulloblastoma 1000 PTCH1 c.707G>A PTCH1 p.W236X 0.0 PCR-Ligation Medulloblastoma X
CBMB13-1 Medulloblastoma 2000 CTNNB1 c.94G>T CTNNB1 p.D32Y 0.0 PCR-Ligation Medulloblastoma X
CBMB2-1 Medulloblastoma 1000 PTCH1 c.3154_3155insCGGC PTCH1 p.T1052fs 5.5 PCR-Ligation Medulloblastoma X
CBMB24-1 Medulloblastoma 5000 KDM6A c.4153C>T KDM6A p.Q1385X 39 SafeSeqS Medulloblastoma X
CBMB3-1 Medulloblastoma 1000 MLL2 c.1652C>T MLL2 p.P551L 10.0 PCR-Ligation Medulloblastoma X
CBMB4-1 Medulloblastoma 2000 CTNNB1 c.98C>T CTNNB1 p.S33F 0.0 PCR-Ligation Medulloblastoma X
CBMB5-1 Medulloblastoma 1000 PTCH1 c.981T>A PTCH1 p.C327X 0.0 PCR-Ligation Medulloblastoma X
CBMB6-1 Medulloblastoma 1000 PTEN c.633delCinsGCG PTEN p.C211fs 0.0 PCR-Ligation Medulloblastoma X
CBMB7-1 Medulloblastoma 1000 CTNNB1 c.110C>G CTNNB1 p.S37C 7.5 PCR-Ligation Medulloblastoma X
CBMB8-1 Medulloblastoma 1000 TP53 c.376-2T>C Not applicable 0.0 PCR-Ligation Medulloblastoma X
CBMB9-1 Medulloblastoma 1000 PTCH1 c.3119_3120insT PTCH1 p.F1040fs 0.0 PCR-Ligation Medulloblastoma X
CB MEL 09 Melanoma 2000 NRAS c.182A>G NRAS p.Q61R 0.0 SafeSeqS 4 57 F X
CB MEL 10 Melanoma 2000 BRAF c.1799T>A BRAF p.V600E 165 SafeSeqS 4 52 F X
CB MEL 11 Melanoma 5000 ALK c.4732C>T ALK p.P1578S 1.1 SafeSeqS 4 40 F X
CB MEL2 Melanoma 5000 BRAF c.1799T>A BRAF p.V600E 1.2 PCR-Ligation 4 32 F X
MEL 03 Melanoma 5000 KRAS c.34G>T KRAS p.G12C 0.0 SafeSeqS 3 71 M
MEL 21 Melanoma 4000 Intra-chromosomal; Deletion - chr4:70925073-chr4:62475744 Not applicable 364 PARE 4 46 F X
MEL 22 Melanoma 4000 TP53 c.639A>G TP53 p.R213R 0.0 SafeSeqS 2 51 M
MEL 23 Melanoma 4000 BRAF c.1799T>A BRAF p.V600E 1,750 SafeSeqS 4 52 F X
MEL 24 Melanoma 4000 BRAF c.1799T>A BRAF p.V600E 6,140 SafeSeqS 4 61 M X
MEL 25 Melanoma 4000 Inter-chromosomal; chr1:182048490-chr12:25928534 Not applicable 60 PARE 4 39 M X
MEL 26 Melanoma 4000 Inter-chromosomal; chr9:125576270-chr21:41610646 Not applicable 1,090 PARE 4 41 M X
MEL 27 Melanoma 4000 Intra-chromosomal; Deletion - chr2:137699753-chr2:137700957 Not applicable 15,600 PARE 4 45 M X
MEL 28 Melanoma 4000 Inter-chromosomal; chr12:42334536-chr11:63813127 Not applicable 90 PARE 4 55 F X
MEL 30 Melanoma 5000 TERT promoter, chr5 g.1295250G>A Not applicable 288 SafeSeqS 4 X
MELP1-1 Melanoma 5000 BRAF c.1799T>A BRAF p.V600E 345 PCR-Ligation 4 48 F X
MELP4-1 Melanoma 2000 BRAF c.1799T>A BRAF p.V600E 0.0 PCR-Ligation 4 35 M X
MELP5-1 Melanoma 5000 BRAF c.1799T>A BRAF p.V600E 220 SafeSeqS 4 68 M X
MELP6-1 Melanoma 5000 BRAF c.1799T>A BRAF p.V600E 57 PCR-Ligation 4 43 F X
MELP7-1 Melanoma 5000 BRAF c.1799T>A BRAF p.V600E 4.7 PCR-Ligation 4 54 M X
MELP8-1 Melanoma 5000 BRAF c.1405G>C BRAF p.G469R 0.0 SafeSeqS 4 X
NB 2464 Neuroblastoma 1500 Intra-chromosomal; Inversion - chr12:6549283-chr12:6539393 Not applicable 0.0 PARE 4 X
NB 2870 Neuroblastoma 1000 Intra-chromosomal; Duplication - chr2:16365880-chr2:15815798 Not applicable 4,050 PARE 4 X
NB 2885 Neuroblastoma 1000 Intra-chromosomal; Duplication - chr19:46265851-chr19:46348530 Not applicable 19 PARE 4 X
NB 2885 F Neuroblastoma 1000 Intra-chromosomal; Duplication - chr19:46265851-chr19:46348530 Not applicable 0.0 PARE 4 X
NB 6321 6 Neuroblastoma 1500 Intra-chromosomal; Duplication - chr8:77658113-chr8:77668843 Not applicable 0.0 PARE 4 X
NB01 Neuroblastoma 1500 Intra-chromosomal; Inversion - chr2:6705809-chr2:19245803 Not applicable 222,000 PARE 4 X
NB02 Neuroblastoma 2200 Intra-chromosomal; Deletion - chr2:30366503-chr17:44326802 Not applicable 680 PARE 4 X
NB03 Neuroblastoma 2000 Intra-chromosomal; Inversion - chr2:15889847-chr2:16118423 Not applicable 925,000 PARE 4 X
NB04 Neuroblastoma 2600 Intra-chromosomal; Inversion - chr2:65488059-chr11:77699660 Not applicable 243,000 PARE 4 X
CB LUNG 17 Non-Small Cell Lung  2000 TP53 c.281C>A TP53 p.S94X 100 SafeSeqS 2 67 M
CB LUNG 19 Non-Small Cell Lung  2000 TP53 c.1045G>T TP53 p.E349X 4.0 SafeSeqS 1 72 M
CB LUNG 20 Non-Small Cell Lung  2000 TP53 c.569C>T TP53 p.P190L 2.5 SafeSeqS 2 77 M
CB LUNG 22 Non-Small Cell Lung  2000 ZBTB4 c.1469G>T ZBTB4 p.G490V 0.0 SafeSeqS 2 77 F
CB LUNG 23 Non-Small Cell Lung  1000 SFRP5 c.139T>C SFRP5 p.Y47H 909 SafeSeqS 2 77 F
1110 Ovarian 2000 TP53 c.524G>A TP53 p.R175H 14,000 SafeSeqS 3 47 F X
CB01-1 Ovarian 2000 TP53 c.614A>G TP53 p.Y205C 180 PCR-Ligation 3 67 F X
CB05-1 Ovarian 2000 TP53 c.725G>T TP53 p.C242F 80,000 PCR-Ligation 3 53 F X
CB06-1 Ovarian 2000 TP53 c.487_488insGAT TP53 p.Y163X 405 PCR-Ligation 3 54 F X
CB09-1 Ovarian 2000 TP53 c.818G>A TP53 p.R273H 200 PCR-Ligation 3 44 F X
CB10-1 Ovarian 2000 TP53 c.843C>A TP53 p.D281E 250 PCR-Ligation 3 74 F X
CB11-1 Ovarian 2000 TP53 c.742C>T TP53 p.R248W 10.0 PCR-Ligation 3 64 F X
OV 101 Ovarian 5000 TP53 c.472C>G TP53 p.R158G 2.5 SafeSeqS 2
PAP 36 Ovarian 5000 PIK3CA c.1637A>T PIK3CA p.Q546L 0.0 SafeSeqS 1
CBPANC 0 Pancreatic Ductal  1000 KRAS c.35G>A KRAS p.G12D 625 BEAMing 4 53 M X
CBPP12-1 Pancreatic Ductal  4500 KRAS c.35G>A KRAS p.G12D 10.0 PCR-Ligation 4 63 F X
CBPP15-1 Pancreatic Ductal  4500 KRAS c.35G>T KRAS p.G12V 2.2 PCR-Ligation 4 62 M X
CBPP16-1 Pancreatic Ductal  4500 KRAS c.35G>T KRAS p.G12V 5,350 PCR-Ligation 2 57 M
CBPP19-1 Pancreatic Ductal  4500 KRAS c.35G>T KRAS p.G12V 5.0 PCR-Ligation 2 67 M
CBPP2-1 Pancreatic Ductal  4500 KRAS c.35G>A KRAS p.G12D 18 PCR-Ligation 2 44 M
CBPP21-1 Pancreatic Ductal  1350 KRAS c.35G>T KRAS p.G12V 84 PCR-Ligation 1 62 F
CBPP24-1 Pancreatic Ductal  4673 KRAS c.35G>A KRAS p.G12D 2.0 PCR-Ligation 2 74 F
CBPP25-1 Pancreatic Ductal  2804 KRAS c.35G>A KRAS p.G12D 24 BEAMing 2 73 M
CBPP26-1 Pancreatic Ductal  4673 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 2 53 M
CBPP28-1 Pancreatic Ductal  2804 KRAS c.35G>T KRAS p.G12V 9.0 PCR-Ligation 2 58 M
CBPP3-1 Pancreatic Ductal  4500 KRAS c.35G>T KRAS p.G12V 10.0 PCR-Ligation 2 50 M
CBPP31-1 Pancreatic Ductal  4800 KRAS c.35G>T KRAS p.G12V 16 PCR-Ligation 4 78 M X
CBPP32-1 Pancreatic Ductal  4800 KRAS c.34G>C KRAS p.G12R 265 PCR-Ligation 4 68 M X
CBPP34-1 Pancreatic Ductal  4800 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 2 61 F
CBPP35-1 Pancreatic Ductal  4800 KRAS c.35G>A KRAS p.G12D 13 PCR-Ligation 2 72 M
CBPP36-1 Pancreatic Ductal  4800 KRAS c.35G>T KRAS p.G12V 0.0 PCR-Ligation 2 59 F
CBPP37-1 Pancreatic Ductal  4800 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 1 63 M
CBPP38-1 Pancreatic Ductal  4800 KRAS c.35G>A KRAS p.G12D 30 PCR-Ligation 2 85 M
CBPP39-1 Pancreatic Ductal  2400 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 2 54 F
CBPP40-1 Pancreatic Ductal  4320 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 3 59 M
CBPP41-1 Pancreatic Ductal  4800 KRAS c.34G>C KRAS p.G12R 1.3 PCR-Ligation 2 71 M
CBPP42-1 Pancreatic Ductal  4800 KRAS c.35G>T KRAS p.G12V 2.1 PCR-Ligation 2 54 F
CBPP44-1 Pancreatic Ductal  4800 KRAS c.35G>T KRAS p.G12V 0.0 PCR-Ligation 1 73 M
CBPP46-1 Pancreatic Ductal  1920 KRAS c.35G>A KRAS p.G12D 19 PCR-Ligation 2 71 M
CBPP47-1 Pancreatic Ductal  2304 KRAS c.34G>C KRAS p.G12R 0.0 PCR-Ligation 2 67 F
CBPP48-1 Pancreatic Ductal  4800 KRAS c.35G>A KRAS p.G12D 6.0 PCR-Ligation 1 49 M
CBPP49-1 Pancreatic Ductal  4000 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 2 82 F
CBPP50-1 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 10.0 PCR-Ligation 4 66 M X
CBPP52-1 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 2,310 PCR-Ligation 2 66 F
CBPP53-1 Pancreatic Ductal  4000 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 2 73 M
CBPP54-1 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 2 72 M
CBPP55-1 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 19 PCR-Ligation 4 73 F X
CBPP57 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 3.3 PCR-Ligation 4 46 M X
CBPP60 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 16 PCR-Ligation 4 66 F X
CBPP6-1 Pancreatic Ductal  4500 KRAS c.35G>T KRAS p.G12V 10.0 PCR-Ligation 1 63 M
CBPP62 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 39 PCR-Ligation 2 53 F
CBPP64 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 19 PCR-Ligation 4 73 F X
CBPP65 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 100 PCR-Ligation 2 64 M
CBPP67 Pancreatic Ductal  2368 KRAS c.35G>T KRAS p.G12V 46 PCR-Ligation 4 75 F X
CBPP68 Pancreatic Ductal  1480 KRAS c.35G>T KRAS p.G12V 0.0 PCR-Ligation 3 67 M
CBPP7-1 Pancreatic Ductal  4050 KRAS c.35G>T KRAS p.G12V 3.0 PCR-Ligation 4 77 M X
CBPP73 Pancreatic Ductal  5000 KRAS c.34G>T KRAS p.G12C 57 PCR-Ligation 4 66 F X
CBPP74 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 2.3 PCR-Ligation 2 78 F
CBPP8-1 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 0.0 PCR-Ligation 2 77 M
CBPRO8 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 20 SafeSeqS 2 74 M
PANC 10 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 24 PCR-Ligation 4 74 M X
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PANC 106 Pancreatic Ductal  2000 KRAS c.35G>T KRAS p.G12V 68 SafeSeqS 1 68 M
PANC 112 Pancreatic Ductal  2000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 46 F
PANC 121 Pancreatic Ductal  2000 KRAS c.38G>A KRAS p.G13D 5.5 SafeSeqS 1 68 F
PANC 13 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 9.5 SafeSeqS 4 66 M X
PANC 135 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 59 F
PANC 137 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 7.1 SafeSeqS 2 53 F
PANC 138 Pancreatic Ductal  3000 KRAS c.34G>T KRAS p.G12C 275 SafeSeqS 2 79 M
PANC 139 Pancreatic Ductal  4000 KRAS c.34G>T KRAS p.G12C 6.1 SafeSeqS 2 74 M
PANC 14 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 4 59 M X
PANC 141 Pancreatic Ductal  2000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 65 F
PANC 144 Pancreatic Ductal  2000 KRAS c.35G>A KRAS p.G12D 135,000 SafeSeqS 2
PANC 146 Pancreatic Ductal  3000 KRAS c.35G>T KRAS p.G12V 1.9 SafeSeqS 2 78 M
PANC 147 Pancreatic Ductal  3000 KRAS c.35G>T KRAS p.G12V 10 SafeSeqS 4 81 M X
PANC 148 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 68 M
PANC 149 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 168 SafeSeqS 2 64 F
PANC 154 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 1 60 F
PANC 155 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 517 SafeSeqS 4 53 M X
PANC 156 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 2,820 SafeSeqS 4 63 F X
PANC 157 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 18 SafeSeqS 4 79 F X
PANC 158 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 197 SafeSeqS 4 79 M X
PANC 160 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 3 79 M
PANC 161 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 4 65 M X
PANC 162 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 3,560 SafeSeqS 4 75 M X
PANC 163 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 1,630 SafeSeqS 4 59 F X
PANC 164 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 326 SafeSeqS 4 55 M X
PANC 165 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 3 55 F
PANC 167 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 1.1 SafeSeqS 2 67 M
PANC 17 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 74 PCR-Ligation 4 66 M X
PANC 171 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 1 75 M
PANC 18 Pancreatic Ductal  4000 KRAS c.35G>T KRAS p.G12V 0.0 PCR-Ligation 2 68 F
PANC 203 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 1 80 F
PANC 233 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 1 80 M
PANC 29 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 1.9 PCR-Ligation 1 67 M
PANC 33 Pancreatic Ductal  4000 KRAS c.35G>A KRAS p.G12D 1.5 PCR-Ligation 2 58 F
PANC 45 Pancreatic Ductal  4500 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 2 60 F
PANC 56 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 55 F
PANC 69 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 63 M
PANC 70 Pancreatic Ductal  1000 KRAS c.35G>A KRAS p.G12D 1,600 SafeSeqS 2 73 M
PANC 71 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 1.2 SafeSeqS 2 78 F
PANC 72 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 2.1 SafeSeqS 2 47 F
PANC 76 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 83 F
PANC 77 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 67 M
PANC 78 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 46 F
PANC 79 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 2.8 SafeSeqS 2 76 F
PANC 80 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 5.2 SafeSeqS 2 83 F
PANC 81 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 63 M
PANC 82 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 2.6 SafeSeqS 2 44 M
PANC 83 Pancreatic Ductal  5000 KRAS c.34G>A KRAS p.G12S 1.1 SafeSeqS 1 65 F
PANC 84 Pancreatic Ductal  4000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 46 M
PANC 85 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 4 60 F X
PANC 86 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 61 M
PANC 87 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 1 60 F
PANC 9 Pancreatic Ductal  3000 KRAS c.35G>T KRAS p.G12V 875 PCR-Ligation 4 80 M X
PANC 91 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 122 SafeSeqS 2
PANC 92 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 1.1 SafeSeqS 2 56 F
PANC 93 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 3.5 SafeSeqS 4 56 M X
PANC 94 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 48 M
PANC 95 Pancreatic Ductal  4000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 84 M
PANC 96 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 3.3 SafeSeqS 2 55 M
PANC 97 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 2.1 SafeSeqS 2 62 F
PANC 98 Pancreatic Ductal  1500 KRAS c.35G>C KRAS p.G12A 4.7 SafeSeqS 1
PANC 99 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 1.2 SafeSeqS 2
PANC100 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 64 F
PANC101 Pancreatic Ductal  2000 KRAS c.38G>A KRAS p.G13D 8.3 SafeSeqS 2 68 M
PANC102 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 54 M
PANC103 Pancreatic Ductal  3000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 1 74 M
PANC104 Pancreatic Ductal  3000 KRAS c.35G>T KRAS p.G12V 45 SafeSeqS 4 75 M X
PANC105 Pancreatic Ductal  2000 KRAS c.35G>T KRAS p.G12V 5.5 SafeSeqS 2 61 F
PANC107 Pancreatic Ductal  2000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 3 66 M
PANC108 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 81 F
PANC109 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 75 M
PANC110 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 71 F
PANC111 Pancreatic Ductal  3500 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 63 F
PANC113 Pancreatic Ductal  3000 KRAS c.34G>T KRAS p.G12C 6.7 SafeSeqS 2 70 M
PANC114 Pancreatic Ductal  2000 KRAS c.34G>T KRAS p.G12C 0.0 SafeSeqS 2 88 M
PANC115 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 1 M
PANC116 Pancreatic Ductal  2000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 83 M
PANC117 Pancreatic Ductal  2000 KRAS c.34G>C KRAS p.G12R 601 SafeSeqS 2 89 M
PANC118 Pancreatic Ductal  1000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 65 M
PANC119 Pancreatic Ductal  2000 KRAS c.35G>A KRAS p.G12D 11 SafeSeqS 2 80 M
PANC120 Pancreatic Ductal  2000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 67 F
PANC122 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 3.7 SafeSeqS 2 72 F
PANC124 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 4 59 M X
PANC125 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 5.5 SafeSeqS 2 74 M
PANC126 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 1 60 F
PANC127 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 54 F
PANC128 Pancreatic Ductal  2500 KRAS c.35G>T KRAS p.G12V 4.4 SafeSeqS 2 62 F
PANC129 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 1.1 SafeSeqS 2 56 F
PANC130 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 62 F
PANC131 Pancreatic Ductal  4000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 62 M
PANC132 Pancreatic Ductal  4000 KRAS c.35G>A KRAS p.G12D 107 SafeSeqS 4 73 F X
PANC133 Pancreatic Ductal  3000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 75 M
PANC134 Pancreatic Ductal  4000 KRAS c.34G>C KRAS p.G12R 4.0 SafeSeqS 1 65 M
PANC136 Pancreatic Ductal  4000 KRAS c.34G>C KRAS p.G12R 0.0 SafeSeqS 2 58 F
PANC140 Pancreatic Ductal  2000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 1 50 M
PANC142 Pancreatic Ductal  2500 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 76 M
PANC143 Pancreatic Ductal  3000 KRAS c.35G>A KRAS p.G12D 9.7 SafeSeqS 2 67 M
PANC145 Pancreatic Ductal  3000 KRAS c.34G>C KRAS p.G12R 7.2 SafeSeqS 2 60 M
PANC150 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 122 SafeSeqS 4 77 M X
PANC151 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 6.3 SafeSeqS 2 83 F
PANC152 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 5.7 SafeSeqS 4 83 M X
PANC153 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 1.6 SafeSeqS 2 69 F
PANC159 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 1 49 F
PANC166 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 76 M
PANC168 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 2 74 M
PANC169 Pancreatic Ductal  5000 KRAS c.34G>C KRAS p.G12R 3.0 SafeSeqS 2 54 M
PANC170 Pancreatic Ductal  5000 KRAS c.35G>A KRAS p.G12D 0.0 SafeSeqS 2 71 M
PANC172 Pancreatic Ductal  5000 KRAS c.35G>T KRAS p.G12V 0.0 SafeSeqS 1 68 F
CBPP11-1 Prostate 4500 KRAS c.35G>A KRAS p.G12D 0.0 PCR-Ligation 4 62 M X
CBPRP1 Prostate 4800 BRCA2 c.9281C>G BRCA2 p.S3094X 173,000 PCR-Ligation 4 63 M X
CBPRP2 Prostate 4800 TP53 c.743G>T TP53 p.R248L 59 PCR-Ligation 4 63 M X
CBPRP3 Prostate 4800 SPOP c.304T>G SPOP p.F102V 0.0 SafeSeqS 4 57 M X
CBPRP5-1 Prostate 5000 RPP30 c.905G>A RPP30 p.R302K 0.0 SafeSeqS 4 68 M X
RCC 10 Renal Cell Carcinoma 5000 VHL c.263G>T VHL p.W88L 0.0 SafeSeqS 4 70 M X
RCC 11 Renal Cell Carcinoma 5000 VHL c.263G>T VHL p.W88L 0.0 SafeSeqS 4 73 M X
RCC 7 Renal Cell Carcinoma 5000 HOOK2 c.1165G>T HOOK2 p.E389X 0.0 SafeSeqS 4 77 M X
RCC PL1 Renal Cell Carcinoma 5000 VHL c.388G>C VHL p.V130L 24 PCR-Ligation 4 49 M X
RCC PL2 Renal Cell Carcinoma 5000 MET c.3687_3688GT>TA MET p.M1229_Y1230IN 665 PCR-Ligation 4 86 M X
CB LUNG 24 Small Cell Lung Cancer 5000 TP53 c.832C>G TP53 p.P278A 320 SafeSeqS 4 X
CB THY 4 Thyroid 5000 NRAS c.182A>G NRAS p.Q61R 0.0 SafeSeqS 4 79 M X
CB THY 5 Thyroid 5000 NF2 c.20C>G NF2 p.S7C 0.0 SafeSeqS 4 54 M X
CB THY 7 Thyroid 5000 TP53 c.743G>A TP53 p.R248Q 1,350 SafeSeqS 4 56 M X
THY 1 Thyroid 5000 BRAF c.1799T>A BRAF p.V600E 0.0 SafeSeqS 4 64 F X
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Table 5-S2. Comparison between circulating tumor DNA fragments containing point 






















BLD 24 Bladder 2 Inter-chromosomal; chr2:204396710-chr1:154286405 3.9 BRAF c.1801A>G BRAF p.K601E 3.4 1.1
CRC 02 Colorectal 1 Inter-chromosomal; chr12:73097777-chr1:63099083 22,000 TP53 c.730G>A TP53 p.G244S 16,115 1.4
CRC 03 Colorectal 1 Intra-chromosomal; chr11:98914172-chr11:98993460 6,415 APC c. 4012C>T APC p.Q1338X 26,155 0.2
CRC 06 Colorectal 1 Intra-chromosomal; chr13:27679603-chr13:25685009 85 KRAS c.182_183AA>CC KRAS p.Q61P 59 1.4
CRC 07 Colorectal 1 Intra-chromosomal; chr4:85109657-chr4:85408635 42 KRAS c.35G>A KRAS p.G12D 49 0.9
CRC 12 Colorectal 4 Intra-chromosomal; chr6:58080933-chr6:67229823 79 KRAS c.35G>A KRAS p.G12D 34 2.3
CRC 14 Colorectal 4 Intra-chromosomal; chr8:141375810-chr8:141405769 31 TP53 c.818G>A TP53 p.R273H 95 0.3
CRC 21 Colorectal 2 Intra-chromosomal; chr1:237741691-chr1:244145093 685 KRAS c.35G>C KRAS p.G12A 745 0.9
CRC 23 Colorectal 4 Intra-chromosomal; chr16:6343641-chr16:6727736 28,500 TP53 c.817C>T TP53 p.R273C 14,500 2.0
CRC 27 Colorectal 2 Intra-chromosomal; chr13:102839339-chr13:105470344 55 KRAS c.35G>A KRAS p.G12D 51 1.1
CRC 30 Colorectal 3 Intra-chromosomal; chr20:2658058-chr20:2770031 1,466,665 KRAS c.35G>A KRAS p.G12D 138,445 10.6
CRC 37 Colorectal 1 Intra-chromosomal; Duplication - chr3:170782510-chr3:170870975 0.0 TP53 c.844C>T TP53 p.R282W 38 0.0
CRC 51 Colorectal 4 Inter-chromosomal; chr8:30060122-chr1:190065347 3,850 APC c.4012C>T APC p.Q1338X 72 53.5
CRC 53 Colorectal 4 Intra-chromosomal; chr16:52977177-chr16:52965488 7,150 TP53 c.452C>A TP53 p.P151H 1,085 6.6
CRC 54 Colorectal 4 Intra-chromosomal; chr11:7250750-chr11:19457296 1,240 KRAS c.35G>T KRAS p.G12V 36 34.4
CRC 55 Colorectal 4 Intra-chromosomal; chr8:38281631-chr8:39225849 295 TP53 c.637C>T TP53 p.R213X 112 2.6
CRC 58 Colorectal 4 Intra-chromosomal; chr20:14839816-chr20:14863644 1,370 KRAS c.35G>A KRAS p.G12D 1,380 1.0
CRC 60 Colorectal 4 Intra-chromosomal; chr17:35277642-chr17:35163714 73,335 TP53 c.817C>T TP53 p.R273C 12,905 5.7
MEL 27 Melanoma 4 Intra-chromosomal; chr2:137699753-chr2:137700957 15,600 BRAF c.1799T>A BRAF p.V600E 260 60.0
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Table 5-S3.  Comparison between plasma and tumor tissue KRAS status in 206 patients with metastatic colorectal cancer. 
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Table 5-S4. Clinical characteristics of patients with discordant tissue and plasma 
KRAS mutation data. 
 
False Negative True Negative P-Value
N = 10 N = 127
Age   
Mean (SD) 55.2 (11.08) 59.02 (12.83)
Median (Range) 58.5 (32, 69) 60 (18, 85) 0.293
No. Missing (%) 0 (0) 2 (2)
     
Gender, N (%)   
Female 3 (30) 51 (41) 0.737
Male 7 (70) 74 (59)
Missing 0 2
      
Race, N (%)   
A 1 (11) 3 (3) 0.447
B 0 (0) 10 (9)
M 0 (0) 1 (1)
O 0 (0) 0 (0)
W 8 (89) 97 (87)
Missing 1 16
  
       
ECOG, N (%)
0 10 (100) 96 (80) 0.653
1 0 (0) 15 (12)
2 0 (0) 6 (5)
3 0 (0) 2 (2)
4 0 (0) 1 (1)
Missing  0 7
        
Met Site - Liver
No 5 (50) 25 (20) 0.072
Yes 5 (50) 100 (80)
Missing   0 2
         
Met Site - Lungs
No 7 (70) 88 (70) >0.99
Yes 3 (30) 37 (30)
Missing    0 2
          
Met Site - Peritoneum
No  8 (80) 89 (71) 0.818
Yes  2 (20) 36 (29)
Missing     0 2
           
Met Site - Pelvis
No   10 (100) 121 (97) >0.99
Yes   0 (0) 4 (3)
Missing      0 2
            
Met Site - Bone
No    9 (90) 122 (98) 0.693
Yes    1 (10) 3 (2)
Missing       0 2
             
Met Site - Brain
No     9 (90) 125 (100) 0.103
Yes     1 (10) 0 (0)
Missing        0 2
              
# of Met Sites
0 0 (0) 3 (2) 0.604
1 8 (80) 77 (62)
2 2 (20) 31 (25)
3 0 (0) 13 (10)
4 0 (0) 0 (0)
Missing         0 3
  
Histological Subtype
Moderately 7 (70) 80 (73) 0.023
Moderately to Poorly 0 (0) 1 (1)
Poorly 1 (10) 17 (15)
Well 1 (10) 0 (0)





Table 5-S4. Continued. 
 
     
Mucinous
No      3 (30) 87 (85) < 0.001*
Yes      7 (70) 15 (15)
Missing 0 25
      
Smoking Status
Distant 3 (30) 19 (16) 0.446
No       6 (60) 93 (78)
Yes       1 (10) 8 (7)
Missing  0 7
       
Family History
No        6 (60) 83 (70) 0.776
Yes        4 (40) 36 (30)
Missing   0 8
        
MSI Status
MSI 1 (50) 1 (8) 0.254
MSS 1 (50) 11 (85)
Stable    0 (0) 1 (8)
Missing 8 114
  
BRAF Status   
Mutation Found 0 (0) 9 (12) 0.95
WT 5 (100) 69 (88)
Missing     5 49
1 6
Prior Surgery
No 2 (20) 35 (28) 0.859
Yes 8 (80) 90 (72)
Missing 0 2
  
Prior Chemotherapy   
No 4 (40) 44 (35) >0.99
Yes 6 (60) 81 (65)
Missing 0 2
   
Prior Radiation   
No  9 (90) 105 (85) >0.99
Yes  1 (10) 19 (15)
Missing  0 3
CEA (+/- 8 weeks)
Mean (SD) 2.14 (0.9) 380.82 (1663.89)
Median (Range) 2 (1, 3) 17 (1, 13864) < 0.001*
No. Missing (%) 3 (30) 24 (19)
       
WBC   
Mean (SD) 5645.56 (2367.93) 7710.57 (3831.43)
Median (Range) 4600 (3480, 11070) 7300 (7.2, 20350) 0.056
No. Missing (%) 1 (10) 5 (4)
        
ALT   
Mean (SD)  21.67 (9.06) 77.56 (165.37)
Median (Range)  18 (9, 34) 24 (7, 922) 0.299
No. Missing (%)  1 (10) 10 (8)
         
Bilirubin   
Mean (SD)   0.66 (0.18) 0.85 (0.91)
Median (Range)   0.7 (0.4, 1) 0.6 (0.1, 8) >0.99
No. Missing (%)   2 (20) 34 (27)
          
Albumin   
Mean (SD)    4.54 (0.25) 4.22 (3.34)
Median (Range)    4.6 (4.1, 4.9) 4 (1.8, 39) 0.002
No. Missing (%)    1 (10) 12 (9)
           
Creatinine   
Mean (SD)     0.88 (0.15) 1.41 (5.92)
Median (Range)     0.8 (0.7, 1.1) 0.8 (0.4, 65) 0.308
No. Missing (%)     1 (10) 9 (7)




Table 5-S5. Clinical characteristics of patients with false negatives in plasma KRAS 





Table 5-S6. Association between clinical characteristics and ctDNA concentration 




Table 5-S6. Continued. 
 
 
       No ref
       Yes -0.761 (-2.077, 0.554) 0.251
Smoking Status
       Distant ref
       No -0.018 (-1.639, 1.603) 0.983
       Yes -0.449 (-3.339, 2.44) 0.757
 
Family History
       No ref
       Yes 0.166 (-1.035, 1.368) 0.783
MSI Status
       MSI ref
       MSS 2.246 (-3.837, 8.329) 0.412
Prior Surgery
       No ref
       Yes -1.58 (-2.694, -0.466) 0.006
Prior Chemotherapy
       No ref
       Yes 0.378 (-0.693, 1.449) 0.484
Prior Radiation
      No ref
      Yes -0.492 (-1.9, 0.917) 0.488
Log CEA (within 8 weeks of 
blood DNA measurement) 0.439 (0.22, 0.658) <.001
  
WBC 0 (0, 0) 0.01
    
Log ALT -0.07 (-0.566, 0.427) 0.78
      
Log Bilirubin 0.267 (-0.581, 1.115) 0.531
        
Log Albumin -0.211 (-1.479, 1.058) 0.741
          
Log Creatinine -0.06 (-0.731, 0.61) 0.857
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Table 5-S7. Association between clinical characteristics and ctDNA concentration 






Table 5-S8. Patient characteristics and plasma mutations detected post-EGFR 
blockade. 













Patient #5 60 M Colorectal  Cancer Panitumumab 7 KRAS c.35G>A KRAS p.G12D 66
EGFR c.2380C>T EGFR p.P794S 168
KRAS c.183C>T KRAS p.Q61H 90
Patient #17 57 F Colorectal  Cancer Panitumumab 31 None Detected None Detected NA
KRAS c.35G>T KRAS p.G12V 120
NRAS c.34G>A NRAS p.G12S 129
Patient #19 42 M Colorectal  Cancer Panitumumab 15 NRAS c.183A>T NRAS p.Q61H 40
KRAS c.35G>T KRAS p.G12V 80
NRAS c.183A>T NRAS p.Q61H 30
NRAS c.182A>G NRAS p.Q61R 82
EGFR c.2142G>C EGFR p.K714N 948
KRAS c.35G>C KRAS p.G12A 40
KRAS c.34G>T KRAS p.G12C 30
KRAS c.34G>A KRAS p.G12S 120
KRAS c.35G>A KRAS p.G12D 104
KRAS c.35G>T KRAS p.G12V 100
KRAS c.35G>C KRAS p.G12A 15
NRAS c.181C>A NRAS p.Q61K 28
59 F Colorectal  Cancer Panitumumab 23 KRAS c.35G>T KRAS p.G12V 40
73 M Colorectal  Cancer Panitumumab 23 KRAS c.35G>T KRAS p.G12V 114
KRAS c.35G>C KRAS p.G12A 1590
KRAS c.34G>T KRAS p.G12C 2160
KRAS c.34G>C KRAS p.G12R 660
KRAS c.35G>A KRAS p.G12D 3900
KRAS c.35G>T KRAS p.G12V 4940
KRAS c.183A>T KRAS p.Q61H 710
KRAS c.182A>T KRAS p.Q61L 640
KRAS c.182A>G KRAS p.Q61R 688
NRAS c.181C>A NRAS p.Q61H 1340
NRAS c.183A>C NRAS p.Q61K 4100
NRAS c.182A>T NRAS p.Q61L 6760
NRAS c.182A>G NRAS p.Q61R 625
Patient #2 53 M Colorectal  Cancer Panitumumab 22 KRAS c.35G>T KRAS p.G12V 93
KRAS c.34G>C KRAS p.G12R 30
KRAS c.183A>T KRAS p.Q61H 220
KRAS c.35G>C KRAS p.G12A 135
KRAS c.35G>T KRAS p.G12V 133
NRAS c.183A>T NRAS p.Q61H 848
NRAS c.181C>A NRAS p.Q61K 98
NRAS c.182A>T NRAS p.Q61L 374
KRAS c.35G>A KRAS p.G12D 61
NRAS c.181C>A NRAS p.Q61K 25
KRAS c.35G>T KRAS p.G12V 244
KRAS c.183A>T KRAS p.Q61H 83
KRAS c.183A>C KRAS p.Q61H 57
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Table 5-S8. Continued. 
 
KRAS c.34G>T KRAS p.G12C 100
KRAS c.183A>C KRAS p.Q61H 429
KRAS c.34G>C KRAS p.G12R 13
KRAS c.183A>T KRAS p.Q61H 394
NRAS c.182A>G NRAS p.Q61R 4
KRAS c.34G>C KRAS p.G12R 208
KRAS c.34G>C KRAS p.G12R 308
KRAS c.181C>G KRAS p.Q61E 139
KRAS c.182_183AA>CC KRAS p.Q61P 265
KRAS c.35G>A KRAS p.G12D 13
KRAS c.35G>T KRAS p.G12V 130
CRC 188 PLS 41 F Colorectal  Cancer Cetuximab 9 KRAS c.34G>T KRAS p.G12C 3
KRAS c.183A>T KRAS p.Q61H 28
KRAS c.183A>C KRAS p.Q61H 13
BRAF c.1799T>A BRAF p.V600E 45
KRAS c.35G>C KRAS p.G12A 131
KRAS c.183A>C KRAS p.Q61H 10
KRAS c.182A>G KRAS p.Q61R 11
NRAS c.182A>T NRAS p.Q61L 2
NRAS c.182A>G NRAS p.Q61R 12
KRAS c.35G>A KRAS p.G12D 173
KRAS c.34G>C KRAS p.G12R 31
KRAS c.35G>T KRAS p.G12V 58
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Figure 5-1. Depiction of circulating tumor DNA. 
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Figure 5-2. Circulating tumor DNA in advanced malignancies. 
(A) Fraction of patients with detectable ctDNA and (B) quantification of mutant fragments. 
Error bars represent the 95% bootstrapped confidence interval of the mean. 
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Figure 5-3. Circulating tumor DNA in localized and non-localized malignancies. 
(A) Fraction of patients with detectable ctDNA in localized (stages I-III) and metastatic 
(stage IV) colorectal, gastroesophageal, pancreatic and breast cancers; (B) fraction of patients 
with detectable ctDNA and (C) quantification of mutant fragments in cancer cases 





Figure 5-4. Scatter plot correlating point mutations with rearrangements in the same 





Figure 5-5. The relationship between ctDNA concentration (mutant fragments per 
mL) and 2-year survival. 
The association between survival and ctDNA concentration was assessed holding known 
prognostic factors (age, ECOG PS, and CEA) constant. The 2-year survival was estimated 
based on a multivariable Cox regression model, in which ctDNA concentration level was 
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Figure 5-6. Heat map of acquired resistance mutations to EGFR blockade in ctDNA 





Figure 5-S1. Comparison of methods for analysis of point mutations in plasma DNA. 
Duplicate aliquots of plasma or serum from 20 different patients were collected.  A mutation 
present in the corresponding tumors was quantified in the first aliquot by Quantification 
Method #1 (PCR-ligation) and in the second aliquot by Quantification Method #2 
(BEAMing in 11 patients and SafeSeqS in 9 patients).  Mutant templates per 5 ml plasma or 
serum are plotted on both the x- and y-axes. In addition to the 20 samples displayed in this 
graph, each of which yielded at least one mutation with both quantification methods, we 
tested 10 other duplicate samples containing low amounts of mutant DNA.  In five of these 
cases, neither of the aliquots tested by the two methods revealed any mutations. In five other 
cases, one method revealed a single mutant template molecule while the other method 
revealed zero.  These results are consistent with expectations based on a Poisson distribution 





Figure 5-S2. Circulating Tumor DNA in advanced malignancies, ranking of the 
fraction of patients with detectable ctDNA. 
For each tumor type, the rank of the proportion of detectable ctDNA is reported, where a 
rank of 1 means having the highest proportion and a rank of 15 means having the lowest 
proportion among the 15 tumor types. Ties were handled by taking the average ranking. The 
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  Location: University of California, San Francisco 
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Awards & Honors 
 
2005 – 2015 Medical Scientist Training Program M.D./Ph.D. Fellowship 
National Institutes of Health 
 
2014  Rising Star Award, Outstanding Alumni of the Year 
  University of Maryland, Baltimore County 
 
2014  The Hans Joaquim Prochaska Research Award, Young Investigators’ Day 
  Johns Hopkins University School of Medicine 
 
2013  Medalist, National Collegiate Inventors Competition 
  Invent Now 
 
2013  30 Under 30, Science and Healthcare 
  Forbes Magazine 
 
2011  Selected Young Scientist Participant, United States Delegation 
  The Council for the 61st Lindau Nobel Laureate Meeting (Lindau, Germany) 
 
2009 – 2010 Graduate Research Fellowship 
  Merck and United Negro College Fund 
 
2006  Summer Research Fellowship 
  American Federation for Aging Research 
 
2005  Emerald Honor Award in Student Leadership 
  Science Spectrum Magazine 
 
2005  Faculty Award of Excellence in the Biological Sciences 
  University of Maryland, Baltimore County 
 
2005  Certificate of General Honors 
  The Honors College of University of Maryland, Baltimore County 
 
2002 – 2005 Undergraduate Research Scholar 
  Howard Hughes Medical Institute  
 
2003 – 2005 Minority Access to Research Careers (MARC) Undergraduate Scholar 
  National Institute of General Medical Sciences 
 
2001 – 2005 Meyerhoff Undergraduate Scholar 
  University of Maryland, Baltimore County 
 
2004  Summer Undergraduate Research Fellowship 
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Presentations & Posters 
 
2014  Time=Lives: The Race to the Starting Line 
  Type: Invited lecture 
  Host: Partnering for Cures, a FasterCures event 
  Location: New York, NY 
 
2014  Next Generation DNA Diagnostics 
  Type: Invited lecture 
  Host: Molecular Diagnostics Laboratory, Johns Hopkins University 
  Location: Baltimore, MD 
 
2014  Showcasing the Bioeconomy: The Future is Now 
  Type: Invited panelist 
  Host: United States Department of State 
  Location: Washington, DC 
 
2006  Antiviral Inhibition of the HIV-1 Capsid Protein 
  Type: Selected poster 
  Host: Student National Medical Association (SNMA) Annual Conference 
  Location: Atlanta, GA 
 
2004  Entropic Switch Regulates Myristate Exposure in the HIV-1 Matrix Protein 
  Type: Selected lecture 
  Host: Annual Biomedical Research Conference for Minority Students (ABRCMS) 
  Location: Dallas, TX 
 
2003  Antiviral Inhibition of the HIV-1 Capsid Protein 
  Type: Selected lecture 
  Host: Annual Biomedical Research Conference for Minority Students (ABRCMS) 
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2013  Science speaker and lab tour guide for local youth of St. Ignatius Academy 
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  Morning Star Baptist Church (Catonsville, MD) 
 
2008 – 2009 Student member, Medical School Admissions Committee 
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2006 – 2007 Student member, Liaison Committee on Medical Education Accreditation Panel 
  Johns Hopkins University School of Medicine 
 
2005  Volunteer HIV counselor 
  Baltimore City Health Department 
 
2005  Instructor, Community Adolescent Sexual Education Program (CASE) 




2004 – 2005 Chapter president, Golden Key International Honour Society 
  University of Maryland, Baltimore County 
 
2002 – 2003 Student member, Institutional Review Board 
  University of Maryland, Baltimore County 
 
2002 – 2005 Tutor, Chemistry Tutorial Center 
  University of Maryland, Baltimore County 
 
2001  Volunteer, Shock Trauma Center 
  University of Maryland Medical System 
 
2001  Tutor, Learning Resources Center 
  University of Maryland, Baltimore County 
 
